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ABSTRACT 
 
PLATELET FACTOR 4 AND VON WILLEBRAND FACTOR FORM AN IMMUNOGENIC, 
PROTHROMBOTIC COMPLEX IN HEPARIN-INDUCED THROMBOCYTOPENIA 
Ian H. Johnston 
Mortimer Poncz, M.D. 
Heparin-induced thrombocytopenia (HIT) is a prothrombotic, thrombocytopenic disorder that 
occurs in patients exposed to heparin due to the development of antibodies directed against 
complexes of platelet factor 4 (PF4) with heparin with other polyanions . We have recently shown 
that the perithrombus endothelium is targeted in HIT. Using a photochemical injury model and an 
endothelialized microfluidic system, we now show that PF4 binds to elongated strands of von 
Willebrand factor (VWF) released from injured endothelium. This binding appears to be periodic 
along the VWF strand and to favor larger VWF strands, suggesting formation of oligomers that may 
cross-link individual VWF subunits. KKO, a monoclonal HIT-like antibody, and HIT patient plasma 
form PF4-VWF-HIT antibody complexes that may stabilize the complexes which, in turn, avidly bind 
platelets, exacerbating thrombus growth in a human whole blood microfluidic system. This increase 
in platelet binding is attenuated by blocking either the platelet FcRIIA or the glycoprotein Ib/IX 
receptor. Charge-based as well as VWF-binding drugs can disrupt the PF4-VWF-HIT complexes.  
Dynamic light scattering studies provide additional support for the concept that PF4 and VWF form 
complexes in vitro. In vivo studies in a passive immunization model of HIT indicate a potential role 
for VWF in the prothrombotic nature of HIT. Thus, these studies newly identify VWF as a potentially 
important polymer involved in the formation of HIT antigenic complexes that contribute to the 
prothrombotic nature of HIT and offer a potential new therapeutic target to mitigate the thrombotic 
complications of affected patients.  
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CHAPTER 1 - Introduction 
 
2 
Hemostasis: Pro-coagulative Factors 
Hemostasis can be seen as the crucial balance between pro-coagulative and anti-
coagulative processes present on and within the vasculature. On the pro-coagulative side, 
hemostasis assures that minor vascular injuries are sealed by platelets (platelets) 
preventing unnecessary blood loss. On the anti-coagulative side, hemostasis assures that 
excessive platelet accumulation or clot formation is mitigated to a level that sustains blood 
flow through an injured vessel1,2. Pro-coagulative processes are driven in large part by the 
serine protease thrombin (activated Factor (F) II, IIa or FIIa), a pivotal component of the 
coagulation cascade. This cascade consists of a series of zymogens that when activated, 
cleave and activate subsequent zymogens culminating in FIIa. The “intrinsic” pathway of 
this cascade leading to IIa initiates with the activation of the plasma zymogen FXII bound 
to a negatively-charged surface, e.g. a catheter, within the vascular lumen. Alternately, 
the “extrinsic” pathway is activated via FVII binding the transmembrane receptor, tissue 
factor (TF), which normally sequestered from the cell surface3–5. In either case, FIIa leads 
to a positive feedback loop by activating FV, FVII and FXI, which generates additional FIIa 
(Figure 1.1). FIIa ultimately promotes coagulation via direct and indirect pathways. 
Directly, FIIa cleaves the plasma protein fibrinogen, which generates fibrin monomers that 
polymerize and constitute most of the protein mass within fibrin clots. Indirectly, FIIa 
activate platelets by cleaving protease-activated receptors (PAR) PAR-1 and PAR-4, and 
activates endothelial cells (ECs) via PAR-1, generating inflammatory cytokines in addition 
to promoting coagulation2,6,7.  
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Hemostasis: Anti-coagulative Factors 
ECs lining the vasculature have a major role in preventing undesirable clot 
formation (Figure 1.2). ECs release prostacyclin (PGI2), nitric oxide (NO), and cluster of 
differentiation (CD) 39 which down-regulate platelet activation within a healthy vascular 
lumen8–11. Additionally, ECs are covered with a layer termed the glycocalyx, a negatively 
charged meshwork composed of glycoproteins and glycolipids that provide a protective 
coating to the vascular wall, by repelling inadvertent interactions of blood cells with the 
vascular surface12–17. EC’s also express thrombomodulin (TM), a multidomain 
transmembrane glycoprotein that binds FIIa, inhibiting its capacity to cleave fibrinogen and 
activate platelets. Binding of FIIa of TM catalyzes (>1000-fold) the formation of activation 
Protein C (APC) from Protein C (PC). When bound to its cofactor, Protein S, APC reduces 
FIIa production indirectly by inactivating the upstream enzymes, FVa and FVIIIa. PC also 
interacts with the PC binding receptor (EPCR) expressed on the EC surface that causes 
a 20-fold increase in APC production. APC is capable of detaching from this complex and 
imposing the previously mentioned anti-coagulative effects; alternatively, while still bound, 
APC is capable of inducing cytoprotective effects including dampening inflammation and 
improving endothelial barrier function via PAR-1. This improved EC barrier contributes to 
APC’s anti-coagulative effects by reducing the production of pro-coagulative EC surfaces 
and access to the pro-coagulative extracellular matrix (ECM)2,8,18–22. EC’s also produce 
tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1); tPA 
cleaves plasminogen into plasmin which is responsible for lysis of fibrin clots. On the other 
hand, inhibition of tPA by PAI-1 prevents premature clot lysis. APC also inhibits PAI-1 
allowing for greater tPA activation of plasmin23–25. 
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Under physiological conditions, in which minor injuries or damage occurs, 
hemostasis is maintained within the vasculature by a balance between these pro- and 
anti-coagulative processes, allowing clot formation where and only as long as it is needed.  
 
Thrombosis 
Thrombosis is an imbalance of these pro- and anti-coagulative factors on a local 
or systemic level favoring clot formation. An imbalance leading to thrombosis can be 
caused by a variety of ailments which include, but are not limited to, significant vascular 
damage, an excessive immune (antibody) or inflammatory response26–28. In any of these 
scenarios, significant changes occur in the microenvironment of the blood vessel 
promoting pro-coagulant processes (Figure 1.3).  
When ECs are activated they shed or endocytose TM and suppress EPCR 
expression19,22,29–33. This decreases APC production leading to an increase in FIIa with the 
effects on coagulation mentioned above. Excess FIIa also enhances PAR 1 cleavage 
leading to increased endothelial inflammatory responses and a decrease in EC barrier 
function21. Moreover, the lack of APC minimizes the inhibition of PAI-1, while increased 
FIIa increases PAI-1 production. Increased PAI-1 significantly inhibits tPA activity, leading 
to greater fibrin clot stability. Additionally, activated ECs express intracellular adhesion 
molecule 1 (ICAM-1) and vascular cell adhesion molecule (VCAM-1) adhesion proteins 
that promote white blood cell binding which further enhance EC activation16,26,34. 
Furthermore, ECs begin to develop additional pro-coagulative properties such as 
expression of TF and release of VWF. TF contributes through its previously mentioned 
function of binding FVIIa and increasing FIIa production. VWF, a multimeric glycoprotein, 
is released from the Weibel-Palade bodies within ECs and helps to stabilize FVIII and 
promote platelet adhesion under high shear stresses35–38. Lastly, the glycocalyx, which 
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normally provides a thick, negatively charged mesh can become damaged or partially 
shed from the EC surface. This allows greater access to the EC surface and greater 
interaction of plasma proteins and circulating cells with the glycosaminoglycan (GAG) that 
make up the glycocalyx; both of these can contribute to pro-coagulative processes by co-
localizing blood cells and cytokines to the EC wall leading to cell activation12,16,17.  
 Platelets play a significant role in hemostasis and, consequently, thrombosis. As 
mentioned previously, platelets transiently bind VWF released from injured ECs via their 
membrane receptor, GPIb-IX-V, which slows down platelet rolling along the vascular 
surface. These transiently bound platelets then can undergo activation by interaction with 
the receptor GPVI, commonly associated with collagen. Platelets also can link other 
platelets via their integrin αIIbβ3, which can bind fibrin or collagen leading to platelet 
activation. As mentioned previously, platelets are also activated by thrombin1,8. In any 
setting, platelets an also be fully activated via their autocrine and paracrine signaling. 
Activated platelets release agonists such as thrombin, TxA2, and ADP which amplify the 
process by promoting the activation of surrounding platelets1,36,39,40. This creates a positive 
feedback in which platelet activation leads to further platelet activation that contributes to 
thrombus structure and stability. This amplification affect can be seen in the structure of 
growing thombi in which platelets toward the center of a thrombi (core) are highly activated 
and densely packed while the outer layers are less activated and loosely packed (Figure 
1.4). 
 
Heparin-Induced Thrombocytopenia (HIT): An Iatrogenic Prothrombotic Disease 
HIT is an iatrogenic immune disorder that develops after treatment with heparin. 
HIT is characterized by a fall in platelet count often accompanied by various thrombotic 
complications, which include pulmonary emboli, myocardial infarction, and deep vein 
6 
thrombosis41–45. Recently, rare cases of HIT have been described where no prior heparin 
exposure was identified46. HIT can be thought of as developing in three steps: initiation, 
activation and propagation (Figure 1.5). Step 1, initiation of HIT is caused by the 
introduction of heparin, a commonly used anticoagulant. Due to its highly negative charge, 
heparin is able to bind the platelet-specific chemokine, platelet factor 4 (PF4, CXCL4) and 
form soluble heparin/PF4 complexes. In some individuals this leads to the formation of 
pathogenic HIT antibodies. This leads to the Step 2: activation, in which these HIT 
antibodies bind to PF4/heparin complexes and cell surface PF4/GAGs complexes, leading 
to cell activation via their surface FcIIA receptors (FcRIIA) and perhaps by complement 
activation. Dermatan sulfate and heparin sulfate are among the GAGs with the highest 
affinity for PF4 that can form complexes that are recognized by HIT antibodies47–49. Among 
the cells expressing FcRIIA that are activated are platelets, likely accounting for the 
observed thrombocytopenia, and monocytes that likely contribute to thrombosis by 
expressing TF43,50,51. ECs are also activated though the lack FcRIIA, perhaps by adherent 
activated platelets and leukocytes and via activation of complement42,43,52. In studies 
described in Chapter 3, we demonstrate that the endothelium is an additional key target 
in HIT. Thus, in Step 2, the activation of the vasculature and several intravascular lineages 
can contribute to the prothrombotic nature of HIT. In Step 3, propagation of thrombosis 
after discontinuation of heparin, we propose that PF4 interacts with other polymeric 
molecules that allow thrombi to extend downstream of the initial thrombus. Among these 
are polyphosphates released by injured/activated platelets and perhaps endothelial 
cells53. Polyphosphates bind PF4 and become antigenic for the HIT-like monoclonal 
antibody KKO. That they form large complexes in vitro demonstrated using dynamic light 
scatter (DLS) technology.  
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We have now observed while simulating HIT in a microfluidic system that PF4 
bound to injured endothelium not only occurs in a diffuse fashion (likely to the glycocalyx), 
but also along specific strand-like structures, which we identify in Chapter 4 as VWF. The 
details of this in vitro and in vivo analysis are described as well as examining the effect of 
targeted therapeutic intervention based on this approach. Another polymeric structure 
identified by us to which PF4 binds are neutrophil extracellular traps (NETs) released by 
activated neutrophils as described in Chapter 5. This effect appears to be more prominent 
in the venous system in in vivo murine studies of HIT. Thus, the release of three polymeric 
molecules will have been described that we propose as central to the propagation and the 
prothrombotic nature of HIT.  
The established treatments for HIT are the immediate cessation of any heparin 
product and the use of direct thrombin inhibitors (DTIs), specifically lepirudin and 
argatroban that bind and inhibit the prothrombotic actions of FIIa or inhibitors of FXa such 
as fondaparinux, rivaraxoaban, or apixaban. These interventions are only partially 
effective in decreasing morbidity and mortality from the thrombotic complications in HIT. 
Such treatments also have limitations in that some require frequent monitoring, have 
increased risk of bleeding, may accumulate with hepatic or renal insufficiency, and some 
are associated with high cost and require hospitalization41,44,54. In Chapters 2-4 we 
propose and test various novel therapeutics based on our observations on the novel new 
mechanisms we describe in HIT.  
 
HIT Modeling 
The recognition that there was a clinical prothrombotic disorder in patients treated 
with heparin took several decades to appreciate55. Progress was and is still limited by the 
severity of illness and the complex clinical settings in which it often develops. Furthermore, 
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clinical diagnosis is challenging and the laboratory confirmation relies on functional assays 
that are often limited to tertiary care centers41,44. To help gain better insight into the 
pathogenesis of HIT, a passive immunization model was developed using double 
transgenic mice that express human platelet IgG Fc receptor IIA FcγRIIA (present on 
human but not on mouse platelets) and human PF4 (hPF4), often on a mouse PF4 
knockout background43,47,56. HIT is induced by infusing KKO, a monoclonal antibody that 
recognizes heparin/hPF4 and heparin-like/hPF4 complexes or HIT immunoglobulins 
isolated from patients with a high likelihood of having HIT. When infused with KKO, mice 
experience thrombocytopenia followed by fibrin-rich thrombi in multiple organs, including 
the pulmonary vasculature. This model is used and elaborated on in the following sections 
to investigate how thrombi develop in the setting of HIT. We recognize that these in vivo 
studies suffer from being mostly based in the murine vasculature and coagulation system 
and concerns arise over translatability to the clinic57,58. We therefore have focused on 
developing an in vitro system that can be either human or murine based and that also 
allows isolation and targeted manipulation of specific cellular components and combining 
these components to obtain specific details of the mechanism of thrombosis in HIT. This 
system, especially the use of the endothelial-lined Bioflux system where a targeted 
hematoporphyrin-photochemical injury is induced in the lining, was key to many of the 
observations on the role of the endothelium in HIT (Chapter 3), the prothrombotic nature 
of PF4-VWF-HIT antibody complexes (Chapter 4), and the formation of PF4-NETs-HIT 
antibody complexes (Chapter 5) in HIT.  
 
Sepsis: An Immune-Based Systemic Disorder 
 Sepsis is a life-threatening condition characterized by impaired microclearance 
combined with sustained excessive inflammation and activation of coagulation. The 
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dysregulated host response to infection leads activation of the complement system and 
systemic thrombosis, among other adverse outcomes to the host. Through exposure to 
the invading pathogen or the resulting inflammatory cytokine release, sepsis can interfere 
with many of the previously mentioned EC-based anti-coagulant mechanisms that 
normally prevent thrombosis. These include, but are not limited to, increasing TF-mediated 
FIIa generation and impairing endogenous anticoagulant mechanisms and fibrin 
removal33,59–62 (Figure 1.6.). During our studies into the progression of HIT, we became 
interested in lessons that may be applicable to sepsis and other inflammatory thrombosis 
models in which patients experienced thrombocytopenia and some develop disseminated 
thrombosis. Patients often develop HIT in the setting of major surgery or widespread 
inflammation as seen in the initial steps of sepsis. Moreover, sepsis and HIT each initiate 
similar elaborate multicellular pathways leading to thrombosis that include activating ECs 
with release of VWF, activation of neutrophils with the release of NETs, activation of 
platelets and sustained progressive pathology that may worsen over the course of hours 
to days33,59–62. Consequently, with collaborators, we developed a microfluidic model of 
inflammatory thrombosis (Chapter 2) and investigated a novel ICAM-1 targeted TM 
therapeutic to combat the formation of fibrin clots (Chapter 6). This allowed us to better 
understand how ECs change in the setting of inflammation and determine if said changes 
could be used to develop new approaches to therapy, especially those that could be used 
in combination with currently employed approaches to treatment with maximally tolerated 
anti-thrombotic drugs.  
 
Summary 
Our incomplete understanding of how thrombosis in HIT is propagated and 
sustained even when heparin is withdrawn and even when maximally tolerated 
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antithrombotic therapy is employed creates a need to see if potential avenues for 
treatment have been overlooked. Furthermore, with only murine models available, there 
are intricacies of the pathogenesis that are difficult to investigate without incorporating 
human ECs. Consequently, this thesis aims to address these shortcomings in several 
ways. First, we used an in vivo laser injury model of HIT in mice to inform the development 
of a “humanized” in vitro microfluidic model (Chapter 2). Chapter 3 summarizes an in vivo 
murine model of HIT that provided the framework for the questions then addressed in the 
“humanized” setting. Chapter 3 describes the proclivity of PF4 and HIT antibody to interact 
with the perithrombus ECs both upstream and downstream of an initial injury site. This 
understanding of ECs involvement led to developing an in vitro microfluidic model using 
human blood that demonstrated similar patterns of PF4 binding to the surface of ECs. 
With this new understanding concerning the importance of ECs to the formation of PF4-
HIT antibody complexes, Chapter 4 and Chapter 5 summarize our understandings of how 
vascular and intravasular cells and proteins contribute to the pathogenesis of HIT. Chapter 
4 summarizes our finding that VWF released from injured ECs may contribute to HIT by 
forming PF4-VWF-HIT antibody complexes. In vitro work displays how these complexes 
induce greater platelet accumulation that is both FcRIIA and GPIb dependent. We also 
showed that VWF targeted therapeutics disrupted these complexes and, in an in vivo 
setting, attenuated thrombosis enhanced by HIT antibodies. Chapter 5 summarizes how 
activated neutrophils release NETs that present an additional site on which PF4-HIT 
antibody complexes form. In vitro microfluidic work in this chapter displays how the 
presence of PF4 impacts NET conformation and causes resistance to deoxyribonuclease 
I (DNase I). The work is translated in vivo showing a significant contribution of neutrophils 
to venous thrombi in a model of HIT through increased neutrophil-EC adhesion and 
neutrophil infiltrations of thrombi leading to even greater cell activation. Considering the 
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impact of inflammation on HIT, Chapter 6 summarizes the use of the inflammatory 
thrombosis model described in Chapter 2 to investigate EC activation as well as a novel 
therapeutic. Chapter 6 presents data from a humanized microfluidic setting that help to 
evaluate the changes in EC protein expression, fibrin deposition, and thrombi formation 
that can occur in the inflammation that accompanies HIT or the similar pathology seen in 
some cases of sepsis. Moreover, this chapter provides insight into the use of a novel 
ICAM-1 targeted TM therapeutic. This thesis culminates with Chapter 7 presenting the 
conclusions, clinical impacts, and future directions for the described studies. 
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Figures 
 
Figure 1.1. The coagulation cascade produces fibrin clots via production of FIIa and 
various positive feedback loops. 
Binding FXII to a negatively charged surface accelerates its autoactivation which 
generates XIIa which cleaves FXI to FXIa, which initiates the intrinsic pathway. High-
molecular-weight kininogen (HMWK) and prekallikrein (Pre-K) accelerate these initial 
activation steps. Kal =kallikrein. Binding of FVII/FVIIa to TF localizes FVIIa, initiating the 
extrinsic pathway. Each of these contributes to the activation of subsequent zymogens, 
including FXa, which is directly responsible for the activating FII. FIIa cleaves fibrinogen 
into fibrin, while also activating FXIII which further assists in clot stability. FIIa indirectly 
contributes by feeding back into the activation of FVIIIa and FVa. Image adapted from 
drawing presented by Professor Dzung Le at UCSD Clinical Chemistry Conference, 
October 2014. 
13 
 
 
 
Figure 1.2. Quiescent ECs provide anti-thrombotic activity. 
The antithrombotic effects of the TM/APC pathways and quiescent ECs. Quiescent ECs 
release PGI2, NO, and CD39 to limit platelet activation. TM binds and lessens FIIa 
mediated conversion of fibrinogen to fibrin by forming a complex which increases APC 
production. APC can stay bound to EPCR and cleave PAR-1 on ECs leading to improved 
cytoprotection and enhanced barrier function. APC can also inactivate FVa and FVIIIa and 
also inhibit PAI-1 allowing for tPA to more effectively cleave fibrin clots. i-IIa/ i-Va/ i-VIIIa 
= inactivated enzymes. 
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Figure 1.3. EC activation promotes pro-thrombotic activity. 
When ECs experience significant damage, they promote pro-coagulative effects that 
contribute to thrombosis. ECs release VWF which bind platelets under high-shear stresses 
and express TF, which promote additional FIIa production. FIIa can also cleave PAR-1 
leading to increased inflammation and reduced cell-barrier function. Additionally, ECs 
shed or endocytose their TM and suppress their EPCR in the setting of inflammation. This 
allows for greater increases in FIIa and greatly relinquishes the anti-coagulative impact of 
APC.  
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Figure 1.4. The gradient of platelet activation that occurs within a clot. 
(A) Displays the presence of a highly activated, densely packed platelet core that is 
overlaid with a loosely packed shell of less activated platelets with an intermediate 
transition zone. (B) As with the gradient of platelet activation, there is a gradient of agonists 
with thrombin being focused at the sight of injury while ADP and TxA2 persist in the 
transition zone and outward to the thrombi shell. (C) Displays how the high density of 
platelets in the thrombus core provide low transport and high solute retention while the 
outer shells provide high transport with low solute retention. Image taken from Brass LF, 
et al. 2016 Blood Advances.  
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Figure 1.5. Proposed sequential steps in the development of prothrombotic 
pathways in HIT. 
Step 1. HIT is initiated by ultralarge immune complexes composed of heparin/PF4 and 
HIT antibody (left). Step 2. PF4 also bind to GAGs on the surface of (intra)vascular and 
cells leading to the activation of platelets, monocytes, ECs, and neutrophils via FcRIIa 
and/or complement pathways. Step 3. ECs activated by immune complexes release VWF, 
neutrophils release DNA in the form of NETs and diverse cell types release PPs, each of 
which combines with PF4 to form antigenic complexes that amplify and propagate the 
thrombus downstream. Studies of novel Step 3 pathways, focused on NETs, but especially 
VWF, form the core of this thesis. 
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Figure 1.6. Sepsis promotes thrombosis by disturbing the normal balance between 
pro and anti-coagulant mechanisms. 
Sepsis promotes thrombosis by activating various cells including ECs via inflammatory 
cytokines such as TNF-α and IL-1β which results in the increase of TF expression. Sepsis 
causes a decrease in PC and subsequently APC further bolstering TF production. The 
activation of ECs under septic conditions causes a reduction in TM which furthers the lack 
of APC production. Sepsis both directly and indirectly, through APC reduction, causes an 
increase in PAI-1 which further promotes thrombosis. Image taken from Cohen J, 2002, 
Nature. 
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CHAPTER 2 – Microfluidic system modeling 
  
 
This chapter presents work featured in the articles: 
Hayes, et al., (2017) Journal of Clinical Investigation 127(3):1090-1098 
Greineder, C., Johnston, I., et al. (2017) Blood Advances 1(18): 1452-1465 
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Motivation for Developing an Endothelialized Microfluidic System 
In the Introduction, I discussed the limitations of the passive immunization murine 
model for mechanistic studies of HIT, including that it is limited to a mostly murine system  
and the difficulties with manipulating individual lineages56–58. Although platelets and 
monocytes have been shown to be significant contributors to the pathogenesis in HIT, the 
contribution of ECs was less developed43,50,53,63. Consequently, the motivation for these 
studies was to investigate avenues through which ECs, particularly following vascular 
injury, contribute to HIT pathogenesis. Understanding these factors could provide valuable 
insight into why thrombosis in HIT propagates in the vasculature, forming long, platelet-
rich “white clots”64–67. We posited that a major contributor is the injured endothelium in HIT 
and that a model system that allowed either diffuse or local endothelial injuries was 
deemed necessary. For diffuse injury, we utilized a tumor-necrosis factor alpha (TNFα) 
injury, which we found leads to increased platelet and neutrophil binding to the 
endothelium in the presence of PF4 and HIT antibodies26,51,68. We utilized a previously 
described hematoporphyrin-induced photochemical endothelial injury to establish a 
focused, localized injury69,70. Such an injury did not result in endothelial loss from the 
microfluidic device or loss of apparent cell-cell contact. Pursuing these studies not only 
provided greater insight into pathogenesis of HIT, but also novel therapeutic avenues 
based on those mechanisms to limit HIT-associated thrombosis.  
 
Microfluidic Device and Setup 
This chapter will focus on the description and characterization of that microfluidic 
model. The model used the Fluxion Bioflux 1000 microfluidic platform with micro-channels 
connecting corresponding wells that allows for the infusion of reagents via an air pressure 
mechanism. The walls of the vessel lumen are composed of the polymer 
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polydimethylsiloxane while the bottom of the plate is a glass cover slip allowing for 
visualization of the channel in real time. This additionally allows, in most cases, for coating 
with an extracellular matrix alone or with subsequent ECs (Figure 2.1). Throughout the 
following chapters, this model was used to provide a human cell-based in vitro system that 
incorporated shear stress to better recapitulate the physiological conditions seen in the 
vasculature. In some instances, the channels were only coated with fibronectin (50 µg/ml, 
Sigma-Aldrich) in phosphate-buffered saline and incubated for 1 hour at 37°C. Once 
coated, these channels were flowed with isolated cells, primarily neutrophils, re-calcified 
human whole blood, or platelets for experimentation (Chapter 5). In other instances of 
using this model, once coated with fibronectin, human umbilical vein ECs (HUVECS, 6-8 
x 106 cells/ml, Lonza) were infused and allowed to grow to confluency (Figure 2.2). 
At confluency (3-5 days), we characterized the monolayers to understand the 
quality of our in vitro “vessel”. We stained the channels (Figure 2.3) for platelet endothelial 
cell adhesion molecule (PECAM-1, CD31) (rabbit anti-human CD31, abcam), actin (Alexa 
Fluor 488 Phalloidin, ThermoFisher Scientific), VWF (rabbit anti-human VWF polyclonal 
antibody, Dako; alternatively, FITC-sheep anti-human VWF polyclonal antibody, abcam), 
P-selectin (rabbit anti-human P-selectin polyclonal antibody, abcam). PECAM-1 verified 
that proper junctions were forming between ECs and that minimal spacing was found 
between adjacent cells, while actin showed that the cells grew with proper cytoskeletal 
support71. VWF and P-selectin staining on uninjured channels showed that the internal 
structure of the ECs where Weibel-Palade bodies would be located, were quiescent as 
they were punctate in nature and not seen on the surface or released from the EC 
monolayer34,36,72,73. Additionally, when uninjured channels were flowed with re-calcified 
human whole blood, minimal to no platelet accumulation was observed. 
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Injury Settings: Hematoporphyrin-Induced Endothelial Injury  
Hematoporphyrin is a heme-pathway intermediate that in porphyria cutanea tarda 
is present in excess due to the absence of uroporphyrinogen decarboxylase (UROD), 
resulting in a light-dependent sclerosing of tissues. Prior studies by others in a microfluidic 
device induced injury to ECs using changes in pressure74, γ radiation75, hypernatremia76, 
physical vascular wall puncturing77, hypoxia78, lasers (405nm)79, and localized heat80. 
However, many of these injuries lacked the ability to be localized, are limited in widespread 
reproducibility, and/or cannot cause EC injury without also denuding them from the 
microfluidic channel wall. In our microfluidic system, we added hematoporphyrin (50 µg/ml 
final concentration, Sigma-Aldrich) and illuminated a localized area of the channel to 
create a demarcated region of endothelial injury. We characterized this injury model by 
showing localized activation of endothelialized microfluidic channels made as described 
above and in Figure 2.4 as represented by localized VWF release detected using a rabbit 
polyclonal anti-human VWF antibody (DAKO) in combination with a goat anti-rabbit Alexa 
Fluor secondary antibody (ThermoFisher Scientific). Additionally, we showed that ECs 
were not denuded by the injury as verified by nuclei stain using Hoescht staining. The 
continued presence of the endothelial lining following injury is essential for our thrombosis 
studies to distinguish from binding of platelets to the underlying fibronectin-coated 
channels. Moreover, when recalcified human whole blood was introduced either during or 
after the injury, platelet accumulation was localized to the injured ECs, but not to the 
upstream or downstream uninjured ECs. Additionally, when looking at hPF4 binding, that 
it was localized to the injury area and was present on the luminal surface of ECs, but not 
in the subliminal space. By altering the shutter on the microscope, we were able to alter 
the radius of this injury causing it to injure more or less of the channel. 
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Injury Settings: TNFα-Induced Endothelial Injury 
To study HIT and the patients vascular state prior to HITs initiation, we developed 
an endothelial injury within our microfluidic system that utilized the inflammatory conditions 
experienced during and post-surgery. TNFα is an inflammatory cytokine primarily released 
by activated macrophages that induces changes in ECs that promote thrombosis. These 
include the upregulation of ICAM-1, VCAM-1, TF and the down-regulation of TM26,51,68. In 
our microfluidic model, we induced an inflammatory injury by incubating our 
endothelialized microfluidic channels with basal media containing TNFα (0-10 ng/ml for 0-
6 hours) at a variety of shear stresses (1-5 dynes/cm2) We characterized this injury model 
by verifying increases in the surface expression of ICAM-1 (mouse anti-human 
monoclonal ICAM-1 antibody, abcam) and VCAM-1 (rabbit anti-human monoclonal 
VCAM-1 antibody, abcam) when endothelialized microfluidic channels were exposed to 
TNFα (Figure 2.5). We saw increases in ICAM-1 and VCAM-1 as seen under 
physiological conditions. Changes in TF and TM were only slightly detectable due to low 
signal to background ratio (not shown). Additionally, we verified that when recalcified 
human whole blood was flowed through TNFα-activated channels, fibrin clots formed in a 
time, and TNFα concentration-dependent manner. 
 
Discussion 
This chapter describes two endothelialized microfluidic systems important for my 
studies of Step 3 propagation in HIT. The photochemical injury model especially allowed 
me to identify VWF strands as an important target binding PF4 and forming HIT antigenic 
sites that have a high affinity for binding platelets that form the core of this thesis. 
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Figures 
 
 
Figure 2.1. Schematic of an endothelialized Fluxion Bioflux 1000 microfluidic plate. 
This microfluidic platform consists of a microfluidic channel that connects two 1 ml wells. 
Using filtered air pressure infused through a pressure sealing lid, the Bioflux is able to 
perfuse reagents from one well, through the endothelialized microfluidic channel, into the 
“outlet” well. The bottom of the microfluidic channel is formed by a glass coverslip allowing 
for real time or post-experimental imaging. In most cases, the microfluidic system is coated 
in extracellular matrix alone or with subsequent ECs. Orange spheres with purple center 
= ECs with nuclei; Lilac solution = reagent solution representative of various reagents 
used in experiments. 
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Figure 2.2. EC growth to confluency in three dimensions of the microfluidic model. 
Three-dimensional (3-D) renderings from confocal images of microfluidic channels coated 
with ECs showing confluency along the top and bottom of channels. Looking down the 
channel (left) and looking along the bottom of the channel (right) with EC nuclei (blue, 
labeled with Hoescht) and cell membranes (white, Vybrant DiD cell labeling from 
ThermoFisher Scientific) microfluidic channels showing the connectivity of cell 
membranes covering the underlying fibronectin coating. 
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Figure 2.3. Characterization of the endothelialized microfluidic channel by 
identifying key protein structures and displaying quiescence by introducing human 
whole blood.  
(A) Confocal images that show PECAM-1 signal around the periphery of cells indicative 
of junctions forming between neighboring ECs and (B) actin throughout the cell body 
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showing the forming of internal cytoskeletons as expected of healthy cells based on 
previous publications. (C) P-selectin and (D) VWF are localized to the nuclei where they 
are presumably stored within the Weibel-Palade Bodies of the ECs as oppose to being 
released or dispersed across the EC monolayer. Nuclei stained with Hoescht (blue) are 
presented in all images. (E) Fluorescently imaged stills from a 40-minute video of whole 
blood being flowed through an endothelialized microfluidic channel taken at 10x. The 
whole blood was labeled with calcein AM which labels platelets and white blood cells. The 
stills show that after 40 minutes of blood flow, there is no significant accumulation of 
platelets within the channel which is indicative of the ECs being quiescent. 
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Figure 2.4. Hematoporphyrin injury causes a localized release of VWF leading to 
localized platelet accumulation and hPF4 deposition. 
(A) Endothelialized channels after an hematoporphyrin injury showing the localized 
release of VWF (cyan) in the channels with minimal to no VWF release downstream. 
Additionally, ECs indicated by their nuclei (blue) are shown to persist throughout the 
channel after injury showing no denudation. (B) Shows that the platelet accumulation 
(white) and hPF4 (green) deposited during injury of re-calcified human whole blood is 
localized to the injury area in which VWF is released. 
A 
B 
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Figure 2.5. Inflammatory thrombosis model displays changes in surface proteins 
and fibrin deposition dependent on TNFα concentration and time of exposure. 
(A) Displays fluorescent confocal images showing increases in ICAM-1 (left, green signal) 
and VCAM-1 (right, red signal) in a TNFα (1-10 ng/ml) and time dependent (2-6 hours) 
manner. (B and C) Displays how the accumulation of fibrin varies with (B) increasing 
concentration of TNFα (1 versus 10 ng/ml, each for 6 hours) and (C) duration (4 hours 
versus 6 hours, each 1 ng/ml) of TNFα preactivation; fibrin deposition occurs more quickly 
with increased TNFα or prolonged channel exposure. Top panels show representative 
fluorescent images at various time points. Left panels show mean fluorescent intensity 
 
C 
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versus time, with mean ± standard error of the mean (SEM) shown for N = 2 channels for 
control (no TNF) groups and N = 3 channels for each experimental group. Right panels 
shows AUC analyses. *P < 0.05 versus control; **P < 0.05 versus each other condition; #, 
not significant (P = 0.14). Fibrin deposition was monitored via red fluorescent anti-fibrin 
monoclonal antibody during perfusion of whole blood through TNFα-activated 
endothelialized channels at shear stress of 5 dynes/cm2. Video stills taken at 10x 
magnification. 
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Chapter 3 – Endothelial antigen assembly leads to thrombotic complications in 
heparin-induced thrombocytopenia 
 
 
This chapter presents work featured in the article: 
Hayes, et al., (2017) Journal of Clinical Investigation 127(3):1090-1098 
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Abstract 
HIT is a prothrombotic disorder initiated by antibodies against complexes between 
hPF4 and heparin. A better understanding of the events in Steps 2 and 3 of HIT that start 
and propagate the prothrombotic state may improve approaches to antithrombotic 
management. Here, we visualized thrombus formation in an in vivo murine model and an 
endothelialized microfluidic system that simulate the pathogenesis of HIT. hPF4 released 
from platelets predominantly bound to peri-injury endothelium and formed HIT antigenic 
complexes that were dissociated by heparin. In mice expressing both hPF4 and human 
FcRIIA, infusion of KKO increased fibrin and platelet deposition at sites of injury, followed 
immediately by antigen formation on proximate ECs. After a few minutes, HIT antigen was 
detected within the thrombus itself at the interface between the platelet core and the 
surrounding shell. We observed similar results in the humanized, endothelialized 
microfluidic system. hPF4 and KKO bound preferentially to photochemically-injured 
endothelium at sites where surface glycocalyx was reduced. These studies support the 
concept that the perithrombus endothelium is a key site of HIT antigen assembly in Steps 
2 and 3. This suggests that disrupting antigen formation along the endothelium or 
protecting the endothelium may provide a therapeutic opportunity to prevent thrombotic 
complications of HIT, while sparing systemic hemostatic pathways. 
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Introduction 
HIT is an iatrogenic disorder initiated by antibodies directed against a complex 
between a positively charged chemokine, hPF4, and heparin81 that can lead to limb- and 
life-threatening arterial or venous thrombi82, which often occur at sites of vascular injury83. 
HIT remains a common and serious disorder, even though the use of unfractionated 
heparin has been restricted to settings such as cardiopulmonary surgery84,85, where it 
remains the anticoagulant of choice86. Present-day management with intense 
anticoagulation has not reduced the incidence of death or amputation, provides 
substantial, but incomplete, protection against recurrent thromboembolism, and is 
associated with a risk of bleeding for which antidotes are not available87. A better 
understanding of the pathobiology of HIT might lead to novel disease-specific approaches 
that prevent immune complex–mediated thrombus formation and propagation, with less 
reliance on intense systemic anticoagulation. 
We have proposed a model to help explain the inordinate risk of thrombosis in 
patients with HIT compared with the thrombosis risk with other antibody-induced 
thrombocytopenias50,88: PF4 released from activated platelets binds to surface GAGs on 
intravascular and vascular cells. Infused heparin, which has a higher affinity for PF4 than 
for other GAGs, removes surface-bound PF4, forming circulating antigenic PF4-heparin 
complexes that fix complement and bind to CD21 on circulating antigen-presenting B 
cells89. PF4 also forms antigenic complexes with GAGs on the surface of platelets88, 
monocytes50, and neutrophils90, leading to cell activation via Fc receptors91, which 
promotes the generation of thrombin and other prothrombotic pathways92. 
ECs are targeted by HIT antibodies, at least in vitro93–95, but the mechanism and 
in vivo relevance are unclear. The endothelium is covered by a complex surface layer 
termed the glycocalyx, which contains heparan sulfate–rich proteoglycans, glycoproteins, 
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and associated plasma proteins17,96 that would be predicted to bind PF4 with greater 
affinity than the platelet surface. Binding of HIT antibody to cultured ECs induces platelet 
adhesion and expression of TF94, but there is little direct evidence that HIT antibodies 
impair the natural antithrombotic properties of the endothelium in more biologically 
relevant models. 
The spatial and temporal events that initiate thrombus development in HIT are not 
well delineated, but are potentially of considerable import. Studies of platelet degranulation 
in the cremaster arteriole laser injury model by our group and others97–99 showed that the 
release of PF4 from platelets activated within a growing thrombus is likely to develop within 
the compacted core after a 2- to 3-minute delay and then expand outward99. This would 
suggest that this high local concentration and sequestration of PF4 would lead to antigen 
formation on platelets within the core and the surrounding shell in preference to circulating 
leukocytes or endothelium and that HIT-associated antibodies must penetrate the core to 
propagate platelet-mediated thrombus extension. However, in HIT, we posit that antigen 
assembly occurs on multiple cell surfaces including monocytes, neutrophils, and ECs. This 
difference is important, because one places the emphasis on interrupting platelet-platelet 
interactions, while the other suggests the value of therapies targeted to ECs, among other 
cell types. 
In this study, we used a previously described passive immunization model of HIT 
in mice double-transgenic for human PF4 and FcRIIA (referred to hereafter as 
hPF4+/FcRIIA+)50,56 and the cremaster arteriole laser injury model100 to study in situ 
thrombus development in HIT. We extended these in vivo findings by using endothelialized 
microfluidic chambers, which allowed us to introduce localized hematoporphyrin-based 
photochemical injury to study the contribution of activated endothelium in a humanized 
system. Our data show that the perithrombus endothelium is a predominant site of HIT 
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antigen formation, surprisingly at sites where the glycocalyx is depleted, followed by lower 
levels of antigen expression at the interface between the thrombus core and shell. These 
studies shift the focus of studies on HIT pathogenesis and intervention to factors that 
regulate antigen assembly and the thrombotic consequences of antibody binding to the 
endothelium, which is the core of this thesis and addressed in the subsequent chapter. 
 
Methods  
Mice and human samples. 
Transgenic mice expressing platelet-specific hPF4101 (hPF4+) and/or human 
FcRIIA expressing its R131 isoform102 (FcRIIA+) were studied. All transgenic mice were 
on a Cxcl4–/– background103, as murine PF4 is not targeted by HIT-associated antibodies47. 
This knockout setting, common to all the mice studied, is not specified hereafter. Genetic 
alterations were confirmed by the appropriate PCR analyses101,102. Mice were studied at 6 
to 10 weeks of age. Only male mice were studied for the cremaster vessel injuries; 
however, we have not noted any prior sex difference in thrombosis in the passive 
immunization HIT murine model using a photochemical injury model50. 
Human blood (10–25 ml) from healthy volunteers for in vitro studies was drawn by 
gravity through a 19-gauge butterfly into sodium citrate (Sigma-Aldrich; 0.38% final 
concentration). Blood samples were stored at room temperature and used within 1 hour 
of being drawn. Deidentified plasma samples were obtained from patients who had a high 
pre-test probability of HIT on the basis of their clinical history104, a positive PF4/heparin 
ELISA, and a positive serotonin release assay105. For plasma samples from healthy 
donors, whole blood was centrifuged (200 g, 15 minutes), followed by centrifugation (2,000 
g, 15 minutes) of the resultant platelet-rich plasma. 
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Heparins, antibodies, pooled IgGs, and other labeled probes.  
Unfractionated porcine heparin (BD Biosciences) and low-molecular-weight 
heparin (enoxaparin; Novaplus) were used in this study. KKO, a mouse IgG 2bK anti-
hPF4/heparin monoclonal antibody, and TRA, a monoclonal IgG isotype control antibody 
47, were purified from hybridoma supernatants. F(ab′)2 fragments of the monoclonal anti-
mouse CD41 antibody MWReg30 (BD Biosciences) were used to detect murine platelets 
in the cremaster laser injury model. Anti–fibrin 59D8 monoclonal antibody was provided 
by Hartmut Weiler of the BloodCenter of Wisconsin (Milwaukee, Wisconsin, USA)106. 
Annexin V labeled with Alexa Fluor 647 was purchased from ThermoFisher Scientific. 
Recombinant FXa labeled with Alexa Fluor 488 was provided by Rodney Camire of the 
Children’s Hospital of Philadelphia (CHOP). Mouse anti-human P-selectin antibody (clone 
CTB201) was purchased from Santa Cruz Biotechnology. Polyclonal rabbit anti-human 
VWF antibody was purchased from Dako. hPF4 was visualized using polyclonal rabbit 
anti-hPF4 antibody (abcam). All antibodies were either labeled using Alexa Fluor 
antibody–labeling kits according to the manufacturer’s instructions or species-appropriate 
Alexa Fluor–conjugated secondary antibodies (all from ThermoFisher Scientific). IgG was 
isolated from plasma from HIT patients and healthy donors using protein G agarose 
(Pierce, ThermoFisher Scientific). 
 
Cremaster laser injury studies.  
Intravital microscopy was performed as previously described107. Vascular injury 
was induced with an SRS NL100 pulsed nitrogen dye laser (440 nm) focused on the vessel 
wall through the microscope objective. Arterioles of 20 to 40 μm diameter were selected, 
and the laser was pulsed until the vessels were perforated and a small number of red 
blood cells escaped. Antibodies and unfractionated porcine heparin were infused as 100-
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μL boluses via a catheter placed into the jugular vein. Widefield and confocal microscopy 
were performed as described previously98. Data were collected and widefield time-lapsed 
images of platelet and fibrin accumulation were analyzed using Slidebook 6.0 (Intelligent 
Imaging Innovations). Confocal Z-stacks were analyzed using Volocity 6.3 (PerkinElmer). 
hPF4+, FcRIIA +, and hPF4+/ FcRIIA + mice were studied. We studied 1–10 injuries per 
mouse during a maximum experimental time of 1 hour. 
 
Endothelialized microfluidic studies.  
Microfluidic studies were performed using a BioFlux 1000 Controller (Fluxion) with 
an attached heating stage set to 37°C as described previously108. The BioFlux controller 
was used in conjunction with a Zeiss Axio Observer Z1 inverted microscope equipped with 
a motorized stage and an HXP-120 C metal halide illumination source. The microscope 
and acquisition were controlled using BioFlux Montage software with a MetaMorph-based 
platform (Molecular Devices). HUVECs and adult human aortic endothelial cells (both from 
Lonza), at passage 3–4 (5 × 106 cells), were seeded onto fibronectin-coated (50 μg/ml, 
Sigma-Aldrich) channels of 48-well BioFlux plates allowed to adhere, then cultured at 37°C 
under 5% CO2 in EC growth media (Lonza) until they reached confluency. 
A HIT-like state was induced by adding KKO (10 μg/ml) to sodium citrate–
anticoagulated whole blood from healthy donors immediately before infusion. Platelets in 
the whole blood were labeled by incubating the blood with 2 mM calcein AM (Thermo 
Fisher Scientific) for 20 minutes prior to infusion. To cause photochemical injury without 
disrupting the EC lining, hematoporphyrin (50 μg/ml final concentration; Sigma-Aldrich) 
was also added to the whole blood prior to infusion69. Channels were exposed to blue light 
using the HXP-120 C light source with 475-nm excitation and 530-nm emission filters, 
allowing real-time, concurrent visualization of calcein AM-loaded platelets and reactive 
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oxygen species (ROS) generation from hematoporphyrin. An exposure time of 50 msec 
at the highest intensity setting on the light source was used for all experiments. The blood 
was recalcified immediately before infusion with calcium chloride (11 mM final 
concentration). Infusion into endothelialized channels was done at a rate of 10 dynes/cm2. 
Following injury, channels were washed with PBS and fixed with 2% paraformaldehyde 
(BD Biosciences) for confocal studies of P-selectin, PF4, and KKO. To measure the 
glycocalyx thickness, HUVECs lining the channels were stained with 1 μg/ml DyLight 488–
labeled Lycospersicon esculentum lectin (Vector Laboratories) for 20 minutes prior to 
fixation109. EC nuclei were visualized after staining with 5 μg/ml Hoescht 33342 
(ThermoFisher Scientific) for 20 minutes. Stained channels were imaged with a Zeiss LSM 
710 laser scanning confocal microscope. Data were analyzed using Slidebook 6.0 for 
photochemical injuries or Volocity 6.3 (PerkinElmer) for confocal images acquired after 
fixation. 
 
Statistics and human and animal Institutional permission. 
Differences between 2 groups were compared using a 2-sided Student’s t test or 
a Mann-Whitney U test. Differences between more than 2 groups were determined by 2-
way ANOVA with Sidak’s correction for multiple comparisons. Occlusion studies were 
compared using a 2-sided Fisher’s exact test. Statistical analyses were performed using 
Microsoft Excel 2011 and GraphPad Prism 6.0 (GraphPad Software). Differences were 
considered significant when P values were less than or equal to 0.05. 
All animal procedures were approved by the IACUC of the CHOP and in 
accordance with NIH guidelines (Guide for the Care and Use of Laboratory Animals. 
National Academies Press. 2011.) and the Animal Welfare Act. Human blood was 
collected after signed, informed consent was provided by healthy donors, and approval 
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for studies using human blood was obtained from the CHOP Institutional Human Review 
Board in accordance with Declaration of Helsinki principles. 
 
Results 
Distribution of HIT antigen after nonimmune vascular injury in hPF4+ mice.  
We previously proposed that a key step in the development HIT was the formation 
of antigen that occurs when positively charged hPF4 binds to negatively charged GAGs 
found on many cell surfaces88. This model predicts that HIT antigen will form at sites of 
vascular injury, even in the absence of HIT-associated antibodies. We tested this 
hypothesis in vivo using a cremaster arteriole laser injury model in hPF4+ mice. Following 
injury, hPF4, detected using a polyclonal anti-hPF4 antibody, and HIT antigen, detected 
using the HIT-like monoclonal antibody KKO47, were present almost immediately on 
widefield microscopy, and the involved area expanded over the ensuing 3 minutes (Figure 
3.1, A and B, respectively). This result demonstrates that hPF4 released from hPF4+ 
platelets as a result of thrombus formation accumulates locally in the form of PF4-
containing complexes that can be recognized by HIT antibody prior to the development of 
HIT. 
We had reported that high doses of heparin attenuated the severity of 
thrombocytopenia in hPF4+/ FcRIIA + mice 88. We postulated that this occurred because 
heparin can dissociate antigenic complexes from platelet surfaces at these 
concentrations88, given its higher affinity for hPF4 than for surface GAGs110. In turn, this 
generates the circulating hPF4-heparin complexes needed to induce an immune 
response110,111. Therefore, we asked whether infusing unfractionated or low-molecular-
weight heparin into hPF4+ mice would mobilize prebound PF4 and decrease retention of 
the HIT antigen at the site of thrombus formation. Binding of KKO to the site of thrombus 
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formation decreased proportionally with the dose of either unfractionated heparin (Figure 
3.1C) or low-molecular-weight heparin (Figure 3.2) infused into hPF4+ mice. Importantly, 
however, even when mice were given 1,000 U/kg unfractionated heparin – a dose 
approximately 10-fold higher than therapeutic doses 112 – about 25% of the HIT antigen 
remained, suggesting that the vasculature continues to be a potential target for immune 
injury. Also of note, mice that did not receive heparin had the highest level of local HIT 
antigenicity, with an approximate 2-fold increase in HIT antigen compared with mice 
receiving a dose in the range normally given clinically (100 U/kg)113. 
 
Study of the prothrombotic state in a murine HIT model.  
We have previously shown that infusion of KKO or HIT-associated IgG (HIT-IgG) 
induces thrombocytopenia and a prothrombotic state in hPF4+/ FcRIIA + mice50,56,88. We 
recapitulated the prothrombotic state in the cremaster arteriole laser injury model. Injection 
of KKO into hPF4+/FcRIIA+ mice enhanced platelet and fibrin accumulation in 
hPF4+/FcRIIA+ mice, but not in hPF4+ mice or in hPF4+/FcRIIA+ mice exposed to the 
isotype control monoclonal antibody TRA47 (Figure 3.3A).  
Patients with HIT may be predisposed to develop thrombi at sites where vessels 
have been injured by catheters83. To simulate this sequence in the cremaster model, we 
induced a thrombus in hPF4+/FcRIIA + mice, followed 5 minutes later by infusion of KKO 
or HIT-IgG. Preexisting thrombi expanded in mice given KKO or HIT-IgG, but not control 
antibodies (Figure 3.3B). These data may underestimate the severity of the prothrombotic 
state because virtually all the vessels became occluded, limiting further thrombus 
expansion (Table 3.1). Neither TRA nor normal IgG control infusions led to renewed 
growth of thrombi or vascular occlusion (Figure 3.3B and Table 3.1). Of note, thrombus 
regrowth began immediately after KKO was infused, and accelerated with time, 
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demonstrating that a preexisting thrombus provides a potent nidus for expansion, leading 
to vascular occlusion in the setting of HIT antibodies.  
 
Analysis of thrombus development in HIT by confocal microscopy.  
To begin to understand why thrombus regrowth was enhanced in HIT, we used 
confocal microscopy to examine the initial steps in thrombus formation following laser-
induced arteriole injury in animals preinfused with KKO. Remarkably, the predominant site 
of KKO binding was the endothelium underlying and surrounding the thrombus, extending 
both upstream and downstream from the site of thrombosis (Figure 3.4A). The upstream 
binding appeared to be related to turbulent blood flow in this area. By 5 minutes after 
injury, KKO began to appear on platelets within the clot, which intensified over time at the 
boundary between the tightly packed core and surrounding looser shell of the thrombus99 
(enlarged image in Figure 3.4A and Figure 3.4B). We posit that this hemispheric zone of 
antigen was formed by the slow spread of α-granule release outward within the core until 
reaching the core-shell interface99. Our studies suggest that more loosely bound platelets 
on the surface of the thrombus or caught in turbulent flow around the thrombus may make 
a more immediate and more significant contribution to the detectable PF4 in the thrombus. 
Moreover, the PF4 released from surface-bound platelets probably adheres better to the 
peri-injury endothelium, with its glycocalyx, which is rich in high-affinity heparan sulfate 
and dermatan sulfate96, rather than to the platelets within the thrombus that express 
chondroitin sulfate on the surface, which has lower affinity for heparin114,115. The platelet-
bound PF4 is likely swept downstream. The overlap of injured endothelium and KKO 
binding for annexin V is shown in Figure 3.4B and for FXa in Figure 3.5 
Infusion of KKO prior to laser injury in hPF4+/ FcRIIA + mice further increased the 
size of the platelet-rich clot, and the total amount of HIT antigen in the perithrombus 
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endothelium increased by approximately 3-fold compared with that detected in controls 
(Figure 3.4C). We observed similar increases in binding of annexin V and FXa to the 
perithrombus endothelium, suggesting that HIT antibodies exacerbated endothelial injury 
that could potentially cause a feed-forward cycle involving PF4-antigen formation, 
antibody binding, new injured endothelium, and spreading thrombosis. 
 
Microfluidic studies of thrombosis in HIT.  
The in situ cremaster laser injury model enabled us to study the details of thrombus 
formation. However, the model is not fully humanized, and it is difficult to deduce the 
separate contributions from individual cellular components. To examine the role of the 
endothelium in HIT in a fully humanized context, we utilized the endothelialized 
microfluidic set up described in Chapter 2. In these studies, we utilized the microfluidic 
model with the hematoporphyrin injury to induce an upstream localized injury during the 
perfusion of human blood containing hematoporphyrin (Figure 3.6A). As described in 
Chapter 2 and expanded on here, platelets adhered to the injured part of the channel, but 
not downstream (Figure 3.6B). Released PF4 was found surrounding platelet clumps and 
along the endothelium within the injured area. A decreasing gradient of PF4 binding to 
“uninjured” endothelium downstream of the injury was also in evidence (Figure 3.6, B–D). 
PF4 did not escape between injured ECs to the abluminal surface (Figure 3.6D), a finding 
that was consistent with retention of cell-cell contact.  
HIT was induced by adding KKO and hematoporphyrin to infused human whole 
blood prior to photochemical injury. KKO induced a significant increase in platelet 
adherence to HUVECs in the injured area compared with that observed with TRA (Figure 
3.7A) and had a similar effect on similarly prepared adult human aortic endothelium 
(Figure 3.8). Downstream of the injury, no difference was noted between KKO and TRA 
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exposure in the uninjured endothelium (Figure 3.7B). KKO also caused an increase of 
approximately 7-fold in PF4 binding to the injured endothelium compared with binding to 
the uninjured area, which was accompanied by an increase of approximately 16-fold in 
KKO binding to the injured endothelium compared with uninjured endothelium (Figure 
3.7C). The injured endothelium showed an increase of approximately 50-fold in P-selectin 
surface expression (P < 0.0001, Figure 3.7D) and a decrease of approximately 55% in 
glycocalyx staining by lectin compared with uninjured endothelium (P < 0.01, Figure 
3.7D). Thus, the increase in binding of PF4 to the endothelium correlated with the loss of 
glycocalyx and its associated GAGs, as had been seen following other EC injuries17,116. 
Consistent with the results obtained with infusion of KKO, infusion of HIT-associated IgG 
(300 μg/ml) along with whole blood led to occlusion of 6 of the 6 channels studied 
compared with 1 of 6 channels exposed to control IgG (P= 0.02, Table 3.1). 
 
Discussion 
HIT differs from other antibody-mediated thrombocytopenias by its propensity for 
significant thromboembolism82,117. We have attributed the prothrombotic state to the 
concurrent activation of multiple cell types by immune complexes. Platelets are dually 
activated by immune complexes through FcRIIA91 and by monocyte-generated 
thrombin108; however, to date, the proposed involvement of the endothelium is based 
entirely on in vitro findings using cultured cells. 
To better understand the prothrombotic nature of HIT in Steps 2 and 3 of the 
proposed pathogenic pathway, we performed video examination of thrombus formation in 
HIT both in vivo and in vitro. These in vivo cremaster studies involved laser-induced 
thrombi rather than spontaneous thrombi, but they allowed a detailed temporal analysis of 
events. We anticipate that the results of future similar studies of spontaneous thrombi in 
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HIT mice would be consistent with our findings. Our in vivo studies showed that released 
PF4 was associated with formation of the HIT antigen, as identified using KKO and by the 
binding of HIT-IgG to every thrombus. Infused heparin stripped this bound and antigenic 
PF4 away from the thrombus, decreasing surface antigenic complexes. These findings 
suggest that the pathogenic contribution of heparin to the development of HIT is solely the 
presentation of antigenic sites on PF4 to immunogenic cells and not enhancing the 
targeting of HIT antibodies onto thrombi. Indeed, stopping heparin may pose an increased 
risk of thrombosis that must be countered by instituting alternative anticoagulants118. 
Our in vivo findings also showed that soon after laser injury and thrombus 
formation, PF4 was localized predominantly on ECs underlying and in the immediate 
vicinity of the clot. It is likely that endothelium-bound PF4 originated from transiently 
adherent platelets within the thrombus “shell”99 or by platelets that had undergone 
activation within areas of turbulent blood flow. Only minutes later did PF4 begin to appear 
at the core-shell interface within the platelet-rich thrombus as a result of spreading 
degranulation, consistent with the appearance of surface P-selectin described by several 
groups98,99,119 and perhaps due to less flow-induced dissociation within the core and 
transition zone within the shell of the clot99. Our studies suggest that most α-granule 
proteins are released from outer layers or the exterior of the thrombus by transiently 
adherent platelets. Proteins that do not have a high affinity for surrounding cell surfaces 
are probably rapidly washed away, while those like PF4 may adhere to cells within or 
surrounding the thrombus. 
The studies in this chapter support a scenario describing the pathogenesis of HIT, 
in which binding of PF4 leads to the formation of immune complexes on the endothelium, 
which may enhance platelet adhesion, enhance thrombin generation, and cause the 
release of additional PF4, which would sensitize the downstream endothelium and lead to 
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a feed-forward pathway that propagates thrombosis. This role would implicate ECs as a 
key contributor to both Steps 2 and 3 in the pathogenesis of HIT (Figure 1.5), which has 
not been previously suggested. Such a phenomenon could contribute to the vessel 
occlusion we observed in the HIT cremaster arteriole model (Figure 3.3B) and, as 
observed by others, to the presence of platelet-rich thrombi, resulting in the alternative 
name for this disorder of “white clot syndrome”65. Whether these extended clots are related 
to a recruitment of undamaged endothelium in HIT needs to be examined. If this model is 
correct, it will be important to identify as potential therapeutic targets the biophysical and 
biochemical changes in the endothelium that promote antigen and antibody binding. 
Moreover, these studies suggest that EC–targeted anti-inflammatory and antithrombotic 
drugs120,121 might provide a rational intervention focused on the primary vortex of 
prothrombotic reactions that lead to thrombotic vascular occlusion.  
The microfluidic photochemical injury studies, while involving a more diffuse 
vascular injury than did the cremaster injuries, support the conclusion that the endothelium 
is a predominant initial harbor for PF4 released from activated platelets and a target for 
HIT antibodies. While PF4 and KKO bind directly to platelets88, monocytes50, and 
neutrophils122, we found that binding was more intense on injured ECs. This is surprising, 
given that the glycocalyx is highly enriched for negatively charged side chains on its 
constituent proteoglycans, syndecans, and glypicans96. These are candidate receptors for 
binding PF4, and one would have expected that with their loss, PF4 binding would have 
decreased. The loss of the glycocalyx involves multiple glycosidases or sheddases123. We 
posited that the enhanced binding to injured glycocalyx may be due to the unveiling of a 
novel high-affinity binding site in the glycocalyx or the release of novel binding molecules 
from the injured endothelium that then reside in the remaining glycocalyx. Surprisingly, 
when we began these studies for a specific PF4-binding target in the next chapter, we 
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discovered that it was VWF that was a prime target and this novel finding serves as the 
central focus of this thesis.  
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Figure 3.1. Widefield cremaster laser injury in a non-HIT hPF4+ murine model: In 
situ studies of hPF4 and HIT antigen distribution in thrombi. 
(A) Representative widefield study of more than 10 cremaster laser injuries in hPF4+ 
mice, with time 0 indicating the onset of injury. Images from a video of a laser injury; 
platelets are indicated in red, hPF4 is indicated in green, and the direction of blood flow 
in the vessel is denoted by blue arrows. Graph shows the accumulation of platelets and 
hPF4 over the study in relative value units (RVU) compared with time 0. (B) Same as in 
(A), but with green showing binding of KKO to indicate the appearance of the HIT 
antigen. (C) Representative images from an experimental video beginning 5 minutes 
after injury, the point at which 103 U/kg heparin was infused intravenously (IV). Platelets 
are indicated in red and KKO binding in green. The graph indicates that various doses 
of heparin were infused beginning 5 minutes after the cremaster injury. Percent mean ± 
1 SEM for binding of KKO after heparin relative to the 5-minute time point is shown. The 
C 
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dashed line represents no change in KKO binding after heparin infusion compared with 
the 5-minute heparin time point. Original magnification, ×60.   
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Figure 3.2. Effect of low molecular weight heparin on KKO binding to a thrombus. 
Effect of various doses of low molecular weight heparin infused beginning 5 minutes 
after the cremaster injury. Mean ± 1 SEM for binding of KKO after low molecular weight 
heparin was infused relative to the 5-minute time point is shown. The dashed line 
indicates the value of KKO binding if there were no change in KKO binding after heparin 
infusion compared to the 5-minute heparin time point.  
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Figure 3.3. Widefield in situ studies of the prothrombotic state in a murine HIT 
model. 
(A) Widefield cremaster arteriole laser injuries were performed in hPF4+/FcRIIA+ and 
hPF4+ mice infused with KKO or control TRA prior to injury. Platelet accumulation is 
shown on the left and fibrin on the right. Six mice from each arm were studied, and each 
mouse had five to six injuries. The AUC was calculated for each injury, then compared 
B 
A 
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between groups by a 2-tailed Mann-Whitney U test. Data represent the mean ± 1 SEM. 
*P < 0.05 comparing hPF4+/FcRIIA+ plus KKO versus either other group. (B) An 
experiment similar to the one depicted in (A), but the injury was performed at time 0, 
and KKO (1 μg/g, IV) was infused 5 minutes later. Images are from an experimental 
video, in which platelets (red) were incorporated into a thrombus 0-4 minutes before or 
5-15 minutes after the infusion of KKO. Blue arrows indicate the direction of blood flow 
in the arteriole; black arrow denotes the growing platelet thrombus. Graph shows the 
mean values for platelet incorporation into thrombi, with a break in the data just before 
5 minutes, when antibodies were infused (vertical arrow). Three injuries were studied in 
each arm. Original magnification, ×60. Ctl, control. 
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Figure 3.4 Confocal microscopic studies of a growing thrombus in HIT showing 
perithrombotic events.  
(A) Confocal microscopic images showing events in a representative cremaster arteriole 
injury in an hPF4+/FcRIIA+ mouse infused with KKO. Platelets are shown in red. KKO 
binding is shown in green. Images on the left are from a real time experimental video 
A 
B 
C
=
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and include blue arrows showing the direction of blood flow. The image in the middle is 
an enlargement of the 5-minute time point, clearly showing a yellow semi-circle at the 
interface between the core and shell of the growing thrombus just becoming visible at 4 
minutes. Images on the right show 3 different views of a 3-D reconstruction of a 
thrombus, with the yellow arrow indicating the direction of blood flow. The dashed white 
circle indicates the outline of the vessel. (B) Confocal microscopic images, as in (A), of 
another thrombus showing platelet accumulation (red) and binding of KKO (green) as 
well as staining with annexin V shown in purple as an indication of endothelial injury 
(50) and overlap with KKO binding shown in white. (C) Mice were preinfused with either 
KKO or TRA prior to creation of a thrombus. Binding of platelets, KKO, annexin V, and 
FXa to sites of vascular injury is shown. Data from the individual studies are shown as 
well as the mean ± 1 SEM (wide and narrow horizontal lines, respectively). The number 
of injuries studied for each parameter is indicated. *P < 0.001 and **P < 0.0001, by 2-
way ANOVA. Original magnification, ×60.  
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Figure 3.5. Overlap in binding of KKO and FXa as an indicator of activated 
endothelium at the site of thrombosis. 
(A) and (B) are confocal images of a representative cremaster laser injury thrombus in a 
HIT mouse done as in Figure 3.4. (A) is the reconstructed image shown from the top/front 
with KKO binding in green (top left image), FXa binding in white (top right), accumulated 
platelets in red (bottom left) and a merged image (bottom right). The direction of blood 
A 
B 
A 
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flow is indicated by the arrows in the KKO alone image as is the magnification. A dotted 
white outline of the vessel is also included in this image for better visualization. (B) is a 
more lateral single cut through the same thrombus as in (A), further showing that the KKO 
binding and FXa binding are at the base of the clot and overlap with directional arrows 
and magnification in the top left image.  
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Figure 3.6. Studies of endothelialized microfluidic channel after photochemical 
injury. 
(A) Schematic of microfluidic chamber with whole blood containing hematoporphyrin 
flowing into an EC–lined channel, with a light source to injure the endothelium. (B) 
Adhesion of platelets (red, top) and PF4 (white, bottom) at the junction between the injured 
and uninjured area from a representative study with infused blood, as in (A). (C) and (D) 
Confocal images of the injured endothelium. (C) Top-down image of adherent platelets 
and released PF4 in the photochemically injured area. (D) Same image as in (C), in a 
sagittal view. Original magnification, ×10 (B) and ×40 (C) and (D).  
A B 
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Figure 3.7. Studies of HIT in the endothelialized microfluidic channel photochemical 
injury system. 
(A) Platelet accumulation along HUVECs after photochemical injury perfused for 15 
minutes with whole human blood containing either KKO or TRA. Data represent the mean 
± 1 SEM. *P < 0.0001, for KKO versus TRA exposure by 2-tailed Student t test. (B) Images 
demonstrate platelets bound to representative fields of photochemically injured and 
uninjured areas of the channels shown in (A) from whole blood containing TRA or KKO. 
(C) Images of representative uninjured and injured areas and graphs of overall 
comparative measurements showing enhanced binding in injured versus uninjured areas 
of PF4 (white) and KKO binding (green) after infusion of whole blood, as in (A). The mean 
relative binding for injured versus uninjured endothelium ± 1 SEM is shown. *P < 0.01 and 
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**P < 0.001, by 2-sided Student’s t test for injured versus uninjured areas, with an 
expectation of 1 and no change in binding (dashed line). (D) Same as in (C), except for P-
selectin staining (yellow) and lectin binding (yellow) in injured endothelium versus the 
downstream uninjured area. Lectin staining of the endothelium was decreased after injury. 
Original magnification, ×20. 
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Figure 3.8. Thrombus growth during photochemical injury in the presence of KKO.  
Similar studies as in Figure 5A, but microfluidic chamber coated with adult human aortic 
ECs. Platelet accumulation along endothelium after photochemical injury perfused with 
whole human blood containing either KKO or TRA for 10 minutes. Mean ± 1 SEM are 
shown.*P<0.01.  
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Tables 
 
Table 3.1. Secondary growth of thrombi in hPF4+/FcRIIA+ mice leading to an 
occluded vessel. 
Cremaster arterioles were injured by laser, and the accumulation of platelets was 
assessed. Five minutes later, KKO or TRA or HIT IgG was infused IV at the indicated 
dose, and the site of injury was observed. The number of injured and occluded vessels 
with cessation of blood flow is indicated. ^P < 0.0001, comparing the outcome after KKO 
versus TRA by 2-tailed Fisher’s exact test. BP < 0.001, comparing the outcome after HIT 
IgG versus control IgG by 2-tailed Fisher’s exact test. 
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CHAPTER 4 – Platelet factor 4 and von Willebrand factor form an immunogenic, 
prothrombotic complex in heparin-induced thrombocytopenia 
 
This chapter presents work featured in the article to be submitted: 
Johnston, et al., (2018).  
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Abstract  
HIT is a prothrombotic, thrombocytopenic disorder that occurs in patients exposed 
to heparin due to the development of antibodies directed against complexes of PF4 and 
heparin and other polymeric molecules. We have recently shown that the perithrombus 
endothelium is especially targeted in HIT. Using a photochemical injury, endothelialized 
microfluidic system, we now show that PF4 selectively binds to released VWF strands on 
injured endothelium. This binding appears to be periodic along the VWF strand and to 
favor larger VWF strands, raising the possibility that binding of PF4 crosslinks VWF 
polymers. KKO and HIT patient plasma recognize these complexes,  forming PF4-VWF-
HIT antibody complexes, which, in turn, avidly bind platelets, exacerbating thrombus 
growth in a human whole blood microfluidic system. This increase in platelet binding can 
be attenuated by that blocking either the platelet FcγRIIa or the GPIb/IX receptor. HIT 
antibodies may stabilize PF4-VWF complexes but charge-based approaches as well as 
drugs that disrupt VWF oligomerization can disrupt PF4-VWF-HIT complexes. In vitro 
studies using dynamic light scattering further support the formation of PF4-VWF 
complexes. Strategies directed at blocking formation PF4-VWF complexes reduce the 
prothrombotic state in a passive immunization murine model of HIT. Thus, these studies 
identify VWF as a newly described and potentially important polymer on which HIT 
antigenic complexes form and propagate the risk of thrombosis in HIT even when heparin 
has been discontinued (Step 3). The PF4-VWF complexes contribute to the prothrombotic 
nature of HIT and may provide a new therapeutic target.  
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Introduction 
HIT is initiated by antibodies targeted to complexes of PF4 and heparin48. HIT 
antibodies, through activation of various cell types such as platelets88, monocytes50, and 
ECs43,93–95 promote the limb and life-threatening pro-thrombotic environment experienced 
by HIT patients. Although initiated with heparin, other polymeric molecules are capable of 
binding PF4 and then being recognized by HIT antibodies, including cell surface GAGs88, 
DNA124, polyphosphates53, and bacterial wall components125. Notwithstanding the recent 
identification of these additional potentially antigenic sites, a more complete 
understanding of their contribution to thrombosis is needed to develop alternative 
treatments options for patients with or at risk for HIT41,118. 
The endothelium has been recognized to bind PF4 and become activated in the 
presence of HIT antibodies over thirty years ago94. We recently showed that both in vitro 
in an endothelialized microfluidic chamber and in vivo in HIT cremaster laser injury studies 
in a murine HIT model that HIT-like antibodies predominantly bound to peri-thrombotic 
endothelium that had undergone vascular injury43. When injured, the endothelium retracts 
or denudes and exposes collagen within the basal membrane52,126–128. The endothelium 
also exhibits changes to its glycocalyx, including a decrease in its thickness that may 
enhance access to proteins on the endothelial luminal surface14–17. Injured, activated 
endothelium also may express a diverse range of new or activated receptors and ligands, 
and procoagulant factors such as TF and P-selectin on their vascular luminal 
surface7,34,100,129–131.  
In this study, we focus on binding of PF4 to VWF, which are, in part, stored within 
Weibel-Palade bodies in resting endothelial cells and which are released following EC 
activation or injury40,72,132. Initial studies focused on our previously described 
endothelialized microfluidic model wherein we induced a localized photochemical injury 
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using hematoporphyrin69,70. Prior studies have shown that these injured endothelial cells 
release VWF as elongated strands under the influence of shear induced by flow43. We 
now find that these VWF strands bind PF4 and subsequently HIT antibodies. We show 
that in this model, platelets bind to these PF4-VWF-HIT antibody complexes and that this 
binding could be reduced by the FcRIIA-blocking antibody IV.388,122,133 as well as the 
GPIb-blocking antibody AK236,134,135. In vitro studies using dynamic light scattering 
confirms the formation of PF4-VWF complexes. In a passive immunization murine model 
of HIT, photochemical injury to the carotid affirms the development of PF4-VWF-HIT 
antibody complexes and their contribution to thrombosis. These studies provide new 
insights into the prothrombotic pathways activated in HIT and extend the number of 
pathobiological polymeric molecules that can contribute to Step 3 in the propagation of 
thrombi in HIT. The clinical implications of these findings are discussed. 
 
Methods 
Human blood samples. 
Deidentified samples of whole blood from healthy human volunteers with no history 
of a bleeding diathesis or known use of medications with anticoagulant effects was drawn 
by gravity through 19-gauge butterfly needles into sodium citrate (0.38% final 
concentration, ThermoFisher Scientific). Blood samples were maintained at room 
temperature and used within 1 hour of being drawn. Deidentified plasma samples were 
also obtained from patients determined to have HIT based on a combination of clinical 
assessment, HIT ELISA positivity, and positive serotonin-release assay (SRA) as 
described previously44,104,105. Similar samples from patients with low probability of HIT 
based on history and negative ELISA and SRA results were used as negative controls. 
Deidentified HUVEC (referred to ECs) were purchased (Lonza). Human blood samples 
66 
were collected after signed, informed consent from healthy donors. Approval for these 
studies was obtained from the CHOP Institutional Human Review Board in accord with the 
Helsinki Principles. 
 
Mice and mouse blood samples.  
Wildtype C57Bl6 mice and transgenic mice on a Cxcr4 gene knockout 
background103, were studied. These double-transgenic mice, previously termed “HIT 
mice”, develop thrombocytopenia and a prothrombotic state when injected with the HIT-
like antibody murine monoclonal antibody KKO or IgG isolated from patients with HIT in a 
passive immunization model of HIT56,88. 
 
Recombinant proteins and antibodies. 
Recombinant hPF4 was isolated from S2 cell media using the Drosophila 
Expression System (Invitrogen), purified, and characterized as described47,136. Final 
protein concentrations were determined using the bicinchoninic acid protein assay 
(Pierce) using bovine serum albumin (BSA) as the standard. KKO, the mouse anti-hPF4-
heparin HIT-like monoclonal antibody, and TRA, a monoclonal IgG isotype control 
antibody, were purified from hybridoma supernatants47. Antibodies used in these studies 
also included a polyclonal rabbit anti-hPF4 antibody (Abcam), a polyclonal rabbit anti-
human VWF (hVWF) antibody (DAKO) or a FITC-prelabeled polyclonal sheep anti-hVWF 
antibody (Abcam). Bound HIT-patient IgG was detected using a rabbit polyclonal, anti-
human IgG antibody (Jackson Immuno Research Laboratories). All antibodies were either 
labeled using Alexa Fluor antibody-labeling kits (ThermoFisher Scientific) or were 
detected using species-appropriate Alexa Fluor-conjugated secondary antibodies (all from 
ThermoFisher Scientific). The FcRIIA-blocking monoclonal antibody IV.388,122,133 was 
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produced in hybridoma cells and purified on Protein G (Invitrogen). The mouse anti-human 
CD42b monoclonal antibody AK2 was purchased from Biorad. 
 
Endothelialized microfluidic setting. 
Endothelialized microfluidic studies were performed as we described previously43 
and in Chapter 2. Briefly, studies were performed using the Bioflux 1000 Controller system 
with an attached 37°C heating stage. The microscope was equipped with a motorized 
stage and an HXP 120 C metal halide illumination source. 48-well Bioflux plates were 
coated with fibronectin (50 µg/ml, Sigma-Aldrich), seeded with HUVECs (passage 3-4, 6-
8 x 106 cells) that were allowed to adhere and cultured at 37°C under 5% CO2 in EC growth 
media (Lonza; basal culture medium (BCM) bovine brain extract with heparin, human 
endothelial growth factor, hydrocortisone, ascorbic acid, gentamicin, amphotericin B, fetal 
bovine serum) until confluent. To induce a photochemical injury, hematoporphyrin (50 
µg/ml final concentration, Sigma-Aldrich) was added to samples and exposed to a blue 
light using the HXP-120 C light source with a 475-nm excitation and 530-nm emission filter 
for 20-30 seconds during perfusion causing a reactive oxygen species injury43,70. PF4 and 
VWF were detected using Alexa Fluor-labeled antibodies. Endothelial cell nuclei were 
labeled with Hoescht 33342 (ThermoFisher Scientific) for 15 minutes at room temperature. 
On the day of experimentation, BCM (described above) was flowed over the channels for 
3-4 hours prior to the experiment. All imaging was performed on a Zeiss Axio Observer 
Z1 inverted microscope or a Zeiss LSM 710 laser scanning confocal microscope as 
described43. Data was analyzed using Imagej or, for confocal images, using Volocity 6.3. 
Colocalization of fluorescent signals was analyzed using a built-in function of Volocity 6.3 
providing Coste’s colocalization coefficients. 
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Analysis of PF4-VWF-HIT antibody complexes. 
All experimental solutions were made in BCM. A localized photochemical injury 
was induced using hematoporphyrin and then the channels were washed with BCM and 
then infused with hPF4 (0-25 µg/ml) in BCM for 10 minutes. In some experiments, at the 
10-minute mark, KKO or TRA (each at 10 µg/ml) or plasma from HIT patients (1:100 
dilution) or a polyclonal rabbit anti-hPF4 antibody (at 2 µg/ml final concentration, 
PeproTech) was added to the PF4 solution and allowed to flow continuously for an 
additional 10 minutes. After a total flow time of 20 minutes, channels were briefly washed 
with BCM, and then fixed for 15 minutes at room temperature with Cytofix Fixation Buffer 
(BD).  
Experiments were performed to determine if PF4 bound primarily to VWF released 
from injured ECs or to plasma VWF. Once VWF-PF4-KKO complexes were formed, a 
BCM solution containing BSA (equimolar to 10 µg/ml of VWF, Sigma-Aldrich) or purified 
human VWF (10 µg/ml final concentration, Haematologic Technologies, Inc.), was flowed 
through the channels. Channels were fixed, labeled for VWF, PF4, and KKO, and binding 
was quantified via confocal imaging to determine how the protein solutions flowed through 
the channels affected formation of VWF-PF4-KKO complexes.  
To examine the effects of drugs known to cleave strands of VWF or drugs known 
to strip PF4 from vascular surfaces, channels with formed PF4-VWF-HIT antibody 
complexes were exposed to various interventions; channels were flowed at 10 dynes/cm2 
for 10 minutes with therapeutics including unfractionated porcine heparin (0-50 units/ml 
final concentration, Novaplus), ADAMTS13 (0-7 nM, R&D Systems), and N-acetylcysteine 
(NAC, 0-10 mg/ml final concentration, Auromedics). In some experiments, heparin (0-0.4 
units/ml) was added to a PF4 (25 µg/ml) and KKO (10 µg/ml)-containing solution and then 
introduced to channels containing PF4-VWF-HIT antibody complexes. After the 10-minute 
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infusion, channels were washed with BCM, fixed with Cytofix Fixation Buffer (BD 
Biosciences), and imaged to observe the presence of PF4, KKO, and/or large VWF 
strands.  
 
Platelet accumulation on PF4-VWF-HIT antibody complexes. 
To track platelet accumulation by PF4-VWF-HIT antibody complexes, whole blood 
from healthy volunteers was collected and labeled with calcein AM (2 µg/ml final 
concentration, ThermoFisher Scientific) at room temperature for 15 minutes. Whole blood 
was recalcified immediately before infusion using 2M CaCl2 (final concentration of 12 mM, 
Sigma-Aldrich), and flowed through the channels at 10 dynes/cm2. Platelet accumulation 
was quantified via total fluorescent intensity within the localized injury area. To test the 
impact of blocking specific receptor/ligands on platelet accumulation on PF4-VWF-HIT 
antibody complexes, IV.388,122,133 (20 µg/ml) and/or AK236,39,135 (60 µg/ml) were added to 
whole blood and allowed to incubated for 30 minutes prior to running the experiment.  
 
Biophysical interaction between VWF and PF4. 
To further examine the physical interaction between VWF and PF4, we utilize 
dynamic light scattering (DLS) analysis. Sample solutions are prepared and allowed to 
mix at room temperature for 15-20 minutes. Samples (500 µL) are then transferred to zeta 
disposable cuvettes (Fisherbrand) and measured in a Zetasizer Nano ZS (Malvern). In 
these experiments, solutions containing hPF4 (10 µg/ml) alone, hVWF alone (0-10 µg/ml), 
and solutions containing hPF4 (10 µg/ml) with various concentrations of hVWF (0-10 
µg/ml) were studied. The size distribution of the resultant soluble particles was measured 
as described previously53,110. 
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Role of VWF in thrombosis in HIT in vivo. 
Thrombosis was induced using a previously described murine model of HIT56,88 by 
infusing KKO following rose bengal photochemical injury to the carotid artery25,50. HIT mice 
were anesthetized using nembutal (80 mg/kg, CHOP animal facilities). Using standard 
surgical methods, the left jugular vein was exposed and mice were infused with either TRA 
(2 mg/kg), KKO (2 mg/kg), or KKO (2 mg/kg) + NAC (0.8 mg/g, Auromedic Pharma) in a 
PBS (220 µL total volume). The injected materials were allowed to circulate for 10-15 
minutes during which time the right common carotid artery was surgically exposed. Rose 
Bengal (50 mg/kg, Sigma-Aldrich) was then infused and a miniature Doppler flow probe 
(Model 0.5VB; Transonic Systems) was positioned around the artery. After 5 minutes of 
measuring flow to assure sufficient signal, a green laser (540 nm) was targeted to the 
carotid artery to induce an occlusive thrombus. Using the data points from Doppler flow 
probe, we evaluated the time to occlusion (blood flow <10% of original and stable for 10 
minutes), and the relative area under the curve (AUC) as measure of clot mass. When 
clots were formed and stable for greater than 10 minutes, measurements were stopped 
and mice euthanized; if vessel occlusion did not occur, experiments were ceased at a 2-
hour time point. When mice were euthanized prior to the 2-hour time point, the final flow 
measurements were extrapolated to estimate AUC.  
 
Statistics. 
Differences between 2 groups were compared using a 2-sided Student’s t-test. 
Differences between more than 2 groups were determined by 1-way ANOVA. All analyses 
were performed on GraphPad Prism 6.0 (GraphPad Software). Differences were 
considered significant when the P values were less than or equal to 0.05. 
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Results 
PF4 binds to elongated strands of VWF released from injured endothelial cells in a 
microfluidic system. 
We described how PF4 released from activated platelets bound predominantly to 
peri-injured endothelium in both the endothelialized microfluidic and in an vivo murine 
model of HIT43 in Chapter 3; however, the target(s) to which the PF4 bound and 
subsequently HIT-like antibodies bound, was not identified. To begin to explore the 
potential PF4-binding sites on injured endothelium, we utilized the hematoporphyrin injury 
model in a HUVEC endothelialized microfluidic model. This model enables us to explore 
a human endothelial surface, to control the composition of the thrombus, and to contrast 
binding to injured and adjacent uninjured endothelium (Figure 4.1A). As previously 
described, this photochemical injury model does not cause the endothelium to detach or 
to lose cell-cell contact43. VWF was clearly released within the injured zone (Figure 4.1B). 
Post-injury, solutions containing recombinant hPF4 were flowed across channels. The 
most extensive binding of hPF4 was restricted to the injured area, less so in the immediate 
downstream region, and was at near-background levels further downstream (Figures 
4.1C and 4.1D). Binding of PF4 within these regions typically followed a linear pattern, 
remarkably similar to the pattern of VWF following release from endothelial cells. 
Therefore, we asked whether the PF4 was indeed binding to the released VWF. Co-
staining for VWF and PF4 showed significant (P=0.02) co-incidental binding as seen in 
enlarged images (Figure 4.2A). PF4 bound preferentially to the most elongated strands 
of VWF (Figure 4.2B and 4.2C).  
 
A HIT-like monoclonal antibody and HIT patient IgGs bind PF4-VWF complexes in vitro. 
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PF4 binds to polymeric molecules other than heparin, including various 
glycoasminoglycans (GAGs)47, DNA and RNA aptamers124, and polyphosphates53. All of 
these complexes are also antigenic for HIT-like antibodies, at least in vitro. Binding of PF4 
to heparin leads to the formation of high molecular weight oligomers that increase antibody 
avidity47,137. To determine if PF4-VWF complexes are antigenic for HIT-like antibodies, we 
induced injury in the microfluidic chambers and introduced PF4 and the HIT-like mouse 
monoclonal antibody KKO, known to replicate key features of patient-derived HIT-like 
antibodies47. Binding of KKO followed the same distribution seen with PF4, with both co-
localizing with the strands of VWF strands released by the injured endothelium (Figure 
4.3A). Binding of KKO was localized primarily to the area of endothelial injury and to the 
immediately downstream region (Figure 4.3B). An enlarged image of this field (Figure 
4.4A) shows that the binding of the KKO to the VWF strands follows a periodic pattern 
with little KKO seen in association with smaller VWF deposits. Detailed analysis of co-
localization confirmed that KKO showed significantly more binding to elongated strands of 
VWF (Figure 4.4B and 4.4C). 
We then asked whether plasma from patients with positive clinical histories, 
ELISAs, and SRAs for HIT IgG would also bind to the PF4-VWF complexes. A 
representative field of IgG binding from one HIT patient compared to a control patient with 
low probability of having HIT is shown (Figure 4.3C). Three of 6 samples from patients 
with HIT caused significant binding of IgG to the VWF released from injured endothelium 
in the presence of added PF4 that was not seen with the control patient sample with low 
probability of HIT (Figure 4.3D).  
 
Physical characterization of the PF4-VWF complexes in vitro. 
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We used DLS as an independent method to study the binding of PF4 to VWF. We 
first examined the particle size of PF4 and VWF alone. PF4 followed a Gaussian-size 
distribution (all less than 10 nm), while VWF displayed a more complex size distribution 
consistent with its polymeric nature and tendency to polymerize138 (Figure 4.5A).  
When PF4 was added to VWF (PF4:VWF = 10 µg:5 µg), particles with a single 
narrow range of masses that followed a Gaussian distribution was seen. The mean mass 
of PF4 ~6-fold higher than the of mass PF4 alone, clearly establishing binding between 
the reactants (Figure 4.5B). When more PF4 was added (PF4:VWF = 10 µg:1 µg), the 
mass of the complex increased to ~40-fold higher than PF4 alone. If using masses of PF4 
tetramers and VWF monomers, it can be estimated that the molar ratio in this scenario is 
about 84:1 (PF4:VWF=316 nM:3.84nM). The molar ratio of reactants cannot be more 
definitively estimated, as we do not know the number of VWF monomers present in the 
starting VWF, the number of molecules in an “open” (permissive) conformation (see 
below) or whether PF4 enhances oligomerization of VWF in vitro. However, of possible 
relevance to this issue, at the highest concentration of PF4 studied (PF4:VWF = 10 µg:10 
µg), the apparent mean mass of the PF4-VWF complexes widened with an appearance 
similar to that of VWF alone. One possible interpretation of these data are that over a 
limited molar ratio of reactants, binding of PF4 cause reorganization of VWF multimers, 
consistent with the appearance of extended strands containing PF4-VWF-KKO observed 
in the microfluidic model. At higher concentrations, PF4 may bind to smaller VWF 
multimers, albeit with lower affinity, which are not cross-linked in the process. This 
parabolic outcome recapitulates the growth and disappearance of PF4/heparin complexes 
in solution and PF4/GAG complexes on cell surfaces as the PF4/polyanion ratio 
increases47,53. 
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The appearance of PF4 is predominantly along elongated strands of VWF released 
by activated ECs. Shear stress alters the 3-dimensional conformation of VWF exposing 
its “A” domains138–140. However, we next wanted to determine if PF4 also binds to plasma 
VWF or to other plasma proteins. To test this, we injured the endothelium as describe 
previously and introduced PF4 and KKO to form PF4-VWF-KKO complexes. Then 
channels were exposed to flowing solutions that contain BSA or purified human VWF. 
Purified human VWF was used at plasma concentrations (10 µg/ml) and BSA was used 
an equimolar concentration. PF4 and KKO binding was assessed by confocal microscopy 
to determine if soluble VWF or BSA would remove complexes formed on released VWF 
compared with buffer alone (Figure 4.5C). Heparin, which removes PF4-HIT antibody 
complexes from other vascular surfaces43,141, was used as the positive control. Heparin, 
at 10x therapeutic concentrations (4 U/ml), removed PF4-VWF-HIT antibody complexes 
from the injured endothelium (Figure 4.8A). In contrast, infused BSA had minimal effect 
on PF4 and KKO binding (Figure 4.5D).  Soluble VWF did not elute PF4 and KKO and, in 
some experiments, appeared to increase PF4 and KKO binding. This might be due to 
binding of soluble VWF to unoccupied sites on PF4 and becoming incorporated within pre-
existing EC-VWF strands. VWF self-association has been shown to be homotypic as 
soluble VWF – but not BSA – is known to associate with immobilized VWF under 
flow142,143; moreover, the self-association of VWF has been shown to assemble 
hemostatically active filamentous networks and induce platelet activation under 
shear17,39,144–146. These findings and recent studies suggest that tethered VWF strands 
released from ECs are preferentially form PF4-VWF-KKO complexes that are not removed 
by soluble VWF, which may actually enhance antigen formation.  
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PF4-VWF-HIT antibody complexes are prothrombotic in vitro. 
Do the PF4-VWF-HIT antibody complexes contribute to the prothrombotic state 
seen in HIT? Using the microfluidic system described in Figure 4.1, we show that the 
endothelium needed to be injured to cause platelet accumulation upon infusion of whole 
human blood (Figure 4.6A). Platelet accumulation was greatest when both PF4 and KKO 
are included and coat the VWF strands (Figure 4.6B and 4.6C). Neither KKO alone nor 
PF4 plus the isotype control monoclonal antibody TRA47 enhanced platelet accumulation. 
Platelet accumulation in the presence of PF4- and KKO-coated VWF became more 
pronounced the longer blood was infused into the channels. 
 
We were interested in understanding which components contribute to platelet 
accumulation on VWF strands. Platelets bind to shear-activated VWF via the GPIb/IX 
complex, in a pathway that can be blocked by the anti-GPIb monoclonal antibody AK2. 
The PF4-VWF-KKO complexes could also enhance platelet activation and adherence via 
their FcRIIA, a process that can be blocked by the anti-FcRIIA monoclonal antibody IV.3. 
We demonstrate that both antibodies blocked the enhanced adherence of platelets in 
whole blood to the VWF strands (Figure 4.7A and 4.7B), though by 40 minutes post-
infusion, blocking the GPIb/IX-VWF axis appears to be more effective. AK2 plus IV.3 was 
not more effective than AK2 alone, suggesting the GPIb/IX-VWF axis plays a crucial role 
in supporting the binding of platelets to the PF4-VWF-HIT antibody complex. 
 
Drug interactions with the PF4-VWF-HIT antibody complexes in vitro. 
Patients who develop HIT are often on therapeutic heparin when they develop 
thrombi41,43,44. Heparin binds to PF4 with high affinity. Therapeutic heparin levels range 
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from 0.1-0.4U/ml147. Therefore, we asked whether PF4-VWF-HIT antibody complexes are 
stable and would persist bound to the endothelium at pharmacologic levels of heparin. 
Heparin at ≥0.4 U/ml reduced PF4 and subsequent KKO binding to the VWF released 
from injured endothelium in the microfluidic system within 10 minutes (Figure 4.8A). 
However, during thrombus development, PF4 levels are estimated to exceed 100 µg/ml122 
and are likely to be persistently released from platelets trapped with thrombi as well. To 
recapitulate this setting, we tested the effect of a flowing a solution containing increasing 
PF4 concentrations (0-100 µg/ml) at a fixed pharmacologic concentration of heparin (0.4 
U/ml) as well as HIT antibody. As PF4 levels increased, both bound PF4 and KKO levels 
increased in the presence of heparin, consistent with the known risk of continuing this 
anticoagulant in patients with clinically active HIT (Figure 4.8B).   
Therapeutic strategies to prevent VWF-related pathobiology have included the use 
of the metalloproteinase ADAMTS13 to lyse WVF strands38,148,149 or NAC to prevent their 
assembly69,150. We asked whether PF4 and or HIT antibody would cause resistance to the 
effect of ADAMTS13 or NAC on reducing the number and length of extruded VWF strands 
after endothelial injury in the microfluidic system. PF4 alone did not protect VWF strands 
from digestion by ADAMTS13 (7 nM) when looking at the number of strands present after 
flow. PF4 plus KKO showed a trend towards protection from ADAMTS13 but the effect did 
not reach statistical significance in the 10 minute time frame in which experiments were 
performed (Figure 4.9A and 4.9B). Neither PF4 with nor PF4 plus KKO protected VWF 
from the effects of NAC (Figure 4.9A and 4.9B). There was no significant differences 
between the length of VWF strands after exposure ADAMTS13 or NAC in the presence of 
PF4 or PF4 plus KKO (Figure 4.9A and 4.9C).  
 
The role of VWF in the prothrombotic HIT murine model. 
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The data shown in Figure 4.9 suggest that PF4 and HIT antibody binding do not 
protect released VWF strands and therefore that both VWF-targeted therapeutics have 
the potential to remove PF4-VWF-KKO targets in vivo. However, we could not test this 
hypothesis by imaging intra-thrombi VWF, which show diffuse staining and cannot be used 
to follow the resolution of elongated strands of multimeric VWF151,152. Consequently, we 
used a functional evaluation to assess the effect of NAC on thrombosis in the HIT mouse 
using the rose bengal photochemical carotid arterial injury model50.  We confirmed our 
prior findings in this model and showed that NAC both prolonged the time to full occlusion 
induced by KKO and the relative AUC (Figure 4.10A and 4.10B). Thus, it appears that 
VWF contributes to arterial thrombosis in this model of HIT and suggests the utility of VWF 
targeted therapeutics. 
 
Discussion 
HIT is an unusually prothrombotic disorder that can have devastating 
consequences even with the withdrawal of heparin and the institution of present-day 
anticoagulants41,43,44,67.  While the disease clearly involves the induction of antibodies that 
oligomerize PF4 with heparin and with surface GAGs on the surface of platelets, its 
prothrombotic nature now is clearly recognized to be in part due to the fact that PF4 also 
forms antigenic complexes with GAGs on other cells including monocytes, endothelial 
cells and neutrophils, leading to the induction of prothrombotic processes43,48,50,88,93,95, e.g. 
the elaboration of tissue factor94. More recent finding indicate that additional polyanions 
induced by HIT antibodies can bind PF4 and serve as antigenic targets that promote 
thrombus extension64–67 and propagate the disorder even when heparin has been stopped 
(Step 3) (Figure 1.5). These include polyphosphates released from platelets and perhaps 
endothelial cells53 DNA found in neutrophil extracellular traps (NETs) released by 
78 
activated neutrophils122, which appear to be especially important in the growth of venous 
thrombi. 
We now show that PF4 also forms antigenic complexes with VWF strands released 
from activated endothelial cells, most likely localized primarily to the arterial side of the 
circulation. The PF4 appears to bind periodically along the elongated strands of VWF. 
Binding of HIT antibodies to PF4-VWF complexes along the vasculature likely offer an Fc-
rich surface that permit binding intravascular cells that express FcRIIA, including 
platelets, neutrophils and monocytes47,50 and provide a surface for activating 
complement89. Our result appear initially differ from a prior study showing PF4 did not 
enhance binding of VWF to platelets153 but did not address whether PF4 can bind to VWF 
as examined in our system. This negative result is, however, consistent with what we 
report: PF4 binds selective to large VWF strands that form under flow in preference to 
VWF in solution. Binding of platelets to PF4-VWF strands was markedly enhanced when 
a HIT-like antibody was also present. We propose that PF4-VWF-HIT antibody complexes 
activate platelets through FcRIIA which stabilizes platelet adhesion to the EC-VWF 
strands under flow. (Figure 4.6 and 4.7). 
Of interest, unlike other polymeric molecules like heparin and polyphosphates, 
VWF is not a polyanion. The mechanism by which VWF becomes a binding site for PF4 
will require additional study. We hypothesize that the binding sites within vWF are exposed 
by shear forces which may also enhance their proximity and thereby enhance their avidity 
for PF4. This is similar to what has been postulated for the effect of unfractionated heparin 
compared with low molecular weigh heparins and fondaparinux. 
NAC, which prevents VWF oligomerization150 attenuated carotid arterial occlusion 
induced by HIT antibody. Unfortunately, attempts to directly visualize the released VWF 
and its complex with PF4 and HIT antibodies were unsuccessful because of intense 
79 
diffuse staining which impeded identification of individual VWF strands.  Studies using 
confocal microscopy are in progress in an attempt to circumvent this problem. 
In summary, PF4 binds to VWF strands extruded from injured endothelial cells and 
forms HIT antigenic complexes. Such targets are periodically distributed along the VWF 
strands under flow conditions, but binding to soluble VWF was not observed. These 
complexes bind platelets through a pathway that involves both FcRIIA- and GPIb/IX-
based pathways. We propose that the release of VWF strands expose a high-density 
epitope that fosters binding of PF4 and HIT antibodies and promotes binding and 
activation of platelets, monocytes and neurtrophils through by their surface FcRIIA and/or 
by activating complement. Depolymerization of VWF strands by NAC attenuates 
thrombotic arterial occlusion induced by HIT antibodies in a mouse model. These findings 
suggest that VWF may play a significant role in the propagation of HIT in space and in 
time (Step 3) (Figure 1.5. VWF may thereby play a role on the arterial side of the 
circulation analogous to the effect of NETs in the propagation of venular injuries, which is 
addressed in Chapter 5. Drugs targeting VWF biology may be an effective new approach 
to therapy in HIT, especially for arteriolar thrombi.  
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Figures 
 
 
 
 
Figure 4.1. PF4 binds to elongated strands of VWF released from injured ECs in a 
microfluidic system.  
(A) Schematic of the endothelialized microfluidic system used for photochemical injury 
studies to targeted regions of the endothelium. (B) Comparison of a representative area 
of uninjured endothelium and hematoporphyrin-injured inured area showing pyknotic 
nuclei and released VWF strands that are only seen after injury. (C) and (D) are stained 
for PF4 using a polyclonal anti-PF4 antibody as well as staining for nuclei and released 
D 
C 
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VWF. (C) shows representative microfluidic channel injured and downstream uninjured 
(DU) areas designated as DU #1 of the first 150µ downstream. Direction of flow is 
indicated by arrows. (D) shows relative binding of PF4 to either an area of 250µ X 150µ 
of the upstream uninjured (UU) region, the injured region, or the DU #1 and DU #2 regions. 
Mean ± 1 SEM are shown with N ≥ 3 with n signifying separate microfluidic channels. P 
values were determined using a one-way ANOVA analysis to compare relative binding to 
the uninjured upstream area of the channel. 
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Figure 4.2. PF4 preferentially binds elongated VWF strands over not-elongated. 
(A) Displays an image of Figure 4.1C showing PF4 (magenta) bound to elongated (yellow 
arrows) or not-elongated (green arrows) VWF (cyan) with nuclei stained with Hoescht 
(blue) (B) Enlarged examples of PF4 bound to elongated or not-elongated VWF isolated 
from (A). (C) The relative colocalization of VWF signal to PF4 signal using Coste’s 
colocalization coefficients showing PF4 binds preferentially to elongated VWF compared 
with not-elongated VWF. Mean + 1 SEM are shown with N > 12 with N signifying 
independent VWF strands analyzed.  
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Figure 4.3 A HIT-like monoclonal antibody and HIT patient IgGs bind PF4-VWF 
complexes in vitro. 
(A) Representative injured area and downstream areas in the microfluidic channels as in 
Figure 1C, but staining for VWF and KKO. (B) Comparison as in Figure 1D for total KKO 
bound. Abbreviations are as Figure 1D. Mean ± 1 SEM are shown. N ≥ 3 representing 
separate microfluidic channels. P values were determined by a one-way ANOVA analysis. 
(C) and (D) are similar to (A) and (B) respectively, but showing only the injured areas. In 
(C), diluted plasma from patients at high risk of having HIT or low-risk controls (Ctl) were 
used. In (D), diluted plasma from these individuals was quantified. Mean ± 1 SEM are 
shown. N ≥ 3 separate channels. P values were determined using a one-way ANOVA to 
A 
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B 
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compare relative binding in the absence of PF4 or in the presence of infused PF4 at 25 
µg/ml for each IgG sample.  
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Figure 4.4. KKO preferentially binds elongated VWF strands over not-elongated 
VWF. 
(A) Displays an image of Figure 4.3A showing KKO (red) bound to elongated (yellow 
arrows) or not-elongated (green arrows) VWF (cyan) with nuclei stained with Hoescht 
(blue). (B) Enlarged examples of KKO bound to elongated or not-elongated VWF isolated 
from (A). (C) The relative colocalization of VWF signal to KKO signal using Coste’s 
colocalization coefficients showing KKO binds preferentially to elongated VWF compared 
with not-elongated VWF. Mean ± 1 SEM are shown with N ≥ 12 with N signifying 
independent VWF strands analyzed.  
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Figure 4.5. Physical characterization of the PF4-VWF complexes in vitro. 
(A) Volume readouts from dynamic light scatter analysis looking at PF4 alone (red, 10 
µg/ml) in comparison to VWF alone at varied concentrations (1 µg/ml = black, 5 µg/ml = 
blue, 10 µg/ml = green). (B) Volume readouts from dynamic light scatter analysis 
evaluating PF4 (10 µg/ml) mixed with the various concentrations of VWF (0 µg/ml = red, 
1 µg/ml = magenta, 5 µg/ml = black, 10 µg/ml = blue). Curves are representative of ≥ 4 
separate experiments. (C) Confocal images displaying PF4 (red) and KKO binding (green) 
in channels in which PF4-VWF-HIT antibody complexes were formed and then infused 
with the indicated solution. Original image magnification is x20. (D) Quantification of PF4 
and KKO binding showing the flowing a solution containing BSA or VWF does not reduce 
the binding of PF4-VWF-HIT antibody complexes within the channel. N ≥ 5. 
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Figure 4.6. PF4-VWF-HIT antibody complexes are prothrombotic in vitro. 
(A) Representative fields of uninjured (top) and injured (bottom) endothelium after 
exposure to a flow of recalcified whole human blood for 10 minutes, demonstrating the 
binding of platelets to the VWF strands. The bottom channel displays the edge of injury 
showing platelets and an uninjured area that resembles the appearance of the control 
uninjured channel (top) (B) Same as in (A), but with the inclusion of PF4 (25 µg/ml) and 
the indicated monoclonal antibody (10 µg/ml) and studied at the time points indicated. 
Binding of KKO and of platelets are shown. (C) Mean ± 1 SEM are shown. N ≥ 6 separate 
studies for the relative level of bound platelets (as quantified by calcein AM) compared to 
injured endothelium with added KKO in the absence of PF4. P values were determined 
using a one-way ANOVA analysis. 
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Figure 4.7. Platelet binding to the PF4-VWF-HIT antibody complexes is dependent 
on both the GPIb/IX receptor and FcRIIA.  
(A) As in Figure 4.6B, representative fields showing platelet accumulation on injured 
endothelium after flowing recalcified whole human blood with or without added PF4 and 
KKO and with or without the GPIb/IX-VWF-blocking antibody AK2 or the FcRIIA-blocking 
A 
B 
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antibody IV.3. (B) Mean ± 1 SEM for N ≥ 6 separate studies for the relative level of bound 
platelets compared to injured endothelium with added KKO, but no PF4. Mean ± 1 SEM 
are shown. N ≥ 3 separate studies with N signifying separate channels. P values were 
determined using a one-way ANOVA analysis. 
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Figure 4.8. Heparin disrupts PF4-VWF-HIT antibody complexes but can be combatted 
by elevated levels of PF4. 
(A) Complexes with VWF were formed by flowing PF4 (25 µg/ml) and KKO (10 µg/ml) along 
the damaged vasculature followed by exposing the channel to a heparin (0-40 U/ml) 
containing solution for ten minutes. Means ± SEM are shown with N ≥ 4. P values were 
determined by one-way ANOVA analysis. (B) Studies showing how PF4 (25 µg/ml) and 
KKO (10 µg/ml) binding in PF4-VWf-HIT antibody complexes changed when washed with 
a solution containing heparin (0-0.4 U/ml), PF4 (5-100 µg/ml), and/or KKO (10 µg/ml) for 
ten minutes. 
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Figure 4.9. Drug interactions with the PF4-VWF-HIT antibody complexes in vitro.  (A-
C) are studies of the effects of ADAMTS13 or NAC on the presence of VWF-PF4 or VWF-
PF4-HIT antibody complexes. (A) Shows representative images from studies as in Figure 
3A with PF4 25 µg/ml infused into each lane. In some studies, KKO (10 µg/ml), 
ADAMTS13 (7 nM) and/or NAC (10 mg/ml) was added as indicated. (B) The data shown 
are the mean ± 1 SEM of the number of VWF strands present in the channel after exposure 
to the indicated solution relative to those present in channels with injury+PF4+KKO. N ≥ 
4 and P values were determined by one-way ANOVA analysis. (C) Shows the mean ± 1 
SEM are shown for the length of VWF relative to the length of the viewing window with N 
≥ 4 independent channels. P values were determined by one-way ANOVA analysis.   
B 
A 
C 
92 
 
Figure 4.10. NAC impedes HIT-exacerbated thrombosis in a rose bengal carotid 
arterial injury model.  
 (A) Displays the time (minutes) to occlusion in a rose bengal photochemical carotid 
arterial injury model comparing mice infused with TRA, KKO, and KKO with n-
acetylcysteine. N ≥ 3. (B) Displays the estimated AUC measured in total milliliters for the 
same mice shown in (A). 
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CHAPTER 5 – Neutrophil accumulation and NET release contribute to thrombosis 
in HIT 
 
This chapter presents work featured in the article that has been submitted:  
Gollomp, K., et al., (2018) submitted 
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Abstract 
 HIT is an immune-mediated thrombocytopenic disorder associated with a severe 
prothrombotic state. We investigated whether neutrophils and NETs contribute to the 
development of thrombosis in HIT. Using an endothelialized microfluidic system and a 
murine passive immunization model, we show that HIT induction leads to increased 
neutrophil adherence to venous endothelium. In HIT mice, endothelial adherence is 
enhanced immediately downstream of nascent venous thrombi, after which neutrophils 
migrate retrograde via a CXCR2-dependent mechanism to accumulate into the thrombi. 
Using a microfluidic system, we found that PF4 binds to NETs, leading them to become 
compact and DNase resistant. PF4-NET complexes selectively bind HIT antibodies, which 
further protect them from nuclease digestion. In HIT mice, inhibition of NET formation 
through Padi4 gene disruption or DNase treatment limited venous thrombus size. Padi4-/- 
did not effect arterial thrombi or severity of thrombocytopenia in HIT. Thus, neutrophil 
activation contributes to the development of venous thrombosis in HIT by enhancing 
neutrophil-endothelial adhesion and neutrophil clot infiltration, where incorporated PF4-
NET-HIT antibody complexes lead to thrombosis propagation. Inhibition of neutrophil 
endothelial adhesion, prevention of their chemokine-dependent thrombus recruitment, or 
suppression of NET release should be explored as strategies to prevent venous 
thrombosis in HIT.  
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Introduction 
HIT is an immune-mediated thrombocytopenic disorder, characterized by venous 
and arterial thrombi154. Even with early recognition and initiation of appropriate therapy, 
thromboembolic complications still occur155. The current standard of care for patients with 
suspected HIT involves intense anticoagulation that carries the risk of significant bleeding 
and only provides partial protection against recurrent thromboembolic events87. While 
avoidance of heparin exposure may prevent the development of HIT156, there are clinical 
settings where heparin remains irreplaceable157. An improved understanding of the 
pathobiology of HIT may help identify targeted therapies to prevent thrombosis without 
subjecting patients to the risk of intense anticoagulation. These insights may also be 
beneficial in the treatment of other inflammatory, prothrombotic conditions ranging from 
antiphospholipid syndrome158  to sepsis159. 
HIT is caused by the development of pathogenic antibodies (HIT antibodies) that 
recognize complexes of heparin and the platelet-specific human chemokine PF488, which 
is released in high concentrations at sites of platelet activation and then binds to surface 
GAGs on platelets160, monocytes50, ECs43, and neutrophils161. HIT antibodies cross-react 
with PF4-GAG complexes after which their Fc termini engage FcRIIA receptors, leading 
to cell activation162. Although the high risk of thrombosis observed in HIT has classically 
been attributed to the assembly of PF4-GAG complexes on platelets, these complexes 
also form on the surface of other cells types, including monocytes50 and neutrophils122. 
Moreover, we recently showed that PF4 and HIT-like antibodies bind predominantly to the 
endothelial surface after vessel wall injury, leading to an increase in the extent of 
endothelial damage upstream and downstream of the initial site of injury43. 
There are multiple factors that suggest neutrophils may contribute to the 
pathogenesis of HIT. Human neutrophils express FcRIIA163 and neutrophil activation via 
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this receptor promotes increased phagocytosis, degranulation, and generation of ROS164. 
PF4 and HIT antibodies have been shown to induce integrin expression on neutrophils122 
and enhance the formation of neutrophil-platelet aggregates165. Myeloperoxidase (MPO) 
levels have also been found to be elevated in plasma obtained from patients with HIT 
compared to plasma from patients with other causes of thrombocytopenia165, suggesting 
that HIT is associated with neutrophil activation. In the setting of infection or inflammation, 
activated neutrophils can contribute to thrombus formation through NETs released 
chromatin that can trap platelets, bind clotting factors, and deactivate natural anti-
coagulants166. 
These findings led us to hypothesize that neutrophils activated by HIT antibodies 
may contribute to the prothrombotic nature of HIT. To address this question, we performed 
studies using an in vitro microfluidic system43 and a passive murine immunization model 
of HIT47. In both systems, we found that exposure to HIT antibodies lead to enhanced 
neutrophil adhesion to the venous endothelium. Following cremaster venule laser injury in 
the murine passive immunization model of HIT, we observed that neutrophils adhered to 
the downstream endothelium and then followed a chemogradient to migrate retrograde 
into the growing thrombi. When activated neutrophils undergo NETosis during HIT, their 
released NETs are bound by PF4, leading to their physical compaction. These PF4-NET 
complexes bind HIT antibodies and become resistant to circulating DNases. Additional 
passive murine immunization HIT studies in mice that are resistant to NET formation due 
to a deficiency in the gene that encodes peptidyl arginine deiminase 4 (PAD4), an enzyme 
that induces chromatin decondensation through the citrullination of histone lysine 
residues167, confirm that NETosis plays a role in the murine model of HIT. The results of 
a corollary analysis of clinical samples obtained from patients diagnosed with HIT, 
suggests that NET formation influences the disease in humans. The relevance of these 
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studies to the development of the prothrombotic state in HIT by Step 3 propagation and 
potential new targets for therapy based on these studies are discussed.  
 
Methods 
Mice and human samples. 
HIT mice were transgenic hPF4+/FcRIIA+ 56. All HIT mice were also on a Cxcl4-/- 
background168, as murine PF4 is not recognized by HIT antibodies103. Genetic alterations 
were confirmed by appropriate PCR analyses101. We used the CRISPR-Cas9 genome 
editing system169 to disrupt Padi4 exon2 in HIT mice (Padi4-/-/HIT mice, Figure 5.13). 
Guide RNA (gRNA) flanking the targeted exon was designed to minimize off-target 
interactions170 (5’-CCTAAGGGCTACACAACCTT-3’ and 5’-GCTGGCTGCTTTCACCTG-
TAC-3’) and injected into harvested embryos at concentrations of 50 ng/μL along with 
Cas9 mRNA 100 ng/μL by the CHOP Transgenic Mouse Core. Oligonucleotide primers 
designed to amplify the 0.2 kb region of the gene encasing Exon 2 (5’-
CATCTGTTCTGCTGCTGGCTG-3’, 5’-CTCCTAAGGGCTACACAACCTTC-3’) were 
used to confirm the presence of the desired gene disruption. Functional abrogation of 
PAD4 activity was confirmed by stimulating neutrophils isolated from the bone marrow of 
Padi4-/- mice and plated on poly-L-lysine-coated slides (Sigma-Aldrich) with 100 nM of 
phorbol-12 myristate 13-acetate (PMA, Sigma-Aldrich) overnight at 37°C and then staining 
the cells with SYTOX green (1 μM) and anti-histone H3 antibody Ab5103 at a dilution of 
1:500 to visualize NET release (Figure 5.13B). Both Padi4+/+/HIT and Padi4-/-/HIT mice 
were studied at 10-30 weeks of age. Only male mice were used in the cremaster vessel 
injury experiments; however, in previous studies, we have not appreciated any sex 
differences in thrombosis in the passive immunization HIT murine model following 
photochemical carotid artery injury50. 
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Deidentified plasma samples were obtained from patients with suspected HIT104. 
All subjects were evaluated with a polyspecific PF4/heparin ELISA (Immucor)47 and a 
serotonin-release assay171,172, and classified as having or not having HIT by a panel of 
three independent expert adjudicators who based their decision on laboratory results and 
clinical findings. Control plasma was obtained from healthy individuals and patients 
diagnosed with immune thrombocytopenia (ITP)173. Citrated plasma was stored at -80°C 
and MPO concentrations were measured by ELISA (Biolegend). IgG was isolated from 
plasma from some HIT patients and healthy donors using protein G agarose (Pierce)50.  
 
Antibodies and other labeled probes.  
KKO, an anti-PF4/heparin monoclonal antibody, and TRA, a mouse IgG 2bK 
isotype control monoclonal antibody47, were purified from hybridoma supernatants. Anti-
Fibrin 59D8 monoclonal antibody was provided by Harmut Weiler of the Blood Center of 
Wisconsin56 PF4 was visualized using a polyclonal rabbit anti-human PF4 antibody 
(abcam). A rabbit anti-citrullinated histone 3 (cit-H3, Ab5103, abcam) was used to 
visualize citrullinated H3 and rabbit anti-MPO antibody (EMD Millipore), was used to label 
NETs. Both of these antibodies were labeled for visualization with a goat anti-rabbit IgG 
H&L Alexa Fluor 594 (ab150080, abcam). F (ab′) 2 fragments of the anti-mouse CD41 
monoclonal antibody MWReg30 and of the anti-mouse Ly-6G antibody 1A8 (BD 
Biosciences) were used to detect murine platelets and neutrophils, respectively, in the 
cremaster laser injury model. HIT antibodies purified from patient plasma samples were 
visualized with an anti-human IgG Fc secondary antibody (eBioscience). All antibodies 
were either labeled using Alexa Fluor antibody-labeling kits according to manufacturer’s 
instructions or species-appropriate Alexa Fluor-conjugated secondary antibodies (all from 
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ThermoFisher Scientific). Extracellular DNA was visualized using SYTOX green or orange 
nucleic acid stain (ThermoFisher Scientific).  
 
NET-lined microfluidic channel studies.  
Experiments were performed using a BioFlux 1000 Controller (Fluxion) with an 
attached heating stage at 37°C as described108. The BioFlux channels were visualized 
with an Axio Observer Z1 inverted microscope (Zeiss) equipped with a motorized stage 
and an HXP-120 C metal halide illumination source. The microscope and image 
acquisition were controlled by BioFlux Montage software with a MetaMorph-based 
platform (Molecular Devices). Isolated human neutrophils (2 x 106 cells/ml) were incubated 
with 1 ng/ml TNFα (Gibco) at room temperature for 10 minutes and then flowed through 
channels coated with 50 μg/ml of fibronectin (Sigma-Aldrich), to which they adhere, and 
then incubated with 100 ng/ml PMA overnight at 37°C. Cell-free DNA (cfDNA) release was 
visualized with 1 μM SYTOX green or orange, and the channels were infused with 
recombinant PF4 (0-200 μg/ml), expressed and purified as we described174, with or without 
unfractionated porcine heparin (0.4 U/ml, BD Biosciences) at 2-5 dynes/cm2. To confirm 
that the cfDNA structures adherent to the microfluidic channel walls were NETs, we 
performed co-immunolocalization in which channels ± PF4 (25 μg/ml) were incubated with 
either anti-cit-H3 at 4°C overnight or anti-MPO at 37°C for 1 hour, and then incubated with 
an Alexa Fluor 594 conjugated secondary antibody for 1 hour at 37°C prior to imaging with 
a Zeiss LSM 710 laser-scanning confocal microscope. Structures with co-localization of 
cfDNA and MPO or citrullinated histones were deemed to be NETs. PF4-NET complexes 
were then incubated with 25 μg/ml of KKO or a polyclonal anti-PF4 antibody (abcam) for 
1 hour at 37°C. NET digestion studies were carried out by infusing the channels with 100 
U/ml DNase I (Sigma-Aldrich) at 2 dynes/cm2 after which the channels were washed with 
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phosphate-buffered saline (PBS, Gibco) and fixed with 2% paraformaldehyde (BD 
Biosciences). To avoid laser-induced changes to the conformation of DNA175, we 
minimized laser exposure during our experiments. To account for this effect when studying 
whether KKO binding to PF4/NET complexes increased resistance to DNase I, we 
compared NET digestion by analyzing videos in which channels with and without KKO 
were included in the same visual field and exposed to UV light for the same amount of 
time. Channels were blocked with PBS with 2% BSA, and PF4-NET complexes were 
visualized by incubating SYTOX-labeled NETs with a rabbit anti-human PF4 antibody at 
37°C for 1 hour, rinsing the channels with PBS flowed at 5 dynes/cm2 for 5 minutes, and 
then incubating with an anti-rabbit secondary antibody at 37°C for 1 hour. KKO was 
labeled with Alexa Fluor 647 (ThermoFisher Scientific) prior to NET channel infusion. NET 
complexes were imaged with a Zeiss LSM 710 laser-scanning confocal microscope. 
Similar studies were done using 100 U/ml bacterial-derived micrococcal nuclease (New 
England Biolabs). Data were analyzed using ImageJ open source image processing 
software176. 
 
Endothelialized channel microfluidic studies. 
We used the TNFα inflammatory thrombosis microfluidic model described in 
Chapter 2. Briefly, endothelialized microfluidic channels were incubated with TNFα (1-10 
ng/ml) to simulate inflammation. Whole blood samples obtained from healthy human 
donors were fluorescently labeled with 2 mM calcein AM to visualize leukocytes and 
platelets and then incubated with KKO or TRA (25 μg/ml) for 15 minutes. The samples 
were then recalcified with CaCl2 (11 mM final concentration) and immediately flowed 
through the channels at 5 dynes/cm2. When using ImageJ to count endothelial-adherent 
cells, size exclusion thresholds were used to distinguish platelets from leukocytes. To 
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assess KKO binding to TNFα-stimulated endothelium, the HUVEC-lined channels were 
infused with PBS containing PF4 (10 μg/ml) and KKO (25 μg/ml) conjugated with Alexa 
Fluor 488 (Invitrogen) at 5 dynes/cm2. Following the infusion, the channels were washed 
with PBS and fixed with 2% paraformaldehyde (BD Biosciences). KKO binding was 
quantified based on fluorescent measurements obtained from a Zeiss LSM 710 laser 
scanning confocal microscope. Levels of KKO-endothelial binding were compared to 
those observed after the whole blood samples containing PF4 and KKO were infused 
through HUVEC channels that had been subjected to hematoporphyrin (50 µg/ml, Sigma-
Aldrich) photochemical injury, as our group has previously described43. 
 
Femoral vein neutrophil rolling studies. 
HIT mice were anesthetized with nembutal and a skin flap extending from the ankle 
to thigh was removed to expose the femoral vein. SYTOX orange (2 nM) and F(ab′)2 
fragments (0.2mg/g mouse) directed against Ly6-G and CD41 were infused as 100 μL 
boluses via a catheter placed into the jugular vein to detect cfDNA, neutrophils, and 
platelets respectively. Confocal microscopy was used as described previously98 to obtain 
videos of neutrophil rolling and adhesion in the femoral vein at baseline and 10 minutes 
after 1 μg/g of KKO was infused via the jugular catheter. Data were collected and confocal 
time-lapsed images were analyzed using Slidebook 6.0 to compare neutrophil behavior 
before and after KKO exposure. 
 
Isolated human neutrophils. 
Human blood was collected after informed consent from healthy aspirin-free 
volunteers through a 19-gauge butterfly needle into 4 ml vacutainers coated with 7.2 mg 
of ethylenediaminetetraacetic acid (Becton Dickinson). Blood samples were stored at 
102 
room temperature and used within 1 hour. Neutrophils were isolated with negative bead 
selection using the MACSxpress Neutrophil Isolation Kit (Miltenyi Biotec). The supernatant 
was collected and centrifuged at 300g for 10 minutes, and the cell pellet was resuspended 
in 2 ml ammonium-chloride-potassium (ACK) lysing buffer (ThermoFisher Scientific) for 5 
minutes to lyse erythrocytes, after which the cells were washed with 10 mLs of Hank’s 
balanced salt solution (HBSS, ThermoFisher Scientific), and then resuspended in HBSS 
containing calcium chloride (1.3 mM) and then manually counted, with trypan blue dye 
exclusion (Gibco) for cell viability.  
 
Bioassay for NET digestion. 
PF4-induced NET resistance to digestion was quantified using a modified version 
of a previously described assay98. Isolated human neutrophils resuspended in HBSS, 
were stimulated with TNFα (1ng/ml) for 5 minutes and transferred to a fibronectin-coated 
(50 μg/ml) 96 well plate with 2 x 105 cells placed in each well. The samples were incubated 
with 100 nM of PMA ≥ 4 hours at 37°C to stimulate NET release. NETs were incubated 
with PF4 (0-50 μg/ml) ± KKO (25 μg/ml). Released cfDNA was labeled with SYTOX green 
(1μM), and a baseline reading was obtained with fluorescence spectrometry, excitation 
485 nm and emission 537nm (SpectraMax M2, Molecular Devices). The samples were 
then incubated with 1U/ml DNase I (Sigma-Aldrich) for 30 minutes at 37°C and a repeat 
fluorescence reading was obtained. The percent original fluorescent intensity was 
measured for each well with higher values reflecting increased DNase I resistance.  
 
Glass slide NET compaction and digestion studies. 
To assess NET behavior without exposure to fibronectin, isolated human 
neutrophils resuspended in HBSS at a concentration of 2 x 106 cells/ml were allowed to 
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settle on uncoated microscope cover glass slides (Fisherbrand) placed in a 24 well tissue-
culture plate (Falcon) for 30 minutes at 37°C. The supernatant was aspirated and 500 μL 
of HBSS containing PF4 (0-50 μg/ml) was added to the wells and incubated at 37°C for 1 
hour. The supernatant was again aspirated and 500 μL of DNase I (100U/ml) was added 
to the wells and incubated on a standard analog rocker (VWR) at 37°C for 1 hour. Images 
of the NETs before and after compaction and digestion were obtained with Axio Observer 
Z1 inverted wide field microscope (Zeiss) and data were analyzed using ImageJ 
opensouce image processing software176. 
 
Cremaster laser injury studies. 
Intravital microscopy was performed as described154 using Padi4+/+ and Padi4-/- 
HIT mice. Arterioles and venules of 20-40μ diameter were studied, and injury was induced 
with an SRS NL100 pulsed nitrogen dye laser (440nm) focused on the vessel wall and 
pulsed until the vessels were perforated as indicated by the release of a small number of 
erythrocytes. Prior to injury induction, SYTOX green or orange (1μM) and F(ab′)2 
fragments (0.2 mg/g mouse) were infused as 100 μL boluses via a catheter placed into 
the jugular vein. After 1-3 injures were made, 1 μg/g of KKO or TRA was infused, and an 
additional 3-4 injuries were made with maximum experimental time per mouse being 2 
hours. In some studies, the mice were treated with the CXCR2 antagonist SCH527123 
(10 mg/kg, Apexbio) resuspended in distilled H20 with 5% dimethyl sulfoxide (Sigma-
Aldrich). In other studies, the mice were treated with an IV bolus of bovine pancrease-
derived DNase 1 (100U/mouse, Sigma-Aldrich) immediately prior to KKO injection and 
laser injury. Widefield and confocal microscopy were performed. Data were collected and 
confocal time-lapsed images of platelet and neutrophil accumulation were analyzed using 
Slidebook 6.0. Confocal Z-stacks were obtained immediately following injury at 5 minutes 
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and again 60 minutes following KKO or TRA infusion. Data were analyzed with Slidebook 
6.0 to measure platelet thrombus volumes. 
 
Statistical analysis. 
Differences between 2 groups were compared using a 2-sided Student’s t test with 
Welsh’s correction or a Mann-Whitney U test. Normal distribution was tested using the 
D’Agostino & Pearson normality test. Differences between >2 groups were determined by 
one- or two-way ANOVA (as appropriate) and a Kruskall-Wallis test was performed when 
data was not normally distributed. Multiplicity corrected p values are reported for multiple 
comparisons. Statistical analyses were performed using Microsoft Excel 2011 and 
GraphPad Prism 7.0 (GraphPad Software). Differences were considered statistically 
significant when P values were ≤0.05. 
 
Study approval. 
Animal procedures were approved by the Institutional animal care and use 
committee (IACUC) of the CHOP and in accordance with NIH guidelines and the Animal 
Welfare Act. Anonymized human blood was collected after signed, informed consent was 
provided by healthy donors, and approval for studies using human blood was obtained 
from CHOP’s Human Review Board in accordance with Declaration of Helsinki principles.  
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Results 
Enhanced neutrophil adhesion to the venular endothelium in HIT. 
Neutrophils are activated when exposed to PF4 and HIT antibodies122. To 
determine if this activation might impact neutrophil-EC interactions, we infused calcein-
AM labeled whole blood through HUVEC-lined microfluidic channels and quantified cell 
adhesion over time. We observed scant leukocyte-endothelium adhesion in unstimulated 
channels that was unchanged by the addition of the HIT-like monoclonal antibody KKO or 
the isotype control TRA (data not shown). However, when the HUVEC cells were pre-
treated with TNFα, there was a two-fold increase in the number of adherent leukocytes in 
samples incubated with KKO, which induces the release of endogenous PF4 from 
platelets47, compared to samples treated with the isotype control TRA (Figures 5.1A, 
5.1B, and 5.1C). We did not observe that TNFα treatment led to an increase in KKO 
binding to the HUVECs (Figure 5.2) supporting that the increase in leukocyte adhesion 
seen in vivo was at least in part a result of leukocyte rather than endothelial activation. We 
then asked if these findings could be recapitulated in vivo using a murine HIT model 
following injection of KKO56. Within 30 minutes of KKO infusion, we observed increased 
neutrophil rolling and adhesion to uninjured cremaster muscle venules, but no neutrophil 
rolling or adhesion occurred in uninjured cremaster arterioles before or after the animals 
were exposed to KKO (Figures 5.1D and 5.1E). We similarly observed an increase in 
neutrophil adhesion in the femoral vein 10 minutes following treatment with KKO (Figures 
1F and 1G).  
 
Enhanced neutrophil involvement in venular thrombosis in HIT. 
106 
We next asked whether exposure to HIT antibodies influences neutrophil 
incorporation into thrombi in vivo in the murine model of HIT. Cremaster vessels were 
injured at time 0 and adherent neutrophils and platelets were quantified at 5 minutes. The 
mice were then infused with KKO or TRA, and the thrombi were reexamined at 60 minutes. 
While there was an increase in platelet accumulation in arterioles following HIT induction, 
only a small number of neutrophils were incorporated into arteriolar thrombi, with a small 
but significant increase following treatment with KKO (Figure 5.3). At sites of venular injury 
prior to HIT-induction, there was platelet and fibrin accumulation (Figure 5.3B and Figure 
5.4, respectively) but only a small number of neutrophils adhered to these thrombi (Figure 
5.3A and 5.3C). In contrast, following HIT induction, there was marked increase in 
neutrophil accumulation within venular thrombi (Figure 5.3C) with a minimal change in 
fibrin accumulation (Figure 5.4) and platelet volume (Figure 5.3B). The rise in neutrophil 
accumulation was not observed following TRA infusion (Figure 5.3A through 5.3C).  
 
A CXCR2-dependent retrograde migration of neutrophil into venular thrombi in HIT. 
To better understand the process of neutrophil accumulation in venular thrombi in 
HIT, we induced laser injuries in venules following KKO infusion, and monitored platelet 
and neutrophil accumulation in these lesions over 5 minutes. While platelets quickly 
adhered directly to the site of venous injury, most neutrophils initially bound to the 
endothelium 30-40 microns downstream of the injury (Figure 5.5). This finding is likely 
due to a combination of increased neutrophil adhesiveness induced by KKO exposure, 
documented in Figure 5.1, in addition to activation of the endothelium downstream of 
cremaster laser injuries in HIT that we have previously described43. These neutrophils 
subsequently migrated in a retrograde direction into the evolving thrombus (Figure 5.5A) 
and 60 minutes following the initial injury, a significantly higher number of neutrophils were 
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present in venular thrombi in mice exposed to KKO compared to those infused with the 
isotype control TRA (Figures 5.5A and 5.5B). We hypothesized that retrograde migration 
of adherent neutrophils into the thrombi was induced by a chemoattractant released by 
activated platelets in the clots. Activated platelets release several chemokines from their 
 granules that cause neutrophil migration by engaging neutrophil surface CXCR2177. To 
test whether the retrograde recruitment of neutrophils to venular thrombi in HIT was 
chemokine-dependent, we treated the mice with the CXCR2 antagonist SCH527123177 
prior to the induction of HIT. We observed that thrombi in mice treated with SCH527123 
before KKO infusion contained significantly fewer neutrophils within their thrombi (Figure 
5.5). Furthermore, these neutrophils were located at the periphery of the platelet-rich 
thrombi and not embedded within them.  
 
In vitro studies of PF4-NET interactions. 
After observing marked HIT-induced neutrophil infiltration in venular thrombi, we 
hypothesized that adherent neutrophils contribute to venous thrombi in HIT, in part, 
through the release of NETs, as described in deep venous thrombosis178. Moreover, 
platelet activation, one of the hallmarks of HIT, can initiate NETosis in inflammatory 
states179,180. Activated platelets release high levels of PF4, which forms high-molecular 
weight aggregates with various polyanions, producing antigens that are recognized by HIT 
antibodies141. We postulated that when PF4 is released in HIT, due to its cationic charge, 
it will bind to cfDNA present in NETs and impact NET biology. To investigate PF4-NET 
interactions in real time, we studied neutrophils adherent to fibronectin-coated microfluidic 
channels stimulated with PMA to release NETs. We confirmed that these cfDNA structures 
were NETs by using co-immunofluorescent staining to show that they contained 
citrullinated histones and MPO (Figure 5.6). The NET-lined channels were then infused 
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at venular flow rates with buffer containing PF4 at concentrations readily attained at sites 
of platelets activation (5-100 µg/ml)122. Prior to exposure to PF4, NETs labeled with 
SYTOX were round and transparent, with a cloud like appearance that we termed “fluffy”. 
When infused with HBSS or human plasma, the NETs extended, and when flow was 
stopped they rebounded to their former shape. Following treatment with either buffer or 
plasma containing PF4, the NETs became opaque and narrow with a sharply tapered tail 
that did not change shape when flow was stopped. (Figure 5.7A, Figure 5.6). Maximum 
compaction, with a 50% reduction in NET area, was achieved when the NETs were flowed 
with HBSS containing PF4 concentrations of ≥10 µg/ml (Figure 5.7B, left, for PF4 ≤25 
µg/ml and not shown for >25 µg/ml). Confocal imaging of the compacted NETs, labeled 
with an anti-PF4 antibody and a fluorophore-conjugated secondary antibody, confirmed 
that PF4 bound to these structures (Figure 5.7A). Total NET DNA content measured by 
fluorescence intensity was preserved following PF4 infusion, excluding the possibility that 
the compacted NET appearance was due to the dissolution of DNA (Figure 5.7B, right). 
Co-immunofluorescent studies of NETs following PF4 infusion demonstrated that 
compaction does not lead to displacement of citrullinated histones or MPO (Figure 5.6).  
We next asked whether PF4-induced changes in NET morphology could impact 
NET behavior. While PF4-free NETs were highly susceptible to DNase I at a concentration 
of 100U/ml, with near complete digestion in <2 minutes, PF4-bound NETs were resistant 
to DNase I, with near-complete protection at PF4 concentrations of ≥10 µg/ml (Figure 
5.7C and 5.7D). The infusion of human plasma containing PF4 was also found to confer 
resistance to DNase I-mediated digestion (Figure 5.8) and similar results were observed 
with the use of bacterial-derived micrococcal nuclease (Figure 5.9). Comparable nuclease 
resistance was also observed in a static system not coated with fibronectin, showing that 
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fibronectin, which has a DNA binding domain and is known to interact with NETs181, is not 
the cause of the observed changes in NET behavior (Figure 5.8).  
Previous in vitro studies reported that NETs are degraded by exposure to 
heparin182, suggesting that NETs should be reduced in patients with recent heparin 
exposure. We found that at a therapeutic concentration of 0.4U/ml147 or at a 
supratherapeutic concentration of 5000U/ml, heparin did not degrade NETs in our 
microfluidic system; however, we observed that exposure to heparin, reversed compaction 
with restoration of fluffy morphology (Figure 5.10A and 5.10B). Confocal imaging of NETs 
labeled with a polyclonal anti-PF4 antibody confirmed that heparin treatment removed PF4 
from the NETs (Figure 5.10A), and DNase I infusion studies confirmed that decompaction 
of NETs restored their susceptibility to endonuclease digestion (Figure 5.10C and 5.10D). 
However, when NETs were exposed to a 25 µg/ml instead of 10 µg/ml of PF4, a 
concentration still within the range typically observed at sites of thrombosis88, NET 
compaction and DNase resistance were maintained during co-infusion with therapeutic 
concentrations of heparin (Figure 5.10C and 5.10D).  
 
In vitro effects of HIT antibodies on PF4-NET complexes 
PF4 has previously been shown to form complexes with DNA aptamers that are 
HIT antigenic targets124. We, therefore examined whether PF4-NET complexes are also 
recognized by KKO and IgG isolated from HIT patient plasma using the microfluidic 
chambers to assess binding and function. We found that KKO and HIT IgG suspended in 
HBSS did not interact with non-compacted NETs, but both bound to PF4-NET complexes 
(Figure 5.11A and Figure 5.12A). KKO dissolved in human plasma also bound 
specifically to PF4-NET complexes. (Figure 5.12A). Antibody binding did not induce 
greater NET compaction, but it enhanced resistance to DNase I digestion (Figure 5.11B). 
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This effect was found to be specific to HIT antibodies, as incubation with a polyclonal anti-
PF4 antibody at 25 μg/ml did not provide similar protection from endonucleases (Figure 
5.11C and 5.11D). Similar results were seen using NETs immobilized to fibronectin-coated 
96-well plates (Figure 5.11E)183.  
 
Thrombosis in the HIT murine model in the presence or absence of PAD4.  
We then asked whether enhanced NET endonuclease resistance and the 
formation of PF4-NET-HIT antibody complexes, observed in vitro, contribute to in vivo 
thrombus development in the murine model of HIT. We hypothesized that the release of 
NETs by thrombus-adherent neutrophils and their subsequent modification by PF4 and 
HIT antibodies may play a role in the prothrombotic state that develops in these animals. 
To better understand the way in which NETosis may contribute to thrombosis in HIT, we 
studied Padi4-/-/HIT mice that are incapable of releasing NETs (Figure 5.13). Previous 
studies have shown that Padi4 knockout mice do not release NETs and are protected from 
venous thrombosis178. Following KKO injection, severity of thrombocytopenia in Padi4-/-
/HIT mice was comparable to that seen in Padi4+/+/HIT controls. (Figure 5.14A) The size 
of arteriolar thrombi following laser injury was unaffected by PAD4 deficiency (Figure 
5.14B) and neutrophil incorporation into venule thrombi following TRA injection was similar 
in Padi4-/- and Padi4+/+ HIT mice. However, after KKO injection, the Padi4-/-/HIT mice 
developed smaller venular thrombi following injury (Figure 5.14C and 5.14D) with 
incorporation of fewer neutrophils (Figure 5.14E). This difference became more 
pronounced with the passage of time (Figure 5.14C). Consistent with these studies in 
Padi4-/- HIT mice, Padi4+/+ HIT mice treated with DNase I prior to KKO infusion, had a 
significant decrease in platelet thrombus volume 60 minutes following injury (Figure 
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5.14C), suggesting that NETs play a role in thrombus growth and stabilization in this 
model.  
 
Clinical indication of NETosis in HIT 
It has been reported that circulating MPO levels are elevated in HIT165, potentially 
implicating neutrophils and NETosis in the pathobiology of HIT. We confirmed this clinical 
finding comparing cfDNA and MPO levels in samples from patients at high- or at low-
likelihood of having HIT44, healthy controls, and patients with immune-thrombocytopenia 
(ITP). Both MPO levels (Figure 5.15A) and cfDNA (Figure 5.15B) were significantly 
higher in individuals diagnosed with HIT compared to healthy controls and patients with 
an alternative cause of immune thrombocytopenia. However, we did not observe a 
significant difference in MPO or cfDNA concentrations between patients diagnosed with 
HIT compared to ill patients evaluated for HIT, but found to have a low probability of having 
the disease. These findings demonstrate that neutrophil activation and NETosis occur in 
multiple proinflammatory/prothrombotic states that commonly occur in hospitalized 
patients.  
 
Discussion  
Over the past several years, it has become increasingly clear that the 
pathophysiology of HIT extends beyond platelet activation in Step 2. It has previously been 
shown that HIT antibody interaction with other cells types including the endothelium43 and 
monocytes50, leads to cell activation and a prothrombotic state as described in Step 2. 
Others have also demonstrated that HIT antibodies activate PF4-exposed neutrophils 
through their FcRIIA receptors, leading to increased expression of Mac-1 on the cell 
surface and enhanced neutrophil aggregate formation122. In this paper, we explore specific 
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pathways by which neutrophils may contribute to thrombosis in Step 2, and propose that 
they do so through multiple steps including the stimulation of neutrophil adhesion to 
inflamed endothelium, the promotion of neutrophil migration into venular thrombi, and the 
formation of antigenic PF4-NET-HIT antibody complexes that contribute to propagation 
via Step 3.  
The basis for enhanced binding of HIT-activated neutrophils to the endothelium in 
large vessels and the microcirculation requires further exploration. Prior studies have 
shown that HIT antibody exposure increases neutrophil surface expression of Mac-1122. 
ECs are also activated by PF4 and HIT antibodies, increasing surface expression of P- 
and E-selectins93. Our finding of enhanced in vitro neutrophil binding parallels the 
increased adhesion seen in vivo in the setting of our murine model of HIT, with or without 
EC injury. We speculate that neutrophil adhesion immediately downstream of growing 
venular injury may be due to increased turbulent flow around larger thrombi, that is known 
to enhance neutrophil adhesion to the endothelial lining184. It may also be due to the 
release of PF4 from activated platelets within the thrombus that results in increased 
assembly of antigenic complexes on the downstream endothelium, leading to more HIT 
antibody binding and endothelial activation43. The role of each of these mechanisms in the 
accumulation of neutrophils in injured venules requires additional investigation to identify 
opportunities for intervention.  
After adhering to the endothelium downstream of thrombosis, many neutrophils 
migrate in a retrograde manner and are incorporated into the venular clots. Retrograde 
migration may occur in response to a chemotactic gradient emanating from degranulating 
platelets. A similar process termed “directed intravascular migration” has been described 
in ischemia-reperfusion injuries, in which degranulating platelets release CXCL7 
(neutrophil activating peptide 2 (NAP2)) and CXCL5 (epithelial-derived neutrophil-
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activating peptide 78 (ENA-78)), leading to CXCR2-dependent neutrophil recruitment185. 
The retrograde migration we observed in venular HIT thrombi is also similar to “neutrophil-
swarming,” a process in which large numbers of neutrophils rapidly accumulate at sites of 
infection or sterile injury where they release NETs186. In support of this hypothesis, we 
show that the retrograde migration of neutrophils into venous thrombi can be abrogated 
with the blockade of CXCR2. Whether NAP2 and/or ENA-78, both released from platelets 
and bound by CXCR2187, contribute to the chemogradient remains to be determined. 
Further investigation needs to be done to ascertain if this pattern of adhesion occurs in 
other prothrombotic disorders associated with venous thrombosis.  
Many groups have proposed that NET release links neutrophil accumulation to 
thrombus progression178,188,189. We posit that NETs released in HIT are uniquely 
prothrombotic because the binding of PF4 and HIT antibodies causes them to become 
immunogenic. Previous studies have shown that nucleic acid binding leads to the 
exposure of the same antigenic epitopes present on PF4/heparin complexes124. Mice 
injected with PF4/nucleic acid complexes develop antibodies that cross-reacted with 
PF4/heparin complexes124. Our microfluidic channel experiments support that PF4 forms 
complexes with chromatin DNA in the same way as PF4 binds heparin to form 
macroaggregates190. Our studies showing that HIT IgG isolated from human plasma binds 
to these PF4-NET complexes, confirms that they contain HIT antigenic epitopes. 
In addition to producing HIT antigenic complexes, we have observed that PF4 
binding leads to chromatin compaction that causes NETs to become DNase resistant. It 
has previously been shown that NET binding to the cationic peptide LL-37 leads to 
enhanced protection from nuclease digestion191, in a manner similar to what we have 
observed with PF4. While DNase-resistant NETs may have increased antimicrobial 
activity, impaired NET degradation has been implicated in the pathogenesis of 
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autoimmune diseases, including anti-phospholipid antibody syndrome and lupus192,193. In 
these disorders, DNase resistance is thought to occur due to the development of anti-NET 
immunoglobulins that interfere with DNase binding to cfDNA183. In HIT, PF4 forms 
complexes with NETs that are bound by HIT antibodies that provide additional protection 
from DNases. These stable, compacted PF4-NET-HIT IgG aggregates then serve as a 
Fc-rich surface that can recruit and activate circulating hematopoietic cells via their 
FcRIIA receptors and activate the complement cascade163. 
To test this hypothesis, we generated Padi4-/- HIT mice that do not undergo 
NETosis167,178,194. In these animals, venular thrombi generated after HIT induction are 
markedly smaller than those observed in animals capable of NET release, with fewer 
incorporated neutrophils and decreased platelet volumes. This suggests that NETs 
contribute to the early stages of venule thrombus growth, enhancing both platelet 
accumulation and neutrophil recruitment. This effect was not observed in laser injury-
induced arteriole thrombi, which have little neutrophil infiltration irrespective of PAD4 
activity. Moreover, the loss of PAD4 activity – and likely NET formation – did not affect the 
severity of thrombocytopenia in HIT mice, suggesting that the development of venular 
thrombi is unrelated to the mechanism underlying the development of thrombocytopenia. 
In vivo NET visualization is technically difficult, and most in vivo studies rely on 
functional analysis. We therefore treated HIT mice with DNase prior to cremaster laser 
injury and found that this led to a significant decrease in cremaster venule thrombus 
platelet volumes. This finding further supports our hypothesis that NETs play a role in 
thrombus growth and stabilization in this model. However unlike in the Padi4-/-/HIT mice, 
the number of thrombus-adherent neutrophils did not fall in accordance with the decrease 
in platelet volumes. This difference may occur because Padi4-/- mice never release NETs, 
whereas PF4-compacted NETs are incompletely degraded by DNase and may still expose 
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PF4-NET-HIT IgG aggregates that can recruit circulating neutrophils. Nonetheless, the 
decrease in venular thrombus size raises the possibility that DNase treatment may be 
effective in preventing the venular prothrombotic state in HIT. 
In summary, we demonstrate that neutrophils contribute to the prothrombotic state 
in Step 2 of HIT (Figure 1.5) through enhanced adhesion to the endothelium downstream 
of venous thrombi and subsequent retrograde migration into these thrombi. There, 
activated neutrophils release NETs that form complexes with PF4 that are subsequently 
bound by HIT antibodies. These PF4-NET-HIT antibody complexes are protected from 
DNases and may contribute to thrombus propagation in Step 3 by exposing an Fc-rich 
surface. Thus, our studies extend the range of PF4-bound HIT antigenic polyanionic 
targets beyond heparin, GAGs, and polyphosphates. This would implicate that neutrophil-
derived NETs, are a key figure in the venular thrombus propagation in HIT (Figure 1.5). 
HIT mice that have neutrophils unable to undergo NETosis have smaller venous thrombi, 
but still develop enhanced arterial clots and thrombocytopenia. Further work is required to 
understand whether neutrophils contribute similarly to the development of venous thrombi 
in other immune/inflammatory prothrombotic states such as the anti-phospholipid antibody 
syndrome and sepsis. More investigation is needed to determine if blocking these 
pathways will help prevent venous thromboembolic complications in patients with HIT or 
other prothrombotic disorders. 
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Figures 
 
 
 
Figure 5.1. Enhanced leukocyte-endothelial adhesion in HIT.  
(A) Calcein-AM labeled blood incubated with KKO (red) or TRA (blue) was infused through 
HUVEC-lined channels exposed to TNF. Representative widefield image of leukocytes 
(white) adhering to the endothelium is shown. Size bar and arrow indicating direction of 
flow are included. Image was obtained with an Axio Observer Z1 inverted microscope 
using x10 magnification. (B) Leukocyte-endothelial adhesion was quantified for KKO (red) 
and TRA (blue). Six channels were studied in each TNFα-exposed arm (lighter colors) and 
3-5 channels in the unexposed arms (darker colors). (C) The final number of adherent 
leukocytes at 15 minutes is shown as mean ± 1 standard deviation (SD). Comparative 
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analysis was performed by Student’s t-test. (D) Representative confocal image of 
neutrophils rolling in a venule before and after KKO infusion. Neutrophils were stained 
using anti-Ly-6G F(ab′)2 fragment (green). Size bar and arrow indicating direction of flow 
are included. Images were obtained with an Olympus BX61WI microscope with a x40/0.8 
numeric aperture water-immersion objective lens. (E) Neutrophil adhesion to cremaster 
arterioles and venules was studied in the HIT murine model prior to and 30 minutes after 
exposure to KKO. Adhesion was defined as neutrophil immobilization for ≥30 seconds. 
Seven and four animals were studied in the venular and arteriole arm, respectively. 
Statistical comparison of binding was preformed using a Kruskall-Wallis one-sided 
ANOVA. (F) Representative confocal image of neutrophil rolling and adhering to the 
femoral vein before and 15 minutes after the infusion of KKO. Images are as in (D). Size 
bar and arrow indicating direction of flow are included. (G) Graph representing neutrophil 
adhesion to the femoral vein ± KKO infusion as in (F). N = 4 per arm. Statistical comparison 
was performed by Student’s t-test. 
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Figure 5.2. TNFα stimulation does not enhance KKO binding to HUVECs. 
(A) Graph showing the mean ± 1 SD of KKO adhesion to microfluidic channels coated 
with a confluent layer of HUVECs after infusion of whole blood or PBS containing PF4 (25 
μg/ml) and Alexa Fluor 488-conjugated KKO. Two fluorescent measurements were 
obtained from each channel. The number of channels per arm is indicated on the graph. 
The channels were either unstimulated, treated with TNFα prior to infusion, or subjected 
to photochemical hematoporphyrin injury. When whole blood was flowed through TNFα-
treated channels, the channels clotted, leading to interference with fluorescence 
measurements. Therefore, we only infused these channels with PBS. Comparative 
statistical analysis was done with a Kruskal-Wallis one-way ANOVA. (B) Representative 
confocal images of an unstimulated channel infused with PBS, an uninjured channel 
infused with whole blood, a TNFα stimulated channel infused with PBS, and a whole blood 
infused channel subjected to photochemical injury on the right half of the presented field. 
In this image, KKO only adheres to the injured portion of the channel to the right of the 
gray dotted line. Scale bar and arrows showing direction of flow are indicated.   
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Figure 5.3. Effect of HIT of neutrophil accumulation in cremaster vessels pre- and 
post-injury.  
 (A) Representative confocal images from cremaster arteriole and venule laser injuries 
showing platelets labeled with anti-CD41 (dark blue) and neutrophils labeled with anti-Ly-
6G (green). Paired images from the same vessel taken at 5 and 60 minutes following laser 
injury. KKO or TRA were infused intravenously beginning at minute 5 after injury. Size bar 
and arrow indicating direction of flow are included. Same microscope and acquisition 
software as in Figure 5.1D. (B) and (C) are graphs quantifying adherent neutrophils and 
platelets in the same thrombi, respectively. Twenty-eight injuries were made in twelve 
KKO-treated mice. Sixteen injuries were made in four TRA-treated mice. Twelve arteriole 
injuries were made in three untreated and three KKO-treated mice. Individual data points 
and mean ± 1 SD are shown. Comparative statistical analysis between 3 or more groups 
was performed by Kruskall-Wallis one-way ANOVA and comparisons between two groups 
was performed with a Student’s t-test.  
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Figure 5.4. Fibrin generation occurs in cremaster laser injuries. 
(A) Cremaster venule thrombus at 5 minutes after injury but prior to KKO exposure in HIT 
mice. Scale bar and arrows showing direction of flow are indicated. Fibrin and platelet 
accumulation are shown alone at the right. A composite image including the neutrophil 
stain is shown on left. (B) The same injury 60 minutes following KKO administration. 
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Figure 5.5. Chemokine-dependency of neutrophil accumulation into venous 
thrombi in HIT. 
(A) Representative confocal images of cremaster venule injuries showing platelet (blue), 
neutrophil (green) and KKO staining (red) at 1-60 minutes following laser injury. Typical 
injuries are shown from mice infused with TRA, KKO, and KKO + SCH527123, a CXCR2 
antagonist195. Size bar and arrow indicating direction of flow are included. Same 
microscope and acquisition software as described in Figure 5.1D. (B) Graphs quantifying 
adherent neutrophils in venule thrombi 5 and 60 minutes following laser injury. Thirty-two 
injuries were made in 12 KKO-treated mice. Seventeen injuries were made in 3 TRA-
treated mice. Eleven injuries were made in 3 KKO + SCH527123-treated mice. Individual 
data points and mean ± 1 SD are shown. Comparative statistical analysis was performed 
by Kruskall-Wallis one-way ANOVA. 
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Figure 5.6. PF4-cfDNA complexes contain both MPO and citrullinated H3. 
(A) Representative confocal image of channel adherent NETs incubated with SYTOX 
green and an anti-citrullinated H3 antibody before (above) and after (below) a 30-minute 
infusion with PF4 (25 µg/ml). Scale bar and arrows showing direction of flow are indicated. 
(B) As in (A), but representative confocal image of channel adherent NETs incubated with 
SYTOX green and an anti-MPO antibody before (above) and after (below) a PF4 infusion.  
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Figure 5.7. Microfluidic studies illustrating PF4-NET interactions.  
(A) Representative confocal images of NETs exposed to PF4 or buffer, demonstrating 
change in morphology. PF4 specifically adhered to the NET DNA, visualized by labeling 
with a polyclonal anti-PF4 antibody (-PF4 Ab), causing the NETs to become compact. 
Side bar and arrow indicating direction of flow are included. (B) Mean ± 1 SD of area 
covered by NETs exposed to the indicated PF4 concentration is shown on the left. 
Simultaneously measured mean fluorescent intensity (MFI) of SYTOX-labeled cfDNA is 
shown on the right. For both, N = 3-6 channels per PF4 concentration, with visualization 
of 30-60 NETs per channel. Comparative statistical analysis was performed by Kruskall-
Wallis one-way ANOVA. (C) Representative widefield images of NETs ± PF4 (10 µg/ml), 
simultaneously infused with DNase I (100U/ml). Near complete digestion of NETs not 
exposed to PF4 occurred within two minutes, whereas NETs compacted with PF4 
remained intact. Size bar and arrows indicating direction of flow are included. (D) Graph 
showing representative changes in NET fluorescent intensity observed over a 5-minute 
infusion of DNase I (100U/ml) in the presence of 0-10 µg/ml PF4. These studies were 
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based on analysis of 3-4 channels for each condition with 30-60 NETs observed in each 
channel. (E) Confocal images were taken of 3 channels per condition following digestion 
and the residual mean volume ± 1 SD of 30-100 NETs per channel was measured. 
Comparative statistical analysis was done by Kruskall-Wallis one-way ANOVA. 
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Figure 5.8. PF4 induces NET compaction and DNase I resistance without 
fibronectin and in the presence of human plasma.  
(A) and (B) are microfluidic channels lined with NETs infused with human plasma ± PF4. 
In (A) on the left is a graph showing the mean NET area ± 1 SD after plasma infusion. 
NET area was measured in 3 channels per condition with > 150 NETs measured per 
condition. Comparative statistical analysis was performed with a Mann-Whitney U-test. 
On the right are widefield representative images showing PF4-induced changes in NET 
morphology. Scale bar and arrows showing direction of flow are indicated. (B) Same as in 
(A), but after a 30-minute infusion of DNase I. NET area was measured in 2 channels per 
condition with >150 NETs measured per condition. (C) and (D) Studies of PF4 binding and 
effects of PF4 incubation on NETs on uncoated glass slides. In (C), the graph represents 
the mean ± 1 SD of NET area following incubation with the indicated concentrations of 
PF4. Two slides were incubated with each PF4 concentrations, and 75-150 NETs were 
measured per slide. Comparative statistical analysis was performed with a Kruskal-Wallis 
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one-way ANOVA. On the right are representative widefield images of NETs incubated with 
buffer containing 0 - 50µg/ml PF4. A scale bar is included. In (D), after the PF4 treatment, 
the NETs were incubated with DNase I and total NET area was measured. On the left, is 
a graph showing the mean ± 1 SD of NET area post-DNase I exposure. Three slides were 
incubated with each concentration of PF4 and comparative statistical analysis was 
performed with a Student’s t-test. On the right, are representative widefield images of 
NETs as in (C), but after DNase digestion. A scale bar is indicated.  
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Figure 5.9 Studies showing NET susceptibility to digestion with micrococcal 
nuclease.  
Microfluidic channel adherent NETs were incubated with PF4 (0-25 µg/ml) and then 
infused with micrococcal nuclease (MNase) at concentrations of 100U/ml for 5 minutes. 
The graph depicts residual area of the NETs incubated with increasing concentrations of 
PF4 following MNase digestion ± 1 SD. These studies were based on analysis of 3 
channels for each condition with 50-100 NETs observed in each channel. Comparative 
statistical analysis was done with a Kruskal-Wallis one-way ANOVA. 
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Figure 5.10. Studies of heparin-mediated NET decompaction and restoration of 
nuclease susceptibility.  
(A) Representative confocal image showing a comparison of two PF4-compacted NET 
channels, following a simultaneous 20-minute infusion with a therapeutic concentration of 
heparin at 0.4U/ml (top) or no added heparin (bottom), after Sytox and anti-PF4 antibody 
staining. Scale bar and arrow showing the direction of flow in the channel are included. 
Same microscope and acquisition software as described in Figure 5.1A. (B) Graph 
demonstrating the mean ± 1 SD of the area occupied by the cfDNA of PF4/NET complexes 
with and without heparin infusion. Six channels with 30-60 visualized NETs per channel 
were studied in each arm and comparative statistical analysis was done with a Student’s 
t-test. (C) Graph showing representative changes in NET fluorescent intensity observed 
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over a 5-minute infusion of DNAse I (100U/ml) in NETs infused with heparin 0.4U/ml and 
the indicated concentrations of PF4. (D) Graph showing the final mean fluorescent 
intensity ± 1 SD of channels as in (C). These studies were based on analysis of 3-7 
channels for each condition with 30-60 NETs observed in each channel. Comparative 
statistical analysis was done by a Kruskal-Wallis one-way ANOVA. 
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Figure 5.11. Microfluidic studies examining HIT-antibody PF4-NET complex 
interactions.  
(A) Representative confocal images of activated neutrophils adherent to fibronectin-
coated channels and stained for cfDNA (white) and KKO binding (red) in the absence and 
presence of 6.5 µg/ml PF4. Size bar and arrow indicating direction of flow are included. 
Same microscope and acquisition software as described in Figure 5.1A. (B) 
Representative widefield images of adherent neutrophils as in (A), but in the presence of 
100U/ml DNase1 and 6.5 µg/ml PF4 ± 25 µg/ml KKO over 2 minutes. Size bar and arrow 
indicating direction of flow are included. (C) Representative graph showing the decrease 
in NET area over a 3-minute DNase I digestion. (D) Mean ± 1 SD of the final area of NETs 
following a 5-minute infusion of DNase I (100 U/ml) in the presence of 6.5 µg/ml PF4 and 
KKO or an anti-PF4 antibody (PF4), each at 25 µg/ml. N = 12 in the PF4 and the 
PF4+KKO treated arms. N = 3 in the PF4 treated arm. Comparative statistical analysis 
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was performed by Kruskall-Wallis one-way ANOVA. (E) PF4-induced resistance to DNase 
digestion under static conditions was measured using a previously described NET 
degradation assay183. The graph shows the mean percent original fluorescent intensity ± 
1 SD. N = 9-10 per arm. Comparative statistical analysis between 3 or more groups was 
performed by Kruskall-Wallis one-way ANOVA and comparisons between two groups was 
performed with the Student’s t-test.  
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Figure 5.12. IgG isolated from HIT patient plasma binds PF4-NET complexes. 
(A) Representative confocal image of PF4-NET complexes incubated with IgG (25 µg/ml) 
isolated from a healthy control patient plasma for 1 hour, stained with SYTOX and anti-
human IgG, showing no human IgG adhering to cfDNA present in NETs. Scale bar and 
arrows showing direction of flow are indicated. (B) Representative confocal image of PF4-
NET complexes incubated with IgG (25 µg/ml) isolated from the plasma of a patient with 
a confirmed diagnosis of HIT, stained with SYTOX and anti-human IgG, showing human 
IgG binding specifically to NET cfDNA. (C) Representative confocal image of PF4-NET 
complexes, stained with SYTOX green, infused with plasma containing KKO, showing that 
KKO still binds specifically to PF4-NET complexes when added to plasma rather than 
buffer. Scale bar and arrows showing direction of flow are indicated. 
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Figure 5.13. CRISPR/Cas9 gene-editing generation of Padi4-/- mice.  
(A) At the top, is a schematic showing the first three exons of the murine Padi4 gene and 
the binding of CRISPR gRNAs designed to disrupt a 0.2 kb region (red) of the Padi4 gene 
encompassing Exon 2. Below the schematic are electrophoresis gels demonstrating the 
disruption of Exon 2 PCR amplification in 4 clones, and below the gels is the DNA 
sequence analysis from a wildtype mouse with the portion of Exon 2 deleted in clone 18 
represented in grey, lower-case letters. At the bottom is the normal murine PAD4 amino 
acid (aa) sequence in red with caps indicating sequence preserved in Clone 18, and small 
letters indicating the aa sequence lost in Clone 18. The PAD4 sequence expected in clone 
18 is shown below with the preserved first 8 aa in red, followed by a frameshift mutation 
(-) leading to 9 altered aa in blue with a premature stop codon (*). (B) Representative 
images of bone marrow-isolated neutrophils obtained from clone 18 Padi4-/- mice and 
Padi4+/+ siblings, plated on a poly-L-lysine coated slide, incubated with buffer alone or 
PMA (100 nM) overnight. Samples were SYTOX green stained to visualize DNA shown in 
green, and anti-histone H3 (citrulline R2+R8+R17) to visualize citrullinated histones (cit-
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His) shown in red. SYTOX and cit-His staining of unstimulated cells shows intact nuclei 
with cit-His staining only observed in Padi4+/+ cells. Staining of PMA stimulated cells shows 
extracellular DNA strands and increased cit-H3 in Padi4+/+ cells. The microscope and 
acquisition software were as described in Figure 5.1A. 
  
135 
 
Figure 5.14. NETosis studies in the passive immunization Padi4-/-/HIT mouse model.  
(A) Platelet counts 4 hours after intraperitoneal injection of KKO or TRA in HIT or FcRIIA+, 
hPF4-/- mice. Padi4 status is indicated. Mean ± 1 SD is shown. Number of mice studied 
per arm is indicated in bars. Comparative statistical analysis was performed by Kruskall-
Wallis one-way ANOVA. (B) Same as in (A), but for arteriole thrombus size as measured 
on confocal imaging after KKO infusion into HIT mice with Padi4 status indicated. 
Statistical analysis performed with a Student’s t-test. (C) and (D) are graphs showing the 
number of adherent neutrophils and the platelet volumes in cremaster venule thrombi in 
HIT mice 60 minutes after laser injury. Individual data points and mean ± 1 SD are shown. 
6 injuries were made in 3 TRA-treated HIT mice, 33 injuries were made in 8 KKO-treated 
Padi4-/- HIT mice, 5 injuries were made in 1 TRA-treated Padi4-/- mouse, 22 injuries were 
made in 13 KKO-treated HIT mice, and 25 injuries were made in 4 KKO-treated HIT mice 
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following infusion of DNase. Comparative statistical analysis was performed with a 
Kruskall-Wallis one-way ANOVA. (E) Representative confocal images demonstrating the 
extent of platelet and neutrophil accumulation at the site of cremaster venule thrombi 
following HIT-induction, 5 and 60 minutes after the inciting laser injury and infusion of KKO 
in Padi4-/- mice compared to Padi4+/+ mice ± DNase. Size bar and arrow indicating 
direction of flow are included. Same microscope and acquisition software as in Figure 
5.1D. 
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Figure 5.15. MPO and cfDNA levels in clinical samples.  
Measurements of (A) MPO and (B) cfDNA levels in plasma from normal controls (Ctl), 
patients diagnosed with ITP, and patients evaluated for HIT that either had a confirmed 
diagnosis (“HIT”) or were unlikely to have HIT (“Non-HIT”). Individual measurements and 
mean ± 1 SD are shown. Comparative statistical analysis was performed by Kruskall-
Wallis one-way ANOVA. 
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Chapter 6 – ICAM-1 – targeted thrombomodulin mitigates tissue factor – driven 
inflammatory thrombosis in a human endothelialized microfluidic model 
This chapter presents work featured in the article: 
Greineder, C., Johnston, I., et al. (2017) Blood Advances 1(18): 1452-1465 
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Abstract 
Diverse human illnesses are characterized by loss or inactivation of endothelial 
TM, predisposing to microvascular inflammation, activation of coagulation, and tissue 
ischemia. Single-chain antibody fragment (scFv/TM) fusion proteins, previously protective 
against end-organ injury in murine models of inflammation, are attractive candidates to 
treat inflammatory thrombosis. However, animal models have inherent differences in TM 
and coagulation biology, are limited in their ability to resolve and control endothelial 
biology, and do not allow in-depth testing of “humanized” scFv/TM fusion proteins, which 
are necessary for translation to the clinical domain. To address these challenges, we 
developed a human whole-blood, microfluidic model of inflammatory, TF-driven 
coagulation that features a multichannel format for head-to-head comparison of 
therapeutic approaches. In this model, fibrin deposition, leukocyte adhesion, and platelet 
adhesion and aggregation showed a dose-dependent response to TNFα activation and 
could be quantified via real-time microscopy. We used this model to compare hTM/R6.5, 
a humanized, intracellular adhesion molecule 1 (ICAM-1)–targeted scFv/TM 
biotherapeutic, to untargeted antithrombotic agents, including soluble human TM (shTM), 
anti–TF antibodies, and hirudin. The targeted hTM/R6.5 more effectively inhibited TF-
driven coagulation in a PC-dependent manner and demonstrated synergy with 
supplemental PC. These results support the translational prospects of ICAM-targeted 
scFv/TM and illustrate the utility of the microfluidic system as a platform to study 
humanized therapeutics at the interface of endothelium and whole blood under flow. 
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Introduction 
More than a century after the first description of purpura fulminans in 1884, the 
relationship between coagulation and systemic inflammation remains the subject of 
considerable interest and study196–198. The thrombotic process that occurs in the setting of 
infection or activation of the immune response is recognized as having distinct elements, 
which distinguish it from normal hemostasis or even other forms of arterial or venous 
thrombosis199. While agents such as antithrombin III and APC initially held promise in 
treating sepsis, their clinical utility has been limited by a lack of efficacy and bleeding 
risks200,201, and the benefit of more standard anticoagulants such as heparin is 
uncertain202,203. Better understanding of the elements of inflammatory thrombosis and 
identification of targets for safe intervention represent a significant medical priority. 
The PC pathway normally functions to limit excessive activation of coagulation, but 
it is suppressed in the setting of systemic inflammation. Inflamed ECs demonstrate loss 
of the natural anti-coagulants TM and EPCR from their luminal surface30,204–207. 
Conversely, TF expression on a variety of cell types in systemic inflammation promotes 
activation of coagulation and is an attractive target for intervention208,209. Existing 
pharmacologic approaches intended to intercept inflammatory activation of coagulation 
may be limited by their inability to localize to TF-expressing procoagulant surfaces. For 
example, soluble human TM (shTM), which is currently being evaluated in a phase 3 
clinical trial of patients with severe sepsis and coagulopathy 
(www.clinicaltrials.govidentifier #NCT0158831), lacks any specific affinity for cellular 
surfaces210. 
My interest in inflammation and the prothrombotic nature of HIT overlapped with 
that in Dr. Vlad Muzykantov laboratory’s interest in pharmacologic approaches to 
attenuate inflammation by specifically targeting TM to activated cellular surfaces211. In their 
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first report of this strategy, recombinant mouse TM was fused to a single-chain antibody 
fragment (scFv) specific for mouse ICAM-1 (CD54). In a murine model of acute lung injury, 
ICAM-1–targeted scFv/TM was found to facilitate interaction with endogenous EPCR, 
reduce inflammatory markers, and improve transendothelial plasma protein leakage212. 
While these studies demonstrated the potential therapeutic benefit of this approach, the 
effect on activation of coagulation was not examined. 
The challenges in demonstrating the efficacy of ICAM-1–targeted TM in TF-driven 
inflammatory thrombosis are several fold. First, there is uncertainty over the clinically 
significant sources of TF in sepsis and related disorders213,214. Differences in cellular 
sources of TF are particularly relevant to scFv/TM, as its distribution is more controlled 
than untargeted “fluid-phase” agents (i.e., soluble TM) and therefore more likely sensitive 
to changes in the relative cellular contributions to thrombin generation. It is challenging to 
discern the contribution of endothelial TF from other sources such as hematopoietic cells, 
epithelium, fibroblasts, pericytes, and smooth muscle215–217. While ECs express TF under 
inflammatory stimuli in vitro, studies have failed to demonstrate a definitive role of 
endothelial TF in murine models218, which may not fully replicate human biology or be 
sensitive to the contribution of endothelial TF to activation of coagulation215–217. TM itself 
demonstrates species-specific differences in the balance between anti-inflammatory and 
anti-thrombotic activity219,220. Finally, translation to human pathologies has been limited by 
the absence of species cross-reactivity of the murine therapeutic. 
To address these challenges and provide a model that can begin to close this 
translational gap, my efforts at using a commercially available, multichannel microfluidic 
system that uses human whole blood perfused through cytokine-activated, human 
endothelial–lined flow chambers, with real-time microscopy for visualization of underlying 
pathophysiologic events were combined with the Muzykantov’s group. This joint effort 
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focused on use of this sytem to study “humanized” scFv/TM therapeutic hTM/R6.5, which 
incorporates both human TM and a human-specific anti–ICAM-1 scFv. This approach 
allowed testing of ICAM-1–targeted scFv/TM as an intervention in TF-driven inflammatory 
thrombosis using an entirely human microfluidic system, employing multiple channels run 
simultaneously, allowing for a side-by-side comparison of therapeutic interventions within 
a single experiment. 
 
Methods 
Venipuncture and whole blood preparation. 
All studies involving human subjects were approved by the University of 
Pennsylvania institutional review board (protocol 822534). Written informed consent from 
healthy volunteer donors was obtained for the use of deidentified blood samples. Whole 
blood samples were collected from the antecubital vein using a 19G butterfly cannula 
system. The first 5 ml of blood was discarded, followed by collection into vacuum tubes 
containing citrate and corn trypsin inhibitor (CTI), a FXII inhibitor, with final concentrations 
of 11 mM and 50 μg/ml, respectively. 
In experiments involving inflammatory activation of whole blood, 50 ng/ml 
lipopolysaccharide (LPS) was added for 90 minutes at 37°C. In experiments involving PC-
deficient blood, whole blood samples were centrifuged for 15 minutes at 1500g at room 
temperature to isolate platelet-poor plasma. 50% of the original plasma was removed and 
replaced with an equivalent volume of PC-immuno-depleted or normal control plasma. CTI 
was then added to maintain the final blood concentration at 50 μg/ml. 
In all experiments, 5 μg/ml Alexa Fluor 568/anti-fibrin monoclonal antibody was 
added to whole blood, along with either calcein-AM (2 μg/ml) or fluorescent anti-leukocyte 
and platelet antibodies (Brilliant Violet anti-CD45 and FITC anti-CD41, each 1.5 μg/ml). 
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Whole blood samples were recalcified just prior to infusion into the microfluidic channels, 
adding CaCl2 to a final concentration of 11 mM. 
 
Microfluidic model of inflammatory thrombosis. 
Endothelialized microfluidic chambers and a TNFα injury were described in 
Chapter 2. On the day of experimentation, endothelialized channels were flow adapted for 
4 to 6 hours at 5 dynes/cm2 at 37°C using TNFα. To induce inflammatory activation of 
ECs, TNFα was added at varying concentrations during the flow adaption period. Fresh 
media was allowed to flow through the channels for 30 minutes to “wash out” residual 
TNFα prior to introduction of whole blood. In some experiments, EC-targeted antibodies 
or recombinant proteins were added during the first 25 minutes of this washout period, 
followed by 5 minutes of flow to remove nonspecifically bound protein. In other 
experiments, antithrombotic agents were mixed into the whole blood. 
While each Bioflux 48-well plate contains 24 flow chambers, whole blood 
experiments were run with no more than 8 channels (4 pairs of 2) at once to minimize the 
time between imaging of each pair of channels. This setup allowed 2 or 3 replicates for 
each of 3 or 4 experimental conditions (e.g., control, TNFα only, TNFα + therapeutic A, 
and TNFα + therapeutic B). A computer interface was used to move a motorized 
microscope stage (Fluxion Biosciences) rapidly between viewing areas, allowing each pair 
of channels to be imaged approximately every 15 to 30 s. Imaging was performed on a 
Zeiss Axio Observer microscope under a ×10/0.25 objective. The focal plane was set to 
be at the interface of the lower wall endothelial layer and the whole blood. Under this 
objective and aperture, we expect the depth of field to be ∼8.5 μm. Fluorescent images 
were acquired using identical settings for all channels, while bright-field images allowed 
direct visualization of flow. 
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Confocal microscopy. 
Channels were fixed by flowing 4% paraformaldehyde at 1 dyne/cm2 into the 
channel for 15 minutes. The cells were washed with PBS and blocked with 5% donkey 
serum prior to adding primary and secondary antibody and staining with Hoechst reagent. 
Imaging was performed using a Zeiss LSM 710 at original magnification ×20. 
 
Data analysis and statistics. 
Each figure represents data from a single experiment with means and standard 
errors derived from replicate channels within that experiment. For analyses, bright-field 
and fluorescence microscopy images were imported into ImageJ and analyzed frame by 
frame using identical acquisition parameters for each experiment. Backgrounds were 
subtracted using an ImageJ rolling-ball algorithm with a radius of 50 pixels. Preset regions 
of interest, covering the entire channel except the areas immediately adjacent to the side 
walls, were used to measure MFI in green and red channels or mean signal intensity in 
the bright-field channel. Frame “time codes” were used to generate time courses, and 
areas under the curve (AUCs) were calculated for statistical comparisons. First-derivative 
curves were calculated with GraphPad statistical software and statistical differences were 
determined using GraphPad Prism 6.0. One-way analysis of variance was performed, 
followed by appropriate multiple comparison (Tukey) test and calculation of multiplicity 
adjusted P values. P < 0.05 was considered statistically significant. 
 
Cells and cell lines. 
HUVECs were purchased and maintained using EGMTM BulletKitTM (Lonza). 
Drosophila S2 cells were maintained in Schneider’s complete medium and transitioned to 
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serum free Insect-Xpress (Lonza) supplemented with 0.5 mM CuSO4 for recombinant 
protein expression. Anti-human ICAM-1 hybridoma (clone R6.5), CHO-hICAM, and CHO-
K1 wild type cells were purchased from ATCC.  
 
Antibodies and other reagents. 
Human α-thrombin, human PC, CTI, and blood collection tubes containing citrate 
and CTI were purchased from Haematologic Technologies. Recombinant human TNFα 
was purchased from Corning. Lipopolysaccharides (LPS) from E. Coli 055:B5 and 
recombinant hirudin were purchased from Sigma-Aldrich. Anti-human VCAM-1 
(polyclonal, BBA19) was purchased from R&D systems. Anti-human TF antibodies were 
purchased from R&D systems and eBioscience (clone HTF-1). FITC conjugated-anti-
CD41 (clone HIP8) was also purchased from eBioscience. Anti-human TM (clone Phx-01) 
and Brilliant Violet anti-CD45 (clone 30-F11) antibodies were purchased from BioLegend. 
Lyophilized, immunodepleted PC-deficient plasma and normal plasma controls were 
purchased from Aniara.  
 
Cloning of R6.5 single chain variable fragment (scFv), soluble human TM (shTM), and the 
hTM/R6.5 fusion protein. 
PCR using 5’ signal peptide primers was used to isolate full length cDNAs for R6.5 
variable heavy chain (VH) and light chain (VL) from hybridoma-derived single stranded 
cDNA, as previously described221. The encoded sequence was compared with the 
previously published full-length sequence of the R6.5 monoclonal antibody variable 
domains and found to be identical222. VH and VL cDNAs were assembled into an scFv 
construct in the pMT/Bip expression vector with the triple flag tag appended to the 3’ end 
of the VL domain. Likewise, cDNAs encoding shTM (Glu22-Ser515) and the hTM/R6.5 
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fusion protein were ligated into the pMT/Bip expression vector (Invitrogen), each with a 
triple Flag tag appended to the 3’ end. For the fusion protein, an Spe I site was added to 
the 5’ end of R6.5 scFv, and the 3’ end of shTM, along with a 13-amino acid rigid linker 
((SSSSG)2AAA).  
 
Recombinant protein expression and purification. 
pMT/shTM, R6.5 scFv, and hTM/R6.5 were each co-transfected with pCoBLAST 
in S2 cells and selected with blasticidin to generate stable cell lines216. Expression and 
purification was performed as previously described216. Briefly, proteins were harvested 
from S2 cell supernatant using an anti-FLAG (M2) affinity column (Sigma-Aldrich), and 
assessed for purity via sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and high-performance liquid chromatography (HPLC). The differences in affinity 
lead to different flow rates and isolation of components from the mixture. 
 
Results 
Production and characterization of human-specific anti-ICAM scFv/TM. 
To create the humanized anti-ICAM scFv/TM complementary DNA (cDNA) 
construct (hTM/R6.5), cDNA encoding the extracellular portion of human TM (Glu22-
Ser515) was fused with the R6.5 scFv cDNA, containing VH and VL domains cloned from 
the corresponding anti–human ICAM-1 hybridoma121,223. The detailed molecular design of 
each construct is shown in Figure 6.1A. Purified R6.5 scFv and hTM/R6.5 migrated as 
single bands on nonreducing SDS-PAGE (Figure 6.1B), with sizes (∼35 kDa and ∼120 
kDa) similar to those seen for previous scFv and scFv/TM fusion proteins (TM runs 
significantly higher than its predicted size due to glycosylation). Similar purity was seen 
on size-exclusion high-performance liquid chromatography, although this method 
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revealed a dimer form of hTM/R6.5, which accounted for ∼20% of total absorbance 
(Figure 6.1C). As shown in Figure 6.1D and 6.1E, hTM/R6.5 demonstrated high affinity, 
specific binding to human ICAM-1 in a flow cytometry based assay with stably-transfected 
CHO cells (Kd = 24 nM) and a cell-based enzyme-linked immunosorbent assay on TNFα–
activated HUVECs (Kd = 9.7 nM), respectively. The fusion protein was functionally active 
when bound to TNFα–activated HUVECs, demonstrating thrombin-dependent PC 
activation after binding and washing to remove nonspecifically-bound protein. At 
concentrations sufficient to saturate available binding sites on these cells (40-50 nM), the 
fusion protein more than compensated for the loss of APC generation caused by activation 
of the ECs by cytokine (P < .01; Figure 6.1F). 
 
Establishing a multichannel system of endothelialized flow channels. 
To enable testing of hTM/R6.5 at the interface of human whole blood and 
endothelium, HUVECs were grown in microfluidic flow chambers until they established 3-
dimensional, fully confluent, endothelialized channels (typically 2-3 days) as displayed in 
Chapter 2. Following 6 hours of flow adaptation at 5 dynes/cm2, a shear stress typical of 
postcapillary venules224, cells displayed the qualities described in Chapter 2. 
 
Characterization of inflammatory thrombosis model. 
The inflammatory thrombosis model was characterized as described in Chapter 2. 
To determine the optimal conditions for testing antithrombotic therapeutics, we defined the 
extent of coagulation in the microfluidic model as a function of the dose and time of 
cytokine exposure. Both higher concentration of TNFα (Figure 2.5B) and longer duration 
of stimulation (Figure 2.5C) led to greater fibrin deposition upon infusion of whole blood. 
These experiments also revealed the advantage afforded by the multichannel format, 
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which allowed comparison of multiple experimental conditions (with replicates) within a 
single experiment. Figure 6.2 shows the relatively small variance within a single 
experiment, compared with the variability across experiments with separate EC 
preparations and whole blood samples. On the basis of these results, each subsequent 
experiment was performed with a single blood sample and EC preparation and 8 
microfluidic channels. 
Apart from fibrin deposition, other physiologically relevant outcomes were found to 
vary with the extent of cytokine activation of the endothelialized channels. In particular, 
adhesion of leukocytes and platelets, based on accumulation of green fluorescence, was 
seen only after TNFα stimulation (Figure 6.3A). Higher doses of TNFα also demonstrated 
earlier disruption and occlusion of blood flow, based on changes in bright-field signal 
intensity (Figure 6.3C). Separately tracking platelets and leukocytes using antibodies to 
platelet αIIb3 labeled in green and antibodies to leukocyte CD45 labeled in blue, we found 
that while that the number of adherent platelets varied with TNFα concentration in the 
range of 1 to 10 ng/ml, the number of adhered leukocytes was similar (Figures 6.3B). We 
confirmed this finding using an automated cell counting algorithm to enumerate adherent 
leukocytes flowing over TNFα–activated channels and found similar numbers of adhered 
leukocytes per channel area in channels treated with either 1 or 10 ng/ml TNFα (Figures 
6.4A). Additional experiments performed across a lower range of TNFα doses (0.1-1.0 
ng/ml) revealed a dose response of leukocyte adhesion to TNFα stimulation within this 
lower range (Figures 6.4B). Finally, flowing whole blood over TNFα–activated channels 
resulted in not only adhesion of leukocytes but also an activation of neutrophils that 
resulted in deposition of NETs225, which could be visualized in real time with nucleic acid 
stains (Figures 6.5)221. 
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Inflammatory thrombosis model is TF driven. 
We next validated the role of TF in initiating coagulation in this model, noting that 
peripheral blood was collected in the presence of CTI, a FXIIa inhibitor222. Figures 6.6A 
shows the experimental design, in which TF inhibitory antibody (or media control) was 
flowed over TNFα–activated endothelialized channels prior to the infusion of whole blood. 
As shown in Figures 6.6B, TF blockade significantly (P = 0.02) reduced fibrin deposition, 
confirming the role of endothelial TF as a driver of coagulation in this model. TF antibody 
decreased the accumulation of green fluorescence (Figures 6.7A), reflecting the sum of 
leukocyte and platelet adhesion. While these cell types were not individually stained in this 
experiment, the morphology suggested a decrease in platelet rather than leukocyte 
adhesion. 
 
Endothelial TM regulates inflammatory activation of coagulation. 
A similar approach was taken to investigate the role of endogenous endothelial TM 
in regulating coagulation in the whole blood microfluidic model. Although TNFα stimulation 
decreases endothelial TM, some APC generation capacity remains (Figures 6.1F). To 
achieve complete inhibition, we used an antibody specific for the fifth epidermal growth 
factor–like domain of TM, which blocks thrombin binding and eliminates nearly all APC 
generation capacity (Figures 6.1F)226. Treatment of TNFα–stimulated channels with this 
antibody prior to the infusion of whole blood significantly increased fibrin deposition (P < 
0.001; Figures 6.6C-D). 
These results established the microfluidic model as a means to test targeted 
therapeutics in a humanized system, with the hypothesis that the ICAM-1 targeted fusion 
protein would localize to activated cellular surfaces, reverse the loss of endothelial TM 
induced by cytokine activation, and abrogate the TF-driven thrombotic response. Indeed, 
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treatment of TNFα–activated endothelialized channels with 50 nM hTM/R6.5, a 
concentration chosen based on the prior binding studies (Figures 6.1E), produced the 
opposite effect of the TM-blocking antibody, completely eliminating fibrin deposition 
(Figures 6.6B-C). As seen previously, effects on green fluorescence mirrored those seen 
for fibrin generation, consistent with a reduction in platelet adhesion (Figures 6.7B). 
 
Comparative testing of antithrombotic agents. 
Given the effectiveness of hTM/R6.5 in the whole blood microfluidic model, we 
next took advantage of the multichannel format to compare its antithrombotic efficacy with 
that of other antithrombotic agents. As a first step, the fusion protein was tested against 
equimolar concentrations of its individual components, shTM and R6.5 scFv. These 
proteins had minimal effects on fibrin deposition when infused during the TNFα washout 
period (Figure 6.8). While expected, this confirmed that both domains of the fusion protein 
are required for its activity and excluded that ICAM-1 blockade alone might be solely 
responsible for the observed anti-thrombotic effect. 
Endothelial-bound hTM/R6.5 was next tested against shTM added directly to 
whole blood. Figure 6.9A shows the experimental design of these experiments. While 
both agents significantly decreased fibrin deposition (Figure 6.9B), the effect of shTM was 
less sustained (P = .05), even at a dose far greater than its IC50 in TF-induced thrombin 
generation assays227. It should be noted that hTM/R6.5 was limited to the protein bound 
to the cells, as the targeted protein was not added to whole blood in these experiments. 
Hirudin (5 U/ml) and hTM/R6.5 (50 nM) were also compared and demonstrated similar 
results (P = 0.03; Figure 6.9C).  
hTM/R6.5 was next compared with shTM following a combination of cytokine 
activation of ECs and inflammatory activation of whole blood (Figure 6.10A). The latter 
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was induced by 90-minute preincubation of the whole blood with 50 ng/ml LPS, conditions 
previously used to induce neutrophil oxidative burst and monocyte TF expression in 
human whole blood228,229. LPS was chosen to better simulate human disease states, such 
as sepsis, in which activated leukocytes and other blood components may contribute to 
inflammatory thrombosis198,199. While both agents demonstrated antithrombotic effect in 
this setting, hTM/R6.5 was significantly more effective in inhibiting fibrin deposition than 
shTM (P = 0.05; Figure 6.10B). 
 
hTM/R6.5 is at least partially PC dependent. 
We next tested the contribution of PC activation to the antithrombotic activity of 
hTM/R6.5. A recently reported antibody, HAPC1573, which binds human APC (but not its 
zymogen) and inhibits its inactivation of FVa and FVIIIa in a dose-dependent manner230, 
was mixed into whole blood (Figure 6.11A). In naive whole blood, HAPC1573 treatment 
produced fibrin deposition similar to equimolar isotype control antibody (P = 0.33), 
although shortened time to peak-fibrin generation was observed. APC inhibition markedly 
increased fibrin deposition in endothelialized channels treated with hTM/R6.5 (P < 0.05), 
although a persistent delay was seen in the time to peak-fibrin generation (Figure 6.11B-
D). This effect, reported in previous TGA studies, has been attributed to direct inhibition 
of thrombin by TM227. 
These results prompted investigation of hTM/R6.5 in the setting of PC deficiency, 
a condition observed in sepsis and other syndromes involving systemic activation of 
coagulation231–233. To achieve the levels of PC deficiency similar to patients with these 
illnesses, we removed 50% of the plasma from donor whole blood and replaced it with an 
equal volume of PC-immuno-depleted (or non-depleted control) plasma (Figure 6.12A). 
Like APC inhibition, partial depletion of plasma PC produced fibrin deposition similar to 
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control whole blood (P = 0.34), with a slight decrease in time to peak-fibrin deposition234. 
PC deficiency dramatically altered the activity of the fusion protein, eliminating its inhibitory 
effect on overall fibrin deposition (P = 0.34; Figure 6.12B-D). In contrast, hTM/R6.5 
produced a delay in time to peak-fibrin generation in both PC-deficient and control whole 
blood, consistent with direct thrombin inhibition by the fusion protein (Supplement Table 
10)227. Finally, addition of exogenous, plasma-derived human PC to the PC-depleted blood 
restored the full antithrombotic effect of hTM/R6.5 (P < 0.05; Figure 6.12B-D). 
 
Discussion 
This is the first report of ICAM-1 targeted fusion proteins as a therapy for TF-driven 
inflammatory thrombosis. Affinity targeting to cellular surfaces has the potential to 
dramatically alter local concentrations and interaction with binding partners, particularly in 
surface-driven phenomena such as coagulation, and the improved efficacy of hTM/ R6.5, 
compared with other therapeutics, including sTM, hirudin, and anti-TF, demonstrates the 
translational potential of this approach. hTM/R6.5 bound to the surface of activated human 
ECs and restored APC generation capacity above that of uninflamed endothelium. 
hTM/R6.5 shares a number of desirable features with its mouse-specific analog, 
YN1/mTM212, and the use of an scFv fragment enables facile genetic fusion to therapeutic 
cargoes and mitigates the Fc and complement-mediated toxicities seen in clinical trials of 
the parental antibody, R6.5, or enlimomab235–238. 
To demonstrate the therapeutic efficacy of human-specific hTM/ R6.5, a 
microfluidic system consisting of entirely human components was developed to model TF-
driven inflammatory thrombosis. Sophisticated in vitro systems have been developed that 
incorporate multiple cell types and reproduce the architecture of microvascular 
networks239–243. Our priority was to establish a comparatively straight- forward model, 
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suitable for testing and comparing targeted scFv/TM with other antithrombotic drugs211,244–
246. Although the model lacks subendothelial components of a true vessel, including 
epithelial tissues, it allows for control over endothelial and leukocyte activation, 
manipulation and treatment of human WB, and quantification of therapeutic effects with 
high spatial and temporal resolution. While the present focus was on abrogation of fibrin 
deposition, additional readouts of inflammatory biology such as leukocyte adhesion and 
generation of neutrophil extracellular traps were also shown to be possible using this 
model system. By calculating first-derivative curves of fibrin fluorescence intensity, we 
provide readouts analogous to common TGA assays. Importantly, the multichannel format 
of this system allows for parallel testing of multiple therapeutic approaches with a single 
blood donor and EC preparation, limiting the impact of these variables, which can 
complicate other complex microfluidic model systems. 
Several limitations of the model should be highlighted. First, PDMS flow chambers 
are rectangular in cross-section and fail to reflect the mechanical compliance of normal 
vasculature247. Use of linear channels with fixed dimensions and no branches limits 
extrapolation to physiologic vascular beds, where inflammatory, TF-driven thrombosis 
may occur heterogeneously248. The important physiologic sources of TF are a matter of 
ongoing investigation249, and as currently constructed, this model is limited to 
hematopoietic and endothelial sources. In addition, only HUVEC cells were investigated 
in the current model, although further optimization to enable culture of and comparison 
with other endothelial sources is ongoing. The current conformation does not permit 
recirculation, so exposure of endothelialized channels to WB flow was limited in duration 
by need to avoid cell settling and activation of the contact pathway (CTI provides ;1 hour 
of inhibition222). While our intention was to model TF-driven thrombosis, the use of CTI 
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may likewise be viewed as a limitation, as it eliminates any contribution of FXII–dependent 
coagulation, believed to play a role in certain systemic inflammatory syndromes250. 
These limitations notwithstanding, the data presented provide several insights into 
the role of the endogenous PC pathway and the action of scFv/TM therapeutics. First, the 
contrasting results with inhibition and augmentation of endothelial TM suggest its 
importance in regulating coagulation under systemic inflammation. Second, the benefit of 
ICAM-targeted TM over its soluble counterpart supports the hypothesis that localization of 
the protein to the cellular membranes enhances its functional activity212,251,252. In fact, the 
difference in potency between these 2 agents may be more significant than their relative 
concentrations would suggest, as only a fraction of hTM/R6.5 molecules would have 
bound to the cell membrane. While ICAM-1 targeting of hTM/R6.5 was limited to 
hematopoietic and ECs in these studies, other cell types, such as epithelium, express 
ICAM-1, and may be both an important source of TF24 and a valuable target of this 
approach253. 
There are several reasons why binding of TM to cell membranes may enhance its 
antithrombotic activity. Cell-surface localization positions TM in proximity to TF and 
prothrombinase complexes assembled on cell membranes, resulting in immediate 
inhibition of thrombin and redirection to PC activation as it is produced254,255. Experiments 
involving antibody inhibition of APC and plasma PC deficiency suggest that PC activation 
is an important mechanism of hTM/R6.5 antithrombotic activity, as the ability of hTM/R6.5 
to decrease the peak rate of fibrin generation was PC dependent. EC surface localization 
may accelerate activation of PC by partnering with endogenous EPCR, promoting PC 
cleavage by the thrombin/TM complex256. Although this was not investigated in the present 
studies, previous studies with the murine-specific analog of hTM/R6.5 demonstrated APC 
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generation by cell-bound fusion protein was inhibited when binding of PC to endothelial 
EPCR was blocked212. 
The contribution of PC activation to the antithrombotic activity of hTM/ R6.5 
suggests a benefit with combination therapy, as pharmacologic replacement of TM alone 
may be insufficient in the setting of PC deficiency (as seen in septic patients231,232). While 
human plasma–derived PC concentrate failed to improve outcomes in sepsis or 
disseminated intravascular coagulation22,257, the synergy observed with pairing of PC and 
hTM/R6.5 suggests that simultaneous PC replacement and targeted delivery of TM may 
be an effective clinical strategy. Further investigation using patient specimens in our 
microfluidic model and confirmation in preclinical animal models will be necessary to 
determine if this combination therapy can surpass numerous previous pharmacologic 
attempts to prevent TF-driven inflammatory thrombosis and disseminated intravascular 
coagulation in the clinical setting. 
These studies present a novel therapeutic approach in sepsis, but that could be 
applicable across various Steps 2 and 3 in HIT’s pathogenesis (Figure 1.5). These studies 
show that ICAM-1-targeted TM is more effective than its soluble form displaying how 
thrombi localization can improve therapeutic efficacy. In reference to HIT, this could be 
utilized to localize therapeutics to HIT relevant targets; these targets could include 
PF4/GAG (as discussed in Chapter 3), PF4/heparin, PF4-VWF-HIT antibody (as 
discussed in Chapter 4), or PF4-NET-HIT antibody (as discussed in Chapter 5) 
complexes. TM could potentially combat HIT thrombosis as it provides both anti-
thrombotic and anti-inflammatory components. Alternatively, therapeutics targeting the 
glycocalyx, VWF, neutrophils, or NETs could also be affective in a localized structure. 
Moreover, by understanding how each target is significant in particular vessels and injury 
settings, the therapeutics can be further tailored to patient conditions. 
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Figure 6.1. Assembly, characterization, and functional activity of hTM/R6.5 
biotherapeutic. 
(A) Molecular design of R6.5 scFv and hTM/R6.5. (B) Size and purity of recombinant 
proteins based on SDS-PAGE (lane 1, R6.5 scFv; lane 2, hTM/R6.5) and (C) size 
exclusion HPLC. hTM/R6.5 has a minor dimer form (indicated by arrow), accounting for 
∼20% of absorbance at 280 nm. (D) hTM/R6.5 binds specifically to human ICAM-1-
expressing CHO cells (CHO-hICAM), but not wild type (CHO wt). Flow cytometry was 
performed on each cell type incubated with different concentrations of fluorescently 
labeled fusion protein. For each reaction, MFI was calculated for 10 000 events. Each 
reaction was done twice, with mean ± SD of the MFI shown. (E) hTM/R6.5 binds strongly 
to TNFα-stimulated HUVECs, but only minimally to non-stimulated cells. Cell-based 
ELISAs were performed on live cells as previously described19 using anti–FLAG-HRP to 
probe for cell-bound fusion protein. Graph shows mean ± SD. (F) In vitro APC generation 
A B C 
D E F 
157 
assay by cell-bound fusion protein, as described previously212. TNFα-stimulated HUVECs 
show reduced APC generation capacity due to loss of surface TM, although some residual 
function is seen in comparison with cells treated with an anti-TM blocking monoclonal 
antibody. For testing the functional activity of cell-bound hTM/R6.5, bvg-stimulated cells 
were incubated for 30 minutes at 37°C with various concentrations of fusion protein and 
then washed to remove nonspecifically bound protein prior to incubation with human 
thrombin (1 nM) and PC (100 nM). At saturating concentrations of hTM/R6.5 (40-50 nM), 
the fusion protein more than compensates for the reduction in PC activation induced by 
TNFα stimulation (*P < .01 versus TNF only). Graph shows mean ± SD, N = 3 for each 
condition. EC50, 50% effective concentration; mOD, 1/1000th of an optical density unit. 
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Figure 6.2. Intra- versus inter-experimental variability.  
Fibrin deposition data from two independent experiments. While some variation is seen 
between replicate channels within the same experiment (error bars show mean ± SEM for 
N = 2-3 channels), the timing and extent of fibrin deposition is fairly consistent, allowing 
meaningful statistical comparisons between experimental groups. In contrast, the MFI 
versus. time curve is markedly different between TNFα-stimulated channels run on 
separate days, preventing pooling of data or comparisons of groups run on separate days.  
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Figure 6.3. Changes in TNFα treatment impact fibrin and platelet accumulation 
which impact time to occlusion.  
(A) Green fluorescence, representing adhesion of leukocytes and platelets (both labeled 
with calcein AM) to the endothelium. Representative image (left panel) shows individual 
A 
B 
C 
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adherent leukocytes (arrows) as well as variably sized clusters of various cell types 
(arrowheads). Graph (right panel) shows mean fluorescence intensity versus time for 
differing TNFα concentrations, mean ± SEM, with N = 2 channels for control and N = 3 
channels for each concentration. (B) Three color experiment, in which fibrin (red), 
leukocytes (blue), and platelets (green) were tracked with distinct fluorophores. Left panel 
shows representative images of endothelialized channels pre-activated with varying doses 
(1 ng/ml versus. 10 ng/ml) of TNFα. Quantitation (right panel) shows that platelets and 
fibrin vary with TNFα concentration, but the number of adherent leukocytes is unchanged 
across doses, ** = P < 0.01, * = P < 0.05, # = n.s. (P = 0.54). (C) Use of brightfield signal 
intensity as a marker of partially disrupted or fully occluded flow, following infusion of whole 
blood into TNFα-stimulated endothelialized channels. Representative image (left panel) 
shows characteristic increase in signal in bottom channel, which had occluded at the time 
point shown. Graph shows mean signal intensity (MSI) versus time for differing TNFα 
concentrations, mean ± SEM, with N = 2 channels for control and N = 3 channels for each 
concentration. 
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Figure 6.4. Quantification of leukocyte numbers in TNFα-activated channels.  
(A) Similar density of adhered leukocytes was observed between channels activated with 
either 1 ng/ml (blue) or 10 ng/ml (red) (N =3/dose) (B) A dose-response of adhered 
leukocytes was seen in a lower range of 0.1-1 ng/ml of TNFα (n=1/dose). Minimal 
leukocyte adhesion was seen in un-activated channels (blue). The density of adhered 
leukocytes was calculated using an automated particle counting algorithm (ImageJ). 
Images from calcein AM-stained blood were converted to binary masks, and particles 
counted using the included “analyze particles” algorithm with a circularity index of 0.5-1. 
To minimize interference from large platelet aggregates, blood was not re-calcified prior 
to infusion over channels in these experiments.  
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Figure 6.5 Exposure of TNFα-activated channels to whole blood results in 
deposition of NETs.  
(A) Staining of extracellular nucleic acid, often in elongated deposits, was seen in TNFα-
activated endothelium (bottom), but not in untreated channels (top). (B) Formation and 
growth of NETs could be monitored in whole blood in real time. Whole blood, stained with 
1 µM cell-impermeant SYTOX nucleic acid stain (green) and 4 µM Hoeschst cell-permeant 
nucleic acid stain (blue), was infused over TNFα (0.5 ng/ml)-activated endothelium. 
Neutrophil nuclei could be seen as small, mobile, poly-lobulated forms (arrowhead), while 
endothelial nuclei were larger, round, and stationary (asterisk). Extracellular DNA 
associated with NETs stained brightly with SYTOX, and dimly with Hoeschst (arrows). 
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Figure 6.6. Endothelial TM regulates TF-driven coagulation in inflammatory 
thrombosis model. 
(A) Schematic showing experimental design. Endothelialized channels were flow adapted 
at shear stress of 5 dynes/cm2, stimulated with 1 ng/ml TNFα for 6 hours, and then treated 
with antibodies or fusion protein during the first 25 minutes of a 30-minute TNFα washout 
period, followed by a 5-minute wash to remove nonspecifically bound protein and, finally, 
infusion of whole blood at shear stress of 5 dynes/cm2. (B) Blockade of endothelial TF 
delays and markedly reduces fibrin deposition (P = 0.02 for AUC of TNF versus TNF + 
A 
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anti-TF antibody). Graph shows mean ± SEM, with N = 2-3 channels per condition. (C) 
Blockade of endothelial TM results in significant increase in fibrin deposition (P < 0.001 
for AUC of TNF only versus TNF + TM blockade), whereas treatment of TNFα-activated 
endothelium with hTM/R6.5 scFv fusion protein completely eliminates fibrin deposition (P 
= 0.03 for AUC of TNF only versus TNF + hTM/R6.5). Graph shows mean ± SEM, with N 
= 2-3 channels per condition. (D) Representative fluorescent images for panel C show 
fibrin deposition within endothelialized channels and demonstrate opposing effects of TM 
inhibition and augmentation. 
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Figure 6.7. Therapeutic comparison of platelet and WBC accumulation during 
inflammatory thrombosis. 
Green fluorescence time curves (left panel) and AUC analysis (right panel), mean ± SEM, 
from (A) TF inhibition experiment (N = 2 channels per condition, *P < 0.05 versus. TNFα 
only), (B) anti-TM versus. hTM/R6.5 experiment (N = 2 channels per condition, *P = 0.03 
for hTM/R6.5 versus anti-TM), (C) shTM versus hTM/R6.5 experiment (N = 2 channels 
per condition, *P = 0.03 for hTM/R6.5 versus TNFα only, # P = 0.08 for shTM versus TNFα 
only), and (D) combined TNF/LPS model (N = 2 channels for TNF/LPS only and N = 3 
channels for each treatment group, *P = 0.04 for shTM versus. TNFα/LPS only, **P = 0.02 
for hTM/R6.5 versus TNFα/LPS only). The effect of each antibody and/or therapeutic on 
C 
D 
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the accumulation of green fluorescence mirrored its effect on fibrin deposition (Figures 
6.6A, 6.6B, 6.10, and 6.11, respectively).  
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Figure 6.8. Both domains of hTM/R6.5 are required to generate an antithrombotic 
effect. 
(A) Experimental design. All proteins were infused in equimolar concentrations (50 nM) 
during the TNF washout period, followed by a 5-minute wash to remove nonspecifically 
bound protein. Flow of media and whole blood was at shear stress of 5 dynes/cm2. (B) 
Only hTM/R6.5 inhibited fibrin deposition, confirming that both the ICAM-1 binding and 
hTM domains must be present to produce an antithrombotic effect. Left panel shows MFI 
versus time, mean ± SEM, with N = 2 channels per condition. Right panel shows AUC 
analysis. * = P < 0.05 versus all other conditions. 
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Figure 6.9. Comparative testing of antithrombotic agents. 
(A) Experimental design, showing distinct timing of treatment with hTM/R6.5 scFv, bound 
to ECs during the first 25 minutes of the TNFα washout period versus soluble agents, 
which were mixed into whole blood. (B-C) Both 100 nM shTM (B) and 5 U/ml hirudin (C) 
inhibited coagulation, but were less effective than hTM/R6.5 (50 nM). Left panels show 
MFI versus time, ± SEM, with N = 2 channels for TNFα only and N = 3 channels for each 
therapeutic. Middle panels show representative fluorescent images. Right panels show 
AUC analyses. * = P < 0.05 versus TNF only; ** = P < 0.05 versus both other conditions; 
#, not significant (P = 0.17). 
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Figure 6.10 hTM/R6.5 has greater antithrombotic activity than shTM in combined 
model of endothelial cytokine activation and endotoxemia.  
(A) Experimental design, showing 6-hr stimulation of endothelialized channels with TNFα 
and 90-minute preactivation of whole blood with LPS (50 ng/ml). In this case, hTM/R6.5 
(50 nM) was infused during the TNFα washout period and mixed into the whole blood. (B) 
The fusion protein provided superior antithrombotic effect. Left panels show MFI versus 
time, mean ± SEM, with N = 2 channels for TNF/LPS only and N = 3 channels for each 
therapeutic. Right panels show AUC analyses. * = P < 0.05 versus TNF/LPS only; ** = P 
< 0.05 versus both other conditions. 
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Figure 6.11. Antithrombotic activity of hTM/R6.5 is largely reversed by APC 
inhibition.  
(A) Design of APC inhibition experiments. Anti-hAPC antibody (HAPC1573) or equimolar 
isotype control were mixed into whole blood at 300 nM concentration. (B) Inhibition of APC 
significantly reduced the antithrombotic effect of hTM/R6.5 while not significantly affecting 
fibrin deposition in endothelialized channels not treated with fusion protein. Graph shows 
A 
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mean ± SEM, with N = 2 channels for each condition. (C) AUC analysis. * = P < 0.05 
versus all other conditions; #, not significant (P = 0.47); ##, not significant (P = 0.72). (D) 
Time curves of the first derivative of fibrin fluorescence intensity demonstrate the effects 
of various combinations of HAPC1573 and hTM/R6.5 on key parameters: peak-fibrin 
generation rate and time to peak-fibrin generation rate. Dotted lines show actual values, 
whereas solid lines show Gaussian functions fitted to these data. 
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Figure 6.12. Antithrombotic activity of hTM/R6.5 is enhanced by PC 
supplementation in the setting of plasma PC deficiency.  
(A) Design of PC deficiency experiments. hTM/R6.5 was infused during the first 25 
minutes of the TNFα washout period, followed by infusion of PC-deficient blood versus 
control blood. (B) The anti-thrombotic effect of hTM/R6.5 was reduced in PC-deficient 
blood and restored with the addition of supplemental PC. Graph shows mean ± SEM, with 
D 
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N = 2 channels for each condition. (C) AUC analysis. * = P < 0.05 versus all other 
conditions; #, not significant (P = 0.33); ##, not significant (P = 0.28). (D) Time curves of 
the first derivative of fibrin fluorescence intensity demonstrate a delay in peak-fibrin 
deposition, but not a reduction in peak height by hTM/R6.5 in PC-deficient whole blood. 
Full efficacy is restored with the addition of supplemental plasma PC. 
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Discussion 
ECs play an important role in the thrombotic complications in HIT. 
In Chapter 3, we showed that in a microfluidic photochemical model of endothelial 
injury and in the cremaster arteriole laser injury model that PF4 and HIT show extensive 
binding to the EC lining upon which platelets accumulate during the process of thrombus 
growth. The area targeted by HIT antibodies spreads downstream of the original injury 
site. These findings are significant because they emphasize the importance of the 
vasculature as a target in HIT and a focus for novel interventions to complement 
contemporary antithrombotic therapies. These include therapeutics directed to endothelial 
PC receptor (EPCR), that block protease-activated receptors120, modify the glycocalyx 
coat258 or inhibit oligomerization of VWF.  
APC bound to EPCR activates PAR1 by a noncanonical cleavage259 leading to 
improved EC barrier function and resistance to injury by TNF260,261. We have shown that 
PF4 binds to TM, enhanced APC generation262. HIT antibodies block this effect, which we 
proposed may contribute to thrombus development. To combat or bypass this effect, we 
envision utilizing the peptide, Parmodulin-2, which blocks the PAR1/G13/RhoA pathway 
and stimulates PAR1/Gq/Rak1 signaling120. This allows for the cytoprotective signaling 
of PAR1 on ECs, but blocks the proinflammatory effects. This would allow us to evaluate 
how maintaining EC health combats being directly bound by PF4 and HIT antibodies. To 
distinguish between Parmodulin’s effects on ECs and its effects on circulating platelets, 
we intend to study Parmodulin-2 in the photochemical injury model, incubating the drug 
with whole blood prior to infusion and hematoporphyrin injury as a baseline. Parmodulin-
2 would be used in comparison to wildtype APC, and 2 variants that retain cytoprotective 
effects with little anticoagulant effects. These studies will be made possible by obtaining 
said parmodulins from Dr. John Griffin at the Scripps Research Institute263,264. The variant 
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5A-APC can be used for studies of murine as well as human endothelium265, this allows 
us to study the therapeutics in the HIT passive immunization murine model. 
We will modify the glycocalyx using heparinase, chondroitinase, and 
hyaluronidase to cleave heparin sulfate, chrondroitin sulfate, and hyaluronan, 
respectively. Treatment with these enzymes reduces the thickness of the glycocalyx layer 
by 26-43% when used individually and up to 90% when used in combination12,15,258. 
Removal of individual GAGs changes diffusion properties; this would suggest that these 
three GAGs are not evenly distributed and differ in their contribution to its permeability. 
Heparinase decreased diffusion, whereas diffusion was enhanced by the other two 
enzymes258. This may imply that heparin sulfate plays a more important structural role and 
its removal causes the collapse of the glycocalyx which compacts surface GAGs and 
prevents solute diffusion. How changes in diffusion affects binding of PF4, HIT antigen 
formation and the impact of immune injury on endothelial coagulant reactions will be 
studied. 
We envision HIT mice will be treated with these enzymes individually or in 
combination, and then will be subject to injuries to cremasteric vessel as described in 
Chapter 3. One key preliminary study will be to determine if removal of the glycocalyx 
affects baseline platelet adhesion and activation by allowing blood cells to interact more 
freely with the vascular wall. Nevertheless, by tracking PF4 and HIT antigen binding in 
these settings as presented in Chapter 3, we will shed light on the significance of the 
glycocalyx to the pathogenesis of HIT. 
 
VWF offers a thrombosis-relevant binding site for HIT antigens and contributes to the 
propagation of HIT.  
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In Chapter 4, we showed that elongated strands of VWF released from EC post 
injury generate extensive binding surfaces for PF4 and HIT antibodies. The PF4-VWF-HIT 
antibody complexes enhanced platelet accumulation in our in vitro microfluidic model. 
These findings are significant for various reasons. First, VWF strands are likely to be found 
in arteries and arterioles and be present under high shear132,266. VWF release occurs under 
inflammatory conditions that often are found in patients with HIT266,267 and are likely to be 
release in response to immune injury. Thus, these new observations suggest that control 
of endothelial activation may reduce the prothrombotic risks of HIT.  
These findings suggest that HIT antibodies bind along the surface of ECs to 
elongated strands of VWF and in doing so enhance platelet accumulation, along with 
additional mechanisms that may be revealed in the future. The role of VWF in thrombus 
formation in the cremaster laser injury model has been uncertain, but our group has shown 
that suppressing ADAMTS13 activity in this model is prothrombotic and results in the 
generation of elongated thrombi268.  As visualized in Chapter 4, VWF strands from injured 
ECs extend downstream along less injured ECs. This quality, in combination with 
formation of PF4-VWF-HIT antibody complexes, implies that VWF continually sensitizes 
ECs downstream of an injury site, allowing downstream thrombus extension in a process 
we called “rolling recruitment” and consistent with thrombus propagation as visualized in 
Step 3 (Figure 1.5). VWF also slows down platelets by allowing them to “roll” along the 
strands of VWF132,269, where they may deliver PF4 to the adjacent downstream EC surface 
extending the area of immune-targeted endothelium. The collective impact of these effects 
support the role of endothelial cells injury and formation of extended strands of VWF in 
the propagation of thrombi in space and extension of the procoagulant risk in time.  
We also demonstrated that at least one proposed VWF-targeted therapeutic, NAC, 
attenuated clot extension induced by HIT antibody in an in vivo model of vascular rose 
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bengal-induced photochemical injury. NAC increased the time to occlusion and indeed 
was completely prevented over the initial two hours following injury. It would be premature 
to indicate VWF as a key contributor to all thrombotic events in HIT patients. However, our 
findings do indicate that VWF-targeted therapeutics may provide a complement or 
alternative to anticoagulants in some settings, e.g. thrombi in arterioles or large arteries, 
and thereby increase the efficacy and potentially permit lower doses to be used and 
thereby decrease the risks of bleeding.  
We propose that the PF4-VWF-HIT antibody complexes contribute to arterial 
thrombi because the necessary antigenic site requires oligomerization of VWF and shear 
forces that open the individual molecules which exposes the requisite binding site. 
Therefore, therapies directed at this complex will be mostly efficacious for arterial thrombi. 
We will test this focusing on the use of recombinant ADAMTS13 as recently described in 
mice270. We propose that such therapeutic intervention will be effective in arteriolar 
thrombi, but not venule thrombi, and therefore, in the rose bengal carotid artery injury 
model, but less so in a jugular injury model. This raises the intriguing possibility that VWF-
directed therapies may help resolve most limb- or life-threatening thrombi caused by 
arterial occlusion.  
Additionally, we speculate that PF4 bound to VWF is physiologically relevant. 
Binding of PF4 to VWF strands under shear may protect it from premature cleavage by 
ADAMTS13 under arterial pressure. This suggests that PF4 might bind near the 
ADAMTS13 binding site in VWF A2 domain138. We therefore propose that future studies 
should also include a better understanding the 3-D structure of the complex between PF4 
and VWF, including identifying the binding site(s). This will include utilizing electron 
microscopy or cryo-electron microscopy to visualize PF4-VWF strand complexes to 
compare against the prior crystallographic studies of the HIT complex using PF4 and 
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fondaparinux137,271. Other studies using small drugs or VWF-derived peptides to compete 
for PF4 binding will be tested as well. Finally, generation of VWF with the site of interest 
mutated may need to be generated to validate PF4’s binding site within the native 
molecule and to study the effect of shear. 
To more definitively evaluate the impact of VWF, we will also be breeding VWF-/-
/HIT mice to study vascular injury. This will be achieved by standard breeding to create 
the double transgenic hPF4+/FcRIIA+ on the VWF-/- background272, but we will also 
perform bone marrow transplant from HIT mice into VWF-/-  mice. These mice will still 
express platelet VWF, but will specifically lack the contribution of EC VWF to thrombi 
development. These mice will be used in the rose bengal carotid artery and jugular vein 
injury models, and the cremaster arteriole and venule laser injury models. Formation of 
the HIT antigen and the time to occlusion will be studied. This will allow us to evaluate 
how VWF impacts vessel occlusion, contributes to the thrombus growth, and alters HIT 
antibody binding patterns relative to the site of injury. We believe that both the full VWF 
knockout and the EC knock will show decreased arterial thrombi, but little or no change in 
venular thrombi.  
 
Neutrophil accumulation and NET release impact venous thrombosis in HIT. 
In Chapter 5, we showed that NETs may play a similar role as VWF in propagating 
HIT thrombi downstream, but on the venous side. After inducing HIT in the murine HIT 
model by infusing KKO, we showed that neutrophils adhered to the venous, but not arterial 
endothelial lining, even without additional injury. Additionally, downstream of a venous 
laser-injury-induced thrombus, there was a marked increase in adhesion of neutrophils. 
These migrated retrograde to be incorporated in the growing thrombus. In an in vitro 
microfluidic model, we displayed that PF4 and HIT antibodies can bind NETs and provide 
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DNase resistance. These all contribute to venous thrombosis by inducing EC and blood 
cell activation, physically contributing to thrombus size, and forming PF4/NET/HIT 
antibody complexes, which further propagate thrombosis. These findings provide insight 
into how neutrophils selectively contribute to venous thrombosis in HIT.  
Moreover, the studies introduce novel avenues for mitigating HIT thrombosis, 
which include inhibiting neutrophil-endothelial adhesion, preventing the chemotaxis of 
neutrophils to growing thrombi, and suppressing NET release or NET lysis. Future studies 
will focus on assessing these therapeutic avenues by using similar models as those 
described in Chapter 5. To impede neutrophil-endothelial adhesion and neutrophil 
chemotaxis, we also propose that blocking antibodies to neutrophil-relevant selectins 
and/or integrins273,274 might decrease the prothrombotic venous risks of HIT. For example, 
crizanlizumab, a P-selectin blocking antibody was shown to significantly lower the rate of 
sickle cell related pain crises in patients with sickle cell disease274. Alternatively, CL2 is an 
antibody that blocks the binding of leukocytes to E-selectin273 and was shown to reduce 
the extent of neutrophil transmigration to a site of inflammation during an acute 
inflammatory response. Each have potential to combat the enhanced adhesion of 
neutrophils seen to the venous lining seen in our studies and to the downstream 
accumulation of neutrophils in venous thrombi.  Recent studies have also shown a mouse 
model which utilizes an adenovirus-mediated expression of endomucin to reduce 
neutrophil adhesion275. Endomucin is a membrane-bound glycoprotein that normally 
prevents leukocyte-EC interaction, but is downregulated with inflammation (TNFα) 
stimulation. This will allow us to evaluate the most effective and therapeutically relevant 
means of impeding neutrophil contribution to HIT thrombosis. Additionally, there is an 
opportunity to target the rates of NET formation or degradation to limit their effects. Our 
future studies will include investigating such agents, which include N-acetylcysteine, 
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DNase I, PAD4 inhibitors, and acetylsalicylic acid150,183,189,194,276,277. Despite the fact that 
anti-VWF and NET agents are not considered anticoagulants, they may still result in 
adverse side effects such as bleeding or immune defects, and therefore, their utility in the 
murine HIT model in conjunction with DTIs needs to be examined. 
 
Novel ICAM-1 targeted therapeutics reduce inflammatory thrombosis in sepsis model 
In Chapter 6, we showed the potential for using ICAM-1-targeted TM to inhibit or 
delay inflammatory thrombosis in an endothelialized microfluidic sepsis model. We were 
able to show that this targeted therapeutic was more effective at inhibiting TF-driven 
thrombosis than untargeted therapeutics such as soluble human TM and hirudin. 
Moreover, we showed this antithrombotic effect was PC-dependent and was 
synergistically effective with supplemental PC. This provides significant insight into 
potential treatments for the inflammatory-driven side of HIT. The current treatments for 
HIT are DTIs, which have limitations in that they have increased risk of bleeding diathesis, 
and consequently, require frequent patient monitoring41,44. The advantages of targeted TM 
is that it will primarily bind where inflammation has induced increased ICAM-1 levels; 
moreover, considering its PC-dependent functionality, the targeted TM will also be 
selectively antithrombotic in regions in which there is sufficient FIIa to bind TM leading to 
increased APC production. Furthermore, because the therapeutic is TM, the other TM 
domains can provide additional anti-inflammatory and anti-activated endothelium effects 
not seen with DTIs. A site selective antithrombotic that also combats inflammatory 
components could provide a unique solution to the VWF- and NET-associated EC-related 
mechanisms of thrombosis seen in HIT. Future studies in this realm will focus on 
integrating this therapeutic into cremaster murine models of HIT to determine the feasibility 
for preventing and mitigating HIT thrombosis on both the venous and arterial sides. There 
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is also interest in utilizing the targeting mechanism used in this therapeutic for other 
antithrombotics. An intriguing therapeutic could be an scFv-derived from a HIT antibody 
like KKO that binds to the PF4 antigenic site exposed when it is bound to GAGs, VWF and 
NETs and that would target a therapeutic to HIT antigen-rich sites. 
 
Impact of the Described Research 
Understanding the prothrombotic nature of HIT. 
From a broader perspective, this research has the potential to impact our 
understanding, research approach, and treatment paradigm around HIT. In gaining a 
better understanding of how the endothelium (Chapter 3), VWF (Chapter 4), and NETs 
(Chapter 5) can form HIT antigenic complexes, we’ve provided new insights into the 
pathophysiology of thrombosis in HIT and the prolonged period of risk for recurrent 
thromboembolic complications (Step 3). We envision HIT as developing in three distinct 
all be it, overlapping, steps: Step 1: initiation by PF4/heparin complexes; Step 2: activation 
of intravascular cells (monocytes, platelets) causing thrombosis; and Step 3: antigen and 
thrombus propagation during which additional PF4 binding surfaces as generated that 
create a procoagulant positive feedback loop that is entirely independent of heparin.  
With these studies, we have opened doors to additional future research questions: 
In what situations are these complexes most paramount to the propagation of HIT? How 
well do the various polymeric targets compete for PF4 in time and space? How do the 
location and affinity of these complexes impact the clinical course of HIT and what are the 
implications for response to current therapy? Future research could include in vivo studies 
using various injury settings with co-visualization of the EC glycocalyx, VWF, and 
neutrophils/NETs. This research could include using microfluidic studies to identify the 
binding preference of PF4 under flow in presence of these various polymeric targets in the 
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absence and/or presence of heparin. Both endothelial cell heterogeneity within the 
vasculature, genetic and epigenetic risk factors remain wide open to exploration as well.  
Ultimately, these studies hold the potential to alter diagnosis and treatment in HIT. 
Across many healthcare fields, researchers are looking for physiological parameters that 
can be used for predictive analytics and predictive diagnosis; these predictive measures 
provide a means of knowing and treating a patient’s pathology before it manifests into a 
tangible phenotype, which helps reduce medical cost, reduce treatment time, and improve 
patient outcomes. Predictive diagnosis would be very valuable in HIT considering its 
endpoints and our studies provide additional parameters that could have predictive 
significance. Prior studies would have placed patients with prior heparin exposure or 
bacterial infections at risk for HIT. But our studies now implicate the composition of the 
glycocalyx, levels and glycosylation of VWF, and neutrophil activation as having a higher 
propensity for HIT associated endpoints. Preemptive measures taken at the first clinical 
sign of HIT could include the use of non-anticoagulant reagents such as blocking 
GP1bAK2 antibody), blocking FcRIIA (IV.3 antibody), or removing ultra-large VWF 
multimers (NAC or ADAMTS13) which may reduce thrombus extension, permit the 
intensity of anticoagulation to be lowered in the setting of thrombocytopenia, and lessen 
the risk of recurrent thrombembolism.  
 
New insights into hemostasis and thrombosis in other clinically relevant settings. 
 These studies may also impact how we should view the relationship between 
hemostasis and thrombosis. Hemostasis is viewed as a delicate balance between pro- 
and anti-coagulative forces with thrombosis being the tipping of that scale. Consequently, 
therapeutics are generally foreign reagents that aim to tip that scale back to balance. This 
attempt to balance leads to the risk of under or overshooting hemostasis allowing clotting 
185 
to continue or causing inadvertent bleeds. Alternatively, our studies show that hemostasis 
and thrombosis should be viewed as a reestablishment of a standard vascular milieu. As 
described in Chapter 6, TM was targeted to ICAM-1; this allowed the therapeutic to 
replenish the TM on the surface of ECs that was shed during injury. Treating thrombosis 
by replenishing the proteins altered during injury presents a potential avenue to more 
precise therapeutics with less side effects. In reference to HIT, reestablishing the 
glycocalyx or correcting concentrations of ADAMTS13 could provide unique treatment 
strategies with less risk that the currently used DTIs.  
 These studies have implications for our understanding of other thrombotic 
disorders. In lupus, antibodies develop to DNA found in NETs. Studies are in progress to 
assess the impact of such antibodies on NET formation and resistance to DNases and the 
risk of thrombosis, as are agents that prevent neutrophil accumulation in thrombi and 
release of NETs. In the catastrophic antiphospholipid syndrome (CAPS), thrombosis may 
involve diffuse endothelial activation which may also involve the release of VWF, 
generation of NETs compacted by PF4, similar to the events we describe here in HIT. 
Whether therapeutics designed to affect thrombus formation of HIT are also pertinent to 
the management of other thrombotic disorders requires additional experimentation.  
 Lastly, these studies should impact how to study vascular injury ex vivo. One of 
the major advances we made was improving the performance of the endothelialized 
microfluidic system. The ability to observe intravascular cell binding to the endothelium 
and the development of thrombosis under physiological flows in real time provided insight 
that would otherwise not be feasible. For example, we observed that the stranded VWF 
had higher affinity for PF4, and subsequently, KKO. The elongation and conformational 
changes presented by VWF when tethered to an EC would be difficult to replicate in other 
ex vivo settings. There are devices that induce shear138,145,150 and may alter VWF 
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confirmation, but none provide the environment of an EC monolayer grown to confluency 
in 3 dimensions displaying large multimeric VWF fibers. Previously, ELISAs or similar 
technologies were the primary means of measuring PF4 and antibody binding. This has 
obvious limitations in not allowing for flow, real time imaging, or the overall cellular 
environment present in the microfluidic setting. Moreover, when considering in vivo 
models, despite providing great insight, they also present certain limitations. Relevant to 
studies of HIT, in vivo models make it more difficult to decipher the minute interactions 
and contributions as we saw with PF4 binding VWF; in vivo imaging of VWF in thrombi 
have historically displayed diffused staining and have not been able to image the strands 
of VWF released by ECs. The microfluidic realm gives us the ability to better recapitulate 
the in vivo environment while still maintaining more control and specificity of unmodified 
or modified cells studied, flow rates and other physical parameters – such as temperature 
and oxygen level – and drug exposure. They allow studies of cells from multiple different 
species and also allow studies of a cell line and primary cells in 3D.  
   
Summary 
 This thesis focused on studies of the prothrombotic processes underlying HIT. We 
found that PF4 and HIT antibodies predominantly bound to perithrombus endothelium in 
the absence of damage and even more so in the setting of HIT. Further investigation led 
to the discovery that VWF and NETs participate in the prothrombotic propagation of 
thrombi in HIT. We observed the formation of PF4-VWF-HIT antibody complexes that 
promoted platelet accumulation that was propagated downstream. These observations 
offer potential new therapeutic targets in HIT, which will be a focus of future studies. In 
addition to the studies on NETs, we also define how neutrophils contribute to venous 
thrombi in HIT. We culminated our studies with an investigation into combatting 
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inflammatory thrombosis in a sepsis model, which provides insights into the effect of 
inflammation which may precede or accompany HIT. Using a novel ICAM-1 targeted TM 
therapeutic, we saw that targeted TM inhibited TF induced thrombosis via a PC-dependent 
pathway more efficiently than soluble reagents. Collectively, this thesis work provides a 
more defined understanding of the pathogenesis of thrombosis in HIT and related 
inflammatory states and provides insights into potential novel therapeutics. 
 
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
1. Brass, L. F., Diamond, S. L. & Stalker, T. J. Platelets and hemostasis: a new 
perspective on an old subject. Blood Adv. 1, 5–9 (2016). 
2. Van De Wouwer, M., Collen, D. & Conway, E. M. Thrombomodulin-protein C-
EPCR system integrated to regulate coagulation and inflammation. Arterioscler. 
Thromb. Vasc. Biol. 24, 1374–1383 (2004). 
3. Green, D. Coagulation cascade. Hemodial. Int. 10, (2006). 
4. Esmon, C. T. The impact of the inflammatory response on coagulation. Thromb. 
Res. 114, 321–327 (2004). 
188 
5. Palta, S., Saroa, R. & Palta, A. Overview of the coagulation system. Indian J. 
Anaesth. 58, 515–523 (2014). 
6. Sagripanti, A. & Carpi, A. Antithrombotic and prothrombotic activities of the 
vascular endothelium. Biomed. Pharmacother. 54, 107–111 (2000). 
7. Yang, Y. & Loscalzo, J. Regulation of tissue factor expression in human 
microvascular endothelial cells by nitric oxide. Circulation 101, 2144–2148 (2000). 
8. Brass, L. Understanding and Evaluating Platelet Function. Hematology 2010, 
387–396 (2010). 
9. Wang, G. R., Zhu, Y., Halushka, P. V, Lincoln, T. M. & Mendelsohn, M. E. 
Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of 
thromboxane receptor by cyclic GMP-dependent protein kinase. Proc. Natl. Acad. 
Sci. U. S. A. 95, 4888–4893 (1998). 
10. Radomski, M. W., Palmer, R. M. J. & Moncada, S. Comparative pharmacology of 
endothelium‐derived relaxing factor, nitric oxide and prostacyclin in platelets. Br. 
J. Pharmacol. 92, 181–187 (1987). 
11. Weiss, H. J. & Turitto, V. T. Prostacyclin (prostaglandin I2, PGI2) inhibits platelet 
adhesion and thrombus formation on subendothelium. Blood 53, 244–250 (1979). 
12. Potter, D. R. & Damiano, E. R. The hydrodynamically relevant endothelial cell 
glycocalyx observed in vivo is absent in vitro. Circ. Res. 102, 770–776 (2008). 
13. Koo, A., Dewey, C. F. & Garcia-Cardena, G. Hemodynamic shear stress 
characteristic of atherosclerosis-resistant regions promotes glycocalyx formation 
in cultured endothelial cells. AJP Cell Physiol. 304, C137–C146 (2013). 
14. Chappell, D. et al. The glycocalyx of the human umbilical vein endothelial cell: An 
impressive structure ex vivo but not in culture. Circ. Res. 104, 1313–1317 (2009). 
15. Van Den Berg, B. M., Nieuwdorp, M., Stroes, E. S. G. & Vink, H. Glycocalyx and 
189 
endothelial (dys) function: From mice to men. Pharmacol. Reports 58, 75–80 
(2006). 
16. Mulivor, A. W. & Lipowsky, H. H. Role of glycocalyx in leukocyte-endothelial cell 
adhesion. Am. J. Physiol. - Hear. Circ. Physiol. 283, H1282–H1291 (2002). 
17. Reitsma, S., Slaaf, D. W., Vink, H., Van Zandvoort, M. A. M. J. & Oude Egbrink, 
M. G. A. The endothelial glycocalyx: Composition, functions, and visualization. 
Pflugers Arch. Eur. J. Physiol. 454, 345–359 (2007). 
18. Esmon, C. T. Thrombomodulin mechanisms function as a model that modulate 
surface of molecular protease specfficity and at the vessel. 9, 946–955 (1995). 
19. Conway, E. M. Thrombomodulin and its role in inflammation. Semin. 
Immunopathol. 34, 107–125 (2012). 
20. Minami, T. et al. Thrombin and Phenotypic Modulation of the Endothelium. 
Arterioscler. Thromb. Vasc. Biol. 24, 41–53 (2004). 
21. Riewald, M., Petrovan, R. J., Donner, A., Mueller, B. M. & Ruf, W. Activation of 
endothelial cell protease activated receptor 1 by the protein C pathway. Science 
(80-. ). 296, 1880–1882 (2002). 
22. Esmon, C. T. Protein C anticoagulant system - Anti-inflammatory effects. Semin. 
Immunopathol. 34, 127–132 (2012). 
23. Brogren, H. et al. Platelets synthesize large amounts of active plasminogen 
activator inhibitor 1. Blood 104, 3943–3948 (2004). 
24. Zaitsev, S. et al. Targeting of a mutant plasminogen activator to circulating red 
blood cells for prophylactic fibrinolysis. J. Pharmacol. Exp. Ther. 332, 1022–31 
(2010). 
25. Eitzman, D. T., Westrick, R. J., Nabel, E. G. & Ginsburg, D. Plasminogen activator 
inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 95, 577–80 
190 
(2000). 
26. Greineder, C. F. et al. ICAM-1–targeted thrombomodulin mitigates tissue factor–
driven inflammatory thrombosis in a human endothelialized microfluidic model. 
Blood Adv. 1, 1452–1465 (2017). 
27. Wagner, D. D. & Burger, P. C. Platelets in Inflammation and Thrombosis. 
Arterioscler. Thromb. Vasc. Biol. 23, 2131–2137 (2003). 
28. Kumar, S. & Krishnaswamy, S. Thrombin formation. Trauma Induc. Coagulopathy 
124, 55–74 (2016). 
29. Malek, A. M., Jackman, R., Rosenberg, R. D. & Izumo, S. Endothelial expression 
of thrombomodulin is reversibly regulated by fluid shear stress. Circ. Res. 74, 
852–860 (1994). 
30. Moore, K. L., Esmon, C. T. & Esmon, N. L. Tumour necrosis factor leads to 
internalisation and degradation of thrombomodulin from the surface of bovine 
aortic endothelial cells in culture. Blood 73, 159–165 (1989). 
31. Montes, R., Puy, C., Molina, E. & Hermida, J. Is EPCR a multi-ligand receptor? 
Pros and cons. Thromb. Haemost. 107, 815–826 (2012). 
32. Danese, S., Vetrano, S., Zhang, L., Poplis, V. A. & Castellino, F. J. The protein C 
pathway in tissue inflammation and injury: pathogenic role and therapeutic 
implications. Blood 115, 1121–1130 (2010). 
33. McLaughlin, J. et al. Regulation of endothelial function by coagulation proteases 
in sepsis. Crit. Care 15, P251 (2011). 
34. Lorenzon, P. et al. Endothelial cell E- and P-selectin and vascular cell adhesion 
molecule- 1 function as signaling receptors. J. Cell Biol. 142, 1381–1391 (1998). 
35. Poirault-Chassac, S. et al. Terminal Platelet Production is Regulated by Von 
Willebrand Factor. PLoS One 8, e63810 (2013). 
191 
36. Endenburg, S. C. et al. On the role of von Willebrand factor in promoting platelet 
adhesion to fibrin in flowing blood. Blood 86, 4158–65 (1995). 
37. Haji-Valizadeh, H., Modery-Pawlowski, C. L. & Sen Gupta, A. A factor VIII-derived 
peptide enables von Willebrand factor (VWF)-binding of artificial platelet 
nanoconstructs without interfering with VWF-adhesion of natural platelets. 
Nanoscale 6, 4765–4773 (2014). 
38. Gogia, S., Kelkar, A., Zhang, C., Dayananda, K. M. & Neelamegham, S. Role of 
calcium in regulating the intra- and extracellular cleavage of von Willebrand factor 
by the protease ADAMTS13. 1, (2017). 
39. Dayananda, K. M., Singh, I., Mondal, N. & Neelamegham, S. von Willebrand 
factor self-association on platelet GpIb?? under hydrodynamic shear: Effect on 
shear-induced platelet activation. Blood 116, 3990–3998 (2010). 
40. Hassan, M. I., Saxena, A. & Ahmad, F. Structure and function of von Willebrand 
factor. Blood Coagul. Fibrinolysis 23, 11–22 (2012). 
41. Warkentin, T. E. HIT: Treatment easier, prevention harder. Blood 119, 1099–1100 
(2012). 
42. Cines, D. B. et al. Endothelial cells in physiology and in the pathophysiology of 
vascular disorders. Blood 91, 3527–3561 (1998). 
43. Hayes, V. et al. Endothelial antigen assembly leads to thrombotic complications in 
heparin-induced thrombocytopenia. J. Clin. Invest. 127, 1090–1098 (2017). 
44. Cuker, A. & Cines, D. B. How I treat heparin-induced thrombocytopenia. Blood 
119, 2209–2218 (2012). 
45. Kelton, J. G. & Warkentin, T. E. Heparin-induced thrombocytopenia: A historical 
perspective. Blood 112, 2607–2616 (2008). 
46. Warkentin, T. E., Basciano, P. a, Knopman, J. & Bernstein, R. a. Spontaneous 
192 
heparin-induced thrombocytopenia syndrome : 2 new cases and a proposal for de 
fi ning this disorder. Blood 123, 3651–3654 (2014). 
47. Arepally, G. M. et al. Characterization of a murine monoclonal antibody that 
mimics heparin-induced thrombocytopenia antibodies. Blood 95, 1533–40 (2000). 
48. Ahmed, I., Majeed, A. & Powell, R. Heparin induced thrombocytopenia: Diagnosis 
and management update. Postgrad. Med. J. 83, 575–582 (2007). 
49. Busch, C., Sawes, J., Pepper, D. S. & Wasteson, A. Binding of platelet factor 4 to 
cultured human umbilical vein endothelial cells. Thromb.Res. 19, 129–137 (1980). 
50. Rauova, L. et al. Monocyte-bound PF4 in the pathogenesis of heparin-induced 
thrombocytopenia. Blood 116, 5021–5031 (2010). 
51. Walenga, J. M., Jeske, W. P., Margaret Prechel, M. & Bakhos, M. Newer insights 
on the mechanism of heparin-induced thrombocytopenia. Semin. Thromb. 
Hemost. 30, 57–67 (2004). 
52. Rabiet, M. J. et al. Thrombin-induced increase in endothelial permeability is 
associated with changes in cell-to-cell junction organization. Arterioscler. Thromb. 
Vasc. Biol. 16, 488–496 (1996). 
53. Cines, D. B. et al. Polyphosphate/platelet factor 4 complexes can mediate 
heparin-independent platelet activation in heparin-induced thrombocytopenia. 
Blood Adv. 1, 62–74 (2016). 
54. Mackman, N. Triggers, targets and treatments for thrombosis. Nature 451, 914–
918 (2008). 
55. Shuster, T. A., Silliman, W. R., Coats, R. D., Mureebe, L. & Silver, D. Heparin-
induced thrombocytopenia: Twenty-nine years later. J. Vasc. Surg. 38, 1316–
1322 (2003). 
56. Reilly, M. P. et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic 
193 
mouse model requires human platelet factor 4 and platelet activation through 
FcgammaRIIA. Blood 98, 2442–2447 (2001). 
57. Perlman, R. L. Mouse Models of Human Disease: An Evolutionary Perspective. 
Evol. Med. Public Heal. eow014 (2016). doi:10.1093/emph/eow014 
58. Justice, M. J. & Dhillon, P. Using the mouse to model human disease: increasing 
validity and reproducibility. Dis. Model. Mech. 9, 101–103 (2016). 
59. Rello, J., Valenzuela-Sánchez, F., Ruiz-Rodriguez, M. & Moyano, S. Sepsis: A 
Review of Advances in Management. Adv. Ther. 34, 2393–2411 (2017). 
60. Polat, G., Ugan, R. A., Cadirci, E. & Halici, Z. Sepsis and Septic Shock: Current 
Treatment Strategies and New Approaches. Eurasian J. Med. 49, 53–58 (2017). 
61. Van Der Poll, T., Van De Veerdonk, F. L., Scicluna, B. P. & Netea, M. G. The 
immunopathology of sepsis and potential therapeutic targets. Nat. Rev. Immunol. 
17, 407–420 (2017). 
62. Xu, J. et al. Extracellular histones are major mediators of death in sepsis. Nat. 
Med. 15, 1318–1321 (2009). 
63. Li, Z. Q. et al. Defining a second epitope for heparin-induced 
thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like 
monoclonal antibody. Blood 99, 1230–1236 (2002). 
64. Melanson, S. W., Silver, B. & Heller, M. B. Deep vein thrombosis, pulmonary 
embolism, and the white clot syndrome. Am. J. Emerg. Med. 14, 558–560 (1996). 
65. Daubert, G. P. The white clot syndrome. J. Clin. Pharm. Ther. 30, 503 (2005). 
66. Towne, J. B., Bernhard, V. M., Hussey, C. & Garancis, J. C. White Clot 
Syndrome: Peripheral Vascular Complications of Heparin Therapy. Arch. Surg. 
114, 372–377 (1979). 
67. Warkentin, T. E. An overview of the heparin-induced thrombocytopenia syndrome. 
194 
Semin. Thromb. Hemost. 30, 273–283 (2004). 
68. Madge, L. A. & Pober, J. S. TNF signaling in vascular endothelial cells. Exp. Mol. 
Pathol. 70, 317–325 (2001). 
69. Nishimura, S. et al. In vivo imaging visualizes discoid platelet aggregations 
without endothelium disruption and implicates contribution of inflammatory 
cytokine and integrin signaling. Blood 119, e45-56 (2012). 
70. Rauova, L. ‘Radical’ model of thrombosis. Blood 119, 1798–1799 (2012). 
71. Cerutti, C. & Ridley, A. J. Endothelial cell-cell adhesion and signaling. Exp. Cell 
Res. 358, 31–38 (2017). 
72. Wagner, D. D. & Bonfanti, R. von Willebrand factor and the endothelium. Mayo 
Clin. Proc. 66, 621–627 (1991). 
73. Kiskin, N. I. et al. Protein mobilities and P-selectin storage in Weibel-Palade 
bodies. J. Cell Sci. 123, 2964–2975 (2010). 
74. Estrada, R., Giridharan, G. A., Nguyen, M. D., Prabhu, S. D. & Sethu, P. 
Microfluidic endothelial cell culture model to replicate disturbed flow conditions 
seen in atherosclerosis susceptible regions. Biomicrofluidics 5, 1–11 (2011). 
75. Jalili-Firoozinezhad, S. et al. Modeling radiation injury-induced cell death and 
countermeasure drug responses in a human Gut-on-a-Chip article. Cell Death 
Dis. 9, 1–36 (2018). 
76. Martin, J. V., Liberati, D. M. & Diebel, L. N. Excess sodium is deleterious on 
endothelial and glycocalyx barrier function. J. Trauma Acute Care Surg. 1, 1 
(2018). 
77. Sakurai, Y. et al. A microengineered vascularized bleeding model that integrates 
the principal components of hemostasis. Nat. Commun. 9, 1–9 (2018). 
78. Diebel, L. N., Martin, J. V. & Liberati, D. M. Microfluidics. J. Trauma Acute Care 
195 
Surg. 84, 1 (2017). 
79. Education, M., Bhubaneswar, A. & Sciences, D. Discover the world ’ s research. 
(2015). 
80. Sylman, J. L., Artzer, D. T., Rana, K. & Neeves, K. B. A vascular injury model 
using focal heat-induced activation of endothelial cells. Integr. Biol. 7, 801–814 
(2015). 
81. Amiral, J. et al. Platelet factor 4 complexed to heparin is the target for antibodies 
generated in heparin-induced thrombocytopenia [4]. Thromb. Haemost. 68, 95–96 
(1992). 
82. Greinacher, A. et al. Clinical features of heparin-induced thrombocytopenia 
including risk factors for thrombosis. A retrospective of 408 patients. Thromb. 
Haemost. 94, 132–135 (2005). 
83. Hong, A. P., Cook, D. J., Sigouin, C. S. & Warkentin, T. E. Central venous 
catheters and upper-extremity deep-vein thrombosis complicating immune 
heparin-induced thrombocytopenia. Blood 101, 3049–3051 (2003). 
84. Martel, N., Lee, J. & Wells, P. S. Risk for heparin-induced thrombocytopenia with 
unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-
analysis. Blood 106, 2710–2715 (2005). 
85. Linkins, L. A. End of the road for heparin thromboprophylaxis. Blood 127, 1945–
1946 (2016). 
86. Riess, F.-C. Anticoagulation management and cardiac surgery in patients with 
heparin-induced thrombocytopenia. Semin. Thorac. Cardiovasc. Surg. 17, 85–96 
(2005). 
87. Kelton, J. G., Hursting, M. J., Heddle, N. & Lewis, B. E. Predictors of clinical 
outcome in patients with heparin-induced thrombocytopenia treated with direct 
196 
thrombin inhibition. Blood Coagul. Fibrinolysis 19, 471–475 (2008). 
88. Rauova, L. et al. Role of platelet surface PF4 antigenic complexes in heparin-
induced thrombocytopenia pathogenesis: Diagnostic and therapeutic implications. 
Blood 107, 2346–2353 (2006). 
89. Khandelwal, S. et al. The antigenic complex in HIT binds to B cells via 
complement and complement receptor 2 (CD21). Blood 128, 1789–1799 (2016). 
90. Petersen, F., Brandt, E., Lindahl, U. & Spillmann, D. Characterization of a 
neutrophil cell surface glycosaminoglycan that mediates binding of platelet factor 
4. J. Biol. Chem. 274, 12376–12382 (1999). 
91. Jg, K. et al. Heparin-induced thrombocytopenia : laboratory studies . 72, (2018). 
92. Warkentin, T. E. et al. Sera from patients with heparin-induced thrombocytopenia 
generate platelet-derived microparticles with procoagulant activity: an explanation 
for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84, 
3691–9 (1994). 
93. Blank, M. et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-
induced thrombocytopenia provoke direct activation of microvascular endothelial 
cells. Int. Immunol. 14, 121–129 (2002). 
94. Cines, D. B., Tomaski, A., Tannenbaum, S. & Articles, C. Immune Endothelial-Cell 
Injury in Heparin-Associated Thrombocytopenia. N. Engl. J. Med. 316, 2018 
(2018). 
95. Visentin, G. P., Ford, S. E., Scott, J. P. & Aster, R. H. Antibodies From Patients 
With Heparin-Induced Thrombocytopenia/Thrombosis Are Specific for Platelet 
Factor-4 Complexed With Heparin or Bound To Endothelial-Cells. J. Clin. Invest. 
93, 81–88 (1994). 
96. Marki, A., Esko, J. D., Pries, A. R. & Ley, K. Role of the endothelial surface layer 
197 
in neutrophil recruitment. J. Leukoc. Biol. 98, 503–515 (2015). 
97. Falati, S. et al. Accumulation of Tissue Factor into Developing Thrombi In Vivo Is 
Dependent upon Microparticle P-Selectin Glycoprotein Ligand 1 and Platelet P-
Selectin. J. Exp. Med. 197, 1585–1598 (2003). 
98. Neyman, M., Gewirtz, J. & Poncz, M. Analysis of the spatial and temporal 
characteristics of platelet-delivered factor VIII based clots. Blood 112, 1101–1108 
(2008). 
99. Stalker, T. J. et al. Hierarchical organization in the hemostatic response and its 
relationship to the platelet-signaling network. Blood 121, 1875–1885 (2013). 
100. Falati, S., Gross, P., Merrill-skoloff, G., Furie, B. C. B. & Furie, B. C. B. Real time 
in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus 
formation in the mouse. Nat. Med. 8, 1175–1180 (2002). 
101. Zhang, C. et al. Localization of distal regulatory domains in the megakaryocyte-
specific platelet basic protein / platelet factor 4 gene locus. 98, 610–618 (2018). 
102. McKenzie, S. E. et al. The role of the human Fc receptor Fc gamma RIIA in the 
immune clearance of platelets: a transgenic mouse model. J. Immunol. 162, 
4311–8 (1999). 
103. Eslin, D. E. et al. Transgenic mice studies demonstrate a role for platelet factor 4 
in thrombosis : dissociation between anticoagulant and antithrombotic effect of 
heparin Transgenic mice studies demonstrate a role for platelet factor 4 in 
thrombosis : dissociation between . 104, 3173–3180 (2011). 
104. Cuker, A. et al. The HIT Expert Probability (HEP) Score: A novel pre-test 
probability model for heparin-induced thrombocytopenia based on broad expert 
opinion. J. Thromb. Haemost. 8, 2642–2650 (2010). 
105. Sheridan, D., Carter, C. & Kelton, J. G. A diagnostic test for heparin-induced 
198 
thrombocytopenia. Blood 67, 27–30 (1986). 
106. Hui, K. Y., Haber, E. & Matsueda, G. R. Monoclonal antibodies to a synthetic 
fibrin-like peptide bind to human fibrin but not fibrinogen. Science 222, 1129–1132 
(1983). 
107. Celi, A. et al. Thrombus formation: Direct real-time observation and digital 
analysis of thrombus assembly in a living mouse by confocal and widefield 
intravital microscopy. J. Thromb. Haemost. 1, 60–68 (2003). 
108. Tutwiler, V. et al. Platelet transactivation by monocytes promotes thrombosis in 
heparin-induced thrombocytopenia. Blood 127, 464–472 (2016). 
109. Barkefors, I., Aidun, C. K. & Ulrika Egertsdotter, E. M. Effect of fluid shear stress 
on endocytosis of heparan sulfate and low-density lipoproteins. J. Biomed. 
Biotechnol. 2007, 65136 (2007). 
110. Suvarna, S. et al. Determinants of PF4/heparin immunogenicity. Blood 110, 4253–
4260 (2007). 
111. Suvarna, S., Qi, R. & Arepally, G. M. Optimization of a murine immunization 
model for study of PF4/heparin antibodies. J. Thromb. Haemost. 7, 857–864 
(2009). 
112. Hirsh, J. & Fuster, V. Guide to anticoagulant therapy. American Heart Association 
(1994). 
113. Soleimannejad, M. et al. Activated Clotting Time Level with Weight Based Heparin 
Dosing During Percutaneous Coronary Intervention and its Determinant Factors. 
J. Cardiovasc. Thorac. Res. 6, 97–100 (2014). 
114. Nader, H. B. Characterization of a heparan sulfate and a peculiar chondroitin 4-
sulfate proteoglycan from platelets. Inhibition of the aggregation process by 
platelet chondroitin sulfate proteoglycan. J. Biol. Chem. 266, 10518–10523 
199 
(1991). 
115. Ward, J. V. & Packham, M. A. Characterization of the sulfated glycosaminoglycan 
on the surface and in the storage granules of rabbit platelets. BBA - Gen. Subj. 
583, 196–207 (1979). 
116. Ushiyama, A., Kataoka, H. & Iijima, T. Glycocalyx and its involvement in clinical 
pathophysiologies. J. Intensive Care 4, 4–5 (2016). 
117. Warkentin, T. E. et al. Heparin-Induced Thrombocytopenia in Medical Surgical 
Critical Illness. Chest 144, 848–858 (2013). 
118. Warkentin, T. E. & Greinacher, A. Heparin-induced thrombocytopenia: 
Recognition, treatment, and prevention - The Seventh ACCP Conference on 
Antithrombotic and Thrombolytic Therapy. Chest 126, 4–6 (2004). 
119. Gross, P. L. Leukocyte-versus microparticle-mediated tissue factor transfer during 
arteriolar thrombus development. J. Leukoc. Biol. 78, 1318–1326 (2005). 
120. Aisiku, O. et al. Parmodulins inhibit thrombus formation without inducing 
endothelial injury caused by vorapaxar. Blood 125, 1976–1985 (2015). 
121. Greineder, C. F. et al. Molecular engineering of high affinity single-chain antibody 
fragment for endothelial targeting of proteins and nanocarriers in rodents and 
humans. J. Control. Release 226, 229–237 (2016). 
122. Xiao, Z., Visentin, G. P., Dayananda, K. M. & Neelamegham, S. Immune 
complexes formed following the binding of anti platelet factor 4 (CXCL4) 
antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. 
Blood 112, 1091–1100 (2008). 
123. Becker, B. F., Jacob, M., Leipert, S., Salmon, A. H. J. & Chappell, D. Degradation 
of the endothelial glycocalyx in clinical settings: Searching for the sheddases. Br. 
J. Clin. Pharmacol. 80, 389–402 (2015). 
200 
124. Jaax, M. E. et al. Complex formation with nucleic acids and aptamers alters the 
antigenic properties of platelet factor 4. Blood 122, 272–281 (2013). 
125. Krauel, K. et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies 
cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 
117, 1370–8 (2011). 
126. Donovan, M. J. & Picciano, P. T. Fibrin Peptides That Mediate Endothelial Cell 
Retraction. 418–428 (1984). 
127. Zucker-Franklin, D. & Philipp, C. S. Platelet production in the pulmonary capillary 
bed: New ultrastructural evidence for an old concept. Am. J. Pathol. 157, 69–74 
(2000). 
128. Chen, J. & López, J. A. Interactions of platelets with subendothelium and 
endothelium. Microcirculation 12, 235–246 (2005). 
129. Hunt, B. J. & Jurd, K. M. Endothelial cell activation. 316, 1328–1329 (2014). 
130. Chen, M. & Geng, J. G. P-selectin mediates adhesion of leukocytes, platelets, and 
cancer cells in inflammation, thrombosis, and cancer growth and metastasis. 
Arch. Immunol. Ther. Exp. (Warsz). 54, 75–84 (2006). 
131. Yoshida, M. et al. Leukocyte adhesion to vascular endothelium induces E-selectin 
linkage to the actin cytoskeleton. J. Cell Biol. 133, 445–455 (1996). 
132. Ruggeri, Z. M. The role of von Willebrand factor in thrombus formation. Thromb. 
Res. 120, S5-9 (2007). 
133. Carlsson, L. E. et al. Heparin-induced thrombocytopenia: new insights into the 
impact of the FcgammaRIIa-R-H131 polymorphism. Blood 92, 1526–31 (1998). 
134. Berndt, M. C., Du, X. & Booth, W. J. Ristocetin-Dependent Reconstitution of 
Binding of von Willebrand Factor to Purified Human Platelet Membrane 
Glycoprotein Ib-IX Complex. Biochemistry 27, 633–640 (1988). 
201 
135. Beumer, S. et al. Platelet adhesion to fibronectin in flow: the importance of von 
Willebrand factor and glycoprotein Ib. Blood 86, 3452–60 (1995). 
136. Park, K. S. et al. Biologic and biochemic properties of recombinant platelet factor 
4 demonstrate identity with the native protein. Blood 75, 1290–5 (1990). 
137. Rauova, L. et al. Ultralarge complexes of PF4 and heparin are central to the 
pathogenesis of heparin-induced thrombocytopenia. Blood 105, 131–138 (2005). 
138. Gogia, S. & Neelamegham, S. Role of fluid shear stress in regulating VWF 
structure, function and related blood disorders. Biorheology 52, 319–335 (2015). 
139. Huizinga, E. G., Plas, R. M. van der, Kroon, J., Sixma, J. J. & Gros, P. Crystal 
structure of the A3 domain of human von Willebrand factor: implications for 
collagen binding. Structure 5, 1147–1156 (1997). 
140. Fu, H. et al. Flow-induced elongation of von Willebrand factor precedes tension-
dependent activation. Nat. Commun. 8, (2017). 
141. Cines, D. B. et al. Heparin-induced thrombocytopenia: An autoimmune disorder 
regulated through dynamic autoantigen assembly/disassembly. J. Clin. Apher. 22, 
31–36 (2007). 
142. Savage, B., Sixma, J. J. & Ruggeri, Z. M. Functional self-association of von 
Willebrand factor during platelet adhesion under flow. Proc. Natl. Acad. Sci. 99, 
425–430 (2002). 
143. Li, Y. et al. Covalent regulation of ULVWF string formation and elongation on 
endothelial cells under flow conditions. J. Thromb. Haemost. 6, 1135–1143 
(2008). 
144. Barg, A. et al. Soluble plasma-derived von Willebrand factor assembles to a 
haemostatically active filamentous network. Thromb. Haemost. 97, 514–526 
(2007). 
202 
145. Shankaran, H., Alexandridis, P. & Neelamegham, S. Aspects of hydrodynamic 
shear regulating shear-induced platelet activation and self-association of von 
Willebrand factor in suspension. Blood 101, 2637–2645 (2003). 
146. López, J. A. & Chung, D. W. VWF self-association: More bands for the buck. 
Blood 116, 3693–3694 (2010). 
147. Brill-Edwards, P., Ginsberg, J. S., Johnston, M. & Hirsh, J. Establishing a 
therapeutic range for heparin therapy. Ann. Intern. Med. 119, 104–109 (1993). 
148. Blanchi, V., Robles, R., Alberio, L., Furlan, M. & Lämmle, B. Von Willebrand 
factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: A severely 
deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 100, 
710–713 (2002). 
149. Pépin, M. et al. ADAMTS-13 and von Willebrand factor predict venous 
thromboembolism in patients with cancer. J. Thromb. Haemost. 14, 306–315 
(2016). 
150. Chen, J. et al. N-acetylcysteine reduced the size and activity of von Willebrand 
factor in human plasma and mice. J. Clin. Invest. 121, 593–603 (2011). 
151. Brill, A. et al. Von Willebrand factor-mediated platelet adhesion is critical for deep 
vein thrombosis in mouse models. Blood 117, 1400–1407 (2011). 
152. Denorme, F. et al. ADAMTS13- - ‐ mediated thrombolysis of t- - ‐ PA resistant 
occlusions in ischemic stroke in mice. 127, 1–5 (2017). 
153. Saku, K., Ahmad, M., Glas-greenwalt, P. & Moti, L. Copyright ( c ) 1985 
Pergamon Press Ltd . All rights reserved . by Editor L . J . Berliner ). 201–212 
(1985). 
154. Nand, S. et al. Heparin-induced thrombocytopenia with thrombosis: incidence, 
analysis of risk factors, and clinical outcomes in 108 consecutive patients treated 
203 
at a single institution. Am. J. Hematol. 56, 12–16 (1997). 
155. Wallis, D. E. et al. Failure of early heparin cessation as treatment for heparin-
induced thrombocytopenia. Am. J. Med. 106, 629–635 (1999). 
156. Linkins, L.-A. et al. Treatment and Prevention of Heparin-Induced 
Thrombocytopenia. Chest 141, e495S–e530S (2012). 
157. Zhou, A. et al. Is the incidence of heparin-induced thrombocytopenia affected by 
the increased use of heparin for VTE prophylaxis? Chest 142, 1175–1178 (2012). 
158. Cervera, R. Antiphospholipid syndrome. Thromb. Res. 151, S43–S47 (2017). 
159. Donze, J., Ridker, P., Finlayson, S. R. G. & Bates, D. Impact of sepsis on 
postoperative risk of arterial and venous thrombosis. J. Am. Coll. Cardiol. 63, 
A2047 (2014). 
160. Rauova, L. et al. Platelet and monocyte antigenic complexes in the pathogenesis 
of heparin-induced thrombocytopenia (HIT). J. Thromb. Haemost. 7, 249–252 
(2009). 
161. Arepally, G. M. Clinical platelet disorders heparin-induced thrombocytopenia. 
Blood 129, 2864–2872 (2017). 
162. Thrombocytopenia, H. & Poncz, M. Mechanistic Basis of. 73–79 (2005). 
doi:10.1053/j.semtcvs.2004.12.007 
163. Qiao, J., Al-Tamimi, M., Baker, R. I., Andrews, R. K. & Gardiner, E. E. The platelet 
Fc receptor, FcγRIIa. Immunol. Rev. 268, 241–252 (2015). 
164. Mayadas, T. N., Tsokos, G. C. & Tsuboi, N. Mechanisms of immune complex-
mediated neutrophil recruitment and tissue injury. Circulation 120, 2012–2024 
(2009). 
165. Khairy, M. et al. Polymorphonuclear leukocyte and monocyte activation induced 
by plasma from patients with heparin-induced thrombocytopenia in whole blood. 
204 
Thromb. Haemost. 92, 1411–1419 (2004). 
166. Martinod, K. & Wagner, D. D. Thrombosis: Tangled up in NETs. Blood 123, 2768–
2776 (2014). 
167. Li, P. et al. PAD4 is essential for antibacterial innate immunity mediated by 
neutrophil extracellular traps. J. Exp. Med. 207, 1853–1862 (2010). 
168. Kowalska, M. A., Rauova, L. & Poncz, M. Role of the platelet chemokine platelet 
factor 4 (PF4) in hemostasis and thrombosis. Thromb. Res. 125, 292–296 (2010). 
169. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. 
Science (80-. ). 339, 819–823 (2013). 
170. Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize 
off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184–191 (2016). 
171. Cuker, A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: 
An integrated approach. Semin. Thromb. Hemost. 40, 106–114 (2014). 
172. Arepally, G. et al. Comparison of PF4/heparin ELISA assay with the 14C-
serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. 
Am J Clin Pathol 104, 648–654 (1995). 
173. Lambert, M. P. & Gernsheimer, T. B. Clinical updates in adult immune 
thrombocytopenia. Blood 129, 2829–2835 (2017). 
174. Sachais, B. S. et al. Dynamic antibody-binding properties in the pathogenesis of 
HIT. Blood 120, 1137–1142 (2012). 
175. Drexler, G. A. & Ruiz-Gómez, M. J. Microirradiation techniques in radiobiological 
research. J. Biosci. 40, 629–643 (2015). 
176. Schindelin, J. et al. Fiji: An open-source platform for biological-image analysis. 
Nat. Methods 9, 676–682 (2012). 
177. Chapman, R. W. et al. A novel, orally active CXCR1/2 receptor antagonist, 
205 
Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell 
hyperplasia in animal models of pulmonary inflammation. J. Pharmacol. Exp. 
Ther. 322, 486–93 (2007). 
178. Brill, A. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. 
J. Thromb. Haemost. 10, 136–144 (2012). 
179. Jenne, C. N., Urrutia, R. & Kubes, P. Platelets: Bridging hemostasis, 
inflammation, and immunity. Int. J. Lab. Hematol. 35, 254–261 (2013). 
180. McDonald, B., Urrutia, R., Yipp, B. G., Jenne, C. N. & Kubes, P. Intravascular 
neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. 
Cell Host Microbe 12, 324–333 (2012). 
181. Monti, M. et al. Integrin-dependent cell adhesion to neutrophil extracellular traps 
through engagement of fibronectin in neutrophil-like cells. PLoS One 12, 1–2 
(2017). 
182. Fuchs, T. A. et al. Extracellular DNA traps promote thrombosis. Proc. Natl. Acad. 
Sci. 107, 15880–15885 (2010). 
183. Hakkim, A. et al. Impairment of neutrophil extracellular trap degradation is 
associated with lupus nephritis. Proc. Natl. Acad. Sci. 107, 9813–9818 (2010). 
184. Begandt, D., Thome, S., Sperandio, M. & Walzog, B. How neutrophils resist shear 
stress at blood vessel walls: molecular mechanisms, subcellular structures, and 
cell–cell interactions. J. Leukoc. Biol. 102, 699–709 (2017). 
185. Ghasemzadeh, M. et al. The CXCR1/2 ligand NAP-2 promotes directed 
intravascular leukocyte migration through platelet thrombi. Blood 121, 4555–4566 
(2013). 
186. Kienle, K. & Lï¿½mmermann, T. Neutrophil swarming: an essential process of the 
neutrophil tissue response. Immunol. Rev. 273, 76–93 (2016). 
206 
187. Chapman, R. W. et al. CXCR2 antagonists for the treatment of pulmonary 
disease. Pharmacol. Ther. 121, 55–68 (2009). 
188. Dyer, M. R. et al. Deep vein thrombosis in mice is regulated by platelet HMGB1 
through release of neutrophil-extracellular traps and DNA. Sci. Rep. 8, 2–3 
(2018). 
189. Wolach, O. et al. Increased neutrophil extracellular trap formation promotes 
thrombosis in myeloproliferative neoplasms. Sci. Transl. Med. 10, 1–2 (2018). 
190. Brandt, S. et al. Polyphosphates form antigenic complexes with platelet factor 4 
(PF4) and enhance PF4-binding to bacteria. Thromb. Haemost. 114, 1189–1198 
(2015). 
191. Neumann, A. et al. Novel role of the antimicrobial peptide LL-37 in the protection 
of neutrophil extracellular Traps against degradation by bacterial nucleases. J. 
Innate Immun. 6, 860–868 (2014). 
192. Leffler, J. et al. Neutrophil Extracellular Traps That Are Not Degraded in Systemic 
Lupus Erythematosus Activate Complement Exacerbating the Disease. J. 
Immunol. 188, 3522–3531 (2012). 
193. Leffler, J. et al. Degradation of neutrophil extracellular traps is decreased in 
patients with antiphospholipid syndrome. Clin. Exp. Rheumatol. 32, (2013). 
194. Lewis, H. D. et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and 
human NET formation. Nat. Chem. Biol. 11, 189–191 (2015). 
195. Holz, O. et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced 
neutrophilia in healthy subjects. Eur. Respir. J. 35, 564–570 (2010). 
196. Levi, M. Recombinant soluble thrombomodulin: Coagulation takes another chance 
to reduce sepsis mortality. J. Thromb. Haemost. 13, 505–507 (2015). 
197. Fiusa, M. M. L., Carvalho-Filho, M. A., Annichino-Bizzacchi, J. M. & De Paula, E. 
207 
V. Causes and consequences of coagulation activation in sepsis: An evolutionary 
medicine perspective. BMC Med. 13, (2015). 
198. Jh, F. & Em, C. Cross Talk Pathways Between Coagulation and Inflammation . 
118, 1–2 (2018). 
199. Engelmann, B. & Massberg, S. Thrombosis as an intravascular effector of innate 
immunity. Nat. Rev. Immunol. 13, 34–45 (2013). 
200. Allingstrup, M., Wetterslev, J., Fb, R., Am, M. & Afshari, A. Antithrombin III for 
critically ill patients . 2016–2018 (2018). 
doi:10.1002/14651858.CD005370.pub3.Full 
201. Martí-Carvajal, A. J., Solà, I., Gluud, C., Lathyris, D. & Anand, V. Human 
recombinant protein C for severe sepsis and septic shock in adult and paediatric 
patients. Cochrane Database Syst. Rev. 3435, 9–10 (2012). 
202. Jaimes, F. et al. Unfractioned heparin for treatment of sepsis: A randomized 
clinical trial (The HETRASE Study). Crit. Care Med. 37, 1185–1196 (2009). 
203. Zarychanski, R. et al. The efficacy and safety of heparin in patients with sepsis: A 
systematic review and metaanalysis. Crit. Care Med. 43, 511–518 (2015). 
204. Boehme, M. W. et al. Release of thrombomodulin from endothelial cells by 
concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. 
Immunology 87, 134–40 (1996). 
205. Macgregor, I. R., Perrie, A. M., Donnelly, S. C. & Haslett, C. Modulation of human 
endothelial thrombomodulin by neutrophils and their release products. Am. J. 
Respir. Crit. Care Med. 155, 47–52 (1997). 
206. Xu, J., Qu, D., Esmon, N. L. & Esmon, C. T. Metalloproteolytic release of 
endothelial cell protein C receptor. J. Biol. Chem. 275, 6038–6044 (2000). 
207. Gu, J. M. et al. Endotoxin and thrombin elevate rodent endothelial cell protein C 
208 
receptor mRNA levels and increase receptor shedding in vivo. Blood 95, 1687–93 
(2000). 
208. He, X. et al. Anti-human tissue factor antibody ameliorated intestinal ischemia 
reperfusion-induced acute lung injury in human tissue factor knock-in mice. PLoS 
One 3, 1–2 (2008). 
209. Witkowski, M., Landmesser, U. & Rauch, U. Tissue factor as a link between 
inflammation and coagulation. Trends Cardiovasc. Med. 26, 297–303 (2016). 
210. Vincent, J.-L. et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 2b 
Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble 
Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated 
Intravascular Coagulation*. Crit. Care Med. 41, 2069–2079 (2013). 
211. Greineder, C. F., Howard, M. D., Carnemolla, R., Cines, D. B. & Muzykantov, V. 
R. Advanced drug delivery systems for antithrombotic agents. Blood 122, 1565–
1575 (2013). 
212. Greineder, C. F. et al. Vascular immunotargeting to endothelial determinant 
ICAM-1 enables optimal partnering of recombinant scFv-Thrombomodulin fusion 
with endogenous cofactor. PLoS One 8, (2013). 
213. Antoniak, S., Witkowski, M., Landmesser, U. & Rauch, U. Editorial Commentary : 
Tissue factor expression by the endothelium : Coagulation or inflammation ? ☆. 
1738, 3–5 (2018). 
214. Witkowski, M. & Rauch, U. Letter to the Editor: Tissue factor of endothelial origin: 
Just another brick in the wall? Trends Cardiovasc. Med. 27, 155–156 (2017). 
215. Drake, T. A., Cheng, J., Chang, A. & Taylor, F. B. Expression of tissue factor, 
thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. 
Am. J. Pathol. 142, 1458–70 (1993). 
209 
216. Shaver, C. M. et al. Myeloid tissue factor does not modulate lung inflammation or 
permeability during experimental acute lung injury. Sci. Rep. 6, (2016). 
217. Shaver, C. M. et al. Regulation of alveolar procoagulant activity and permeability 
in direct acute lung injury by lung epithelial tissue factor. Am. J. Respir. Cell Mol. 
Biol. 53, 719–727 (2015). 
218. Pawlinski, R. et al. Hematopoietic and nonhematopoietic cell tissue factor 
activates the coagulation cascade in endotoxemic mice. Blood 116, 806–814 
(2010). 
219. Crikis, S. et al. Antiinflammatory and anticoagulant effects of transgenic 
expression of human thrombomodulin in mice. Am. J. Transplant. 10, 242–250 
(2010). 
220. Raife, T. J. et al. Human thrombomodulin knock-in mice reveal differential effects 
of human thrombomodulin on thrombosis and atherosclerosis. Arterioscler. 
Thromb. Vasc. Biol. 31, 2509–2517 (2011). 
221. Brinkmann, V., Laube, B., Abu Abed, U., Goosmann, C. & Zychlinsky, A. 
Neutrophil Extracellular Traps: How to Generate and Visualize Them. J. Vis. Exp. 
(2010). doi:10.3791/1724 
222. Colace, T. V., Tormoen, G. W., McCarty, O. J. T. & Diamond, S. L. Microfluidics 
and Coagulation Biology. Annu. Rev. Biomed. Eng. 15, 283–303 (2013). 
223. Smith, C. W. et al. Recognition of an endothelial determinant for CD18-dependent 
human neutrophil adherence and transendothelial migration. J. Clin. Invest. 82, 
1746–1756 (1988). 
224. Lipowsky, H. Shear Stress in the Circulation. Flow-Dependent Regul. Vasc. Funct. 
SE  - 2 28–45 (1995). doi:10.1007/978-1-4614-7527-9_2 
225. Clark, S. R. et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare 
210 
bacteria in septic blood. Nat. Med. 13, 463–469 (2007). 
226. Ikezoe, T. et al. The fifth epidermal growth factor-like region of thrombomodulin 
exerts cytoprotective function and prevents SOS in a murine model. Bone Marrow 
Transplant. 52, 73–79 (2017). 
227. Mohri, M., Sugimoto, E., Sata, M. & Asano, T. The inhibitory effect of recombinant 
human soluble thrombomodulin on initiation and extension of coagulation--a 
comparison with other anticoagulants. Thromb. Haemost. 82, 1687–93 (1999). 
228. Böhmer, R. H., Trinkle, L. S. & Staneck, J. L. Dose effects of LPS on neutrophils‐ 
in a whole blood flow cytometric assay of phagocytosis and oxidative burst. 
Cytometry 13, 525–531 (1992). 
229. Butenas, S., Bouchard, B. A., Brummel-Ziedins, K. E., Parhami-Seren, B. & Mann, 
K. G. Tissue factor activity in whole blood. Blood 105, 2764–2770 (2005). 
230. Zhao, X. et al. Targeted Inhibition of Activated Protein C Anticoagulant Activity By 
Monoclonal Antibody HAPC1573 for Treatment of Hemophilia Cookie Notification 
and Disclosure : 1–7 (2018). 
231. Takahashi, H. et al. Protein C levels in disseminated intravascular coagulation 
and thrombotic thrombocytopenic purpura: its correlation with other coagulation 
parameters. Thromb. Haemost. 54, 445–449 (1985). 
232. Fisher, C. J. & Yan, S. B. Protein C levels as a prognostic indicator of outcome in 
sepsis and related diseases. Crit. Care Med. 28, S49–S56 (2000). 
233. Lb, W., Fang, X. & Ma, M. Protein C and thrombomodulin in human acute lung 
injury . 285, (2018). 
234. Coll, E., Robles-Carrillo, L., Reyes, E., Francis, J. L. & Amirkhosravi, A. 
Assessment of protein C anticoagulant pathway by thrombin generation assay in 
the presence of endothelial cells. J. Thromb. Haemost. 11, 1916–1919 (2013). 
211 
235. Salmela, K. et al. A randomized multicenter trial of the anti-ICAM-1 monoclonal 
antibody (enlimomab) for the prevention of acute rejection and delayed onset of 
graft function in cadaveric renal transplantation: A report of the European Anti- 
ICAM-1 Renal Transplant Study gr. Transplantation 67, 729–736 (1999). 
236. Investigators, E. A. S. T. Use of anti-ICAM-1 therapy in ischemic stroke: results of 
the Enlimomab Acute Stroke Trial. Neurology 57, 1428–34 (2001). 
237. Cosimi, A. B. et al. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in 
nonhuman primates with renal allografts. J. Immunol. 144, 4604–12 (1990). 
238. Vuorte, J. et al. Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes 
activation of neutrophils in whole blood. J. Immunol. 162, 2353–7 (1999). 
239. Zheng, Y. et al. In vitro microvessels for the study of angiogenesis and 
thrombosis. Proc. Natl. Acad. Sci. 109, 9342–9347 (2012). 
240. Tsai, M. et al. In vitro modeling of the microvascular occlusion and thrombosis that 
occur in hematologic diseases using microfluidic technology. J. Clin. Invest. 122, 
408–418 (2012). 
241. Tourovskaia, A., Fauver, M., Kramer, G., Simonson, S. & Neumann, T. Tissue-
engineered microenvironment systems for modeling human vasculature. Exp. 
Biol. Med. 239, 1264–1271 (2014). 
242. Ew, E. Organs-on-chips at the frontiers of drug discovery . 14, 4–5 (2018). 
243. Ma, R., Ss, K., Kt, P. & Zheng, Y. Micropatterning and Assembly of 3D 
Microvessels . 2–3 (2018). doi:10.3791/54457 
244. Carnemolla, R. et al. Targeting thrombomodulin to circulating red blood cells 
augments its protective effects in models of endotoxemia and ischemia-
reperfusion injury. FASEB J. 31, 761–770 (2017). 
245. Ch, V., Dc, P., Db, C., Dl, S. & Vr, M. Delivery of drugs bound to erythrocytes : 
212 
new avenues for an old intravascular carrier . 6, 1–2 (2018). 
246. Fuentes, R. E. et al. A chimeric platelet-targeted urokinase prodrug selectively 
blocks new thrombus formation. J. Clin. Invest. 126, 483–494 (2016). 
247. Polacheck, W. J., Li, R., Uzel, S. G. M. & Kamm, R. D. Microfluidic platforms for 
mechanobiology. Lab Chip 13, 2252 (2013). 
248. Lupu, C. et al. Tissue factor-dependent coagulation is preferentially up-regulated 
within arterial branching areas in a baboon model of Escherichia coli sepsis. Am. 
J. Pathol. 167, 1161–1172 (2005). 
249. Antoniak, S. & Mackman, N. Letter to Editor response: Endothelial cell tissue 
factor and coagulation. Trends Cardiovasc. Med. 27, 4–6 (2017). 
250. Nickel, K. F., Long, A. T., Fuchs, T. A., Butler, L. M. & Renné, T. Factor XII as a 
therapeutic target in thromboembolic and inflammatory diseases. Arterioscler. 
Thromb. Vasc. Biol. 37, 13–20 (2017). 
251. Ding, B. Sen et al. Anchoring fusion thrombomodulin to the endothelial lumen 
protects against injury-induced lung thrombosis and inflammation. Am. J. Respir. 
Crit. Care Med. 180, 247–256 (2009). 
252. Greineder, C. F. et al. Dual targeting of therapeutics to endothelial cells: 
Collaborative enhancement of delivery and effect. FASEB J. 29, 3483–3492 
(2015). 
253. Tosi, M. F. et al. Induction of ICAM-1 expression on human airway epithelial cells 
by inflammatory cytokines: effects on neutrophil-epithelial cell adhesion. Am. J. 
Respir. Cell Mol. Biol. 7, 214–221 (1992). 
254. Stern, D., Nawroth, P., Handley, D. & Kisiel, W. An endothelial cell-dependent 
pathway of coagulation. Proc. Natl. Acad. Sci. U. S. A. 82, 2523–2527 (1985). 
255. Ivanciu, L., Krishnaswamy, S. & Camire, R. M. New insights into the 
213 
spatiotemporal localization of prothrombinase in vivo. Blood 124, 1705–1714 
(2014). 
256. Stearns-Kurosawa, D. J., Kurosawa, S., Mollica, J. S., Ferrell, G. L. & Esmon, C. 
T. The endothelial cell protein C receptor augments protein C activation by the 
thrombin-thrombomodulin complex. Proc. Natl. Acad. Sci. U. S. A. 93, 10212–6 
(1996). 
257. Manco-Johnson, M. J. et al. Efficacy and safety of protein C concentrate to treat 
purpura fulminans and thromboembolic events in severe congenital protein C 
deficiency. Thromb. Haemost. 116, 58–68 (2016). 
258. Gao, L. & Lipowsky Herbert H., H. H. Composition of the endothelial glycocalyx 
and its relation to its thickness and diffusion of small solutes. Microvasc. Res. 80, 
394–401 (2010). 
259. Mosnier, L. O., Sinha, R. K., Burnier, L., Bouwens, E. A. & Griffin, J. H. Biased 
agonism of protease-activated receptor 1 by activated protein C caused by 
noncanonical cleavage at Arg46. Blood 120, 5237–5246 (2012). 
260. Hemostasis, Thrombosis, and Vascular Biology_ The ligand occupancy of 
endothelial protein C receptor switches the protease-activated receptor 1-
dependent signaling specificity of thrombin from a permeability-enhancing to a 
barrier-protective response .pdf. 
261. Riewald, M. & Ruf, W. Protease-activated receptor-1 signaling by activated 
protein C in cytokine-perturbed endothelial cells is distinct from thrombin 
signaling. J. Biol. Chem. 280, 19808–19814 (2005). 
262. Kowalska, M. A. et al. Antibodies associated with heparin-induced 
thrombocytopenia (HIT) inhibit activated protein C generation: New insights into 
the prothrombotic nature of HIT. Blood 118, 2882–2888 (2011). 
214 
263. Mosnier, L. O., Yang, X. V. & Griffin, J. H. Activated protein C mutant with minimal 
anticoagulant activity, normal cytoprotective activity, and preservation of thrombin 
activable fibrinolysis inhibitor-dependent cytoprotective functions. J. Biol. Chem. 
282, 33022–33033 (2007). 
264. Guo, H. et al. Neuroprotective activities of activated protein C mutant with reduced 
anticoagulant activity. Eur. J. Neurosci. 29, 1119–1130 (2009). 
265. Kerschen, E. J. et al. Endotoxemia and sepsis mortality reduction by non-
anticoagulant–activated protein C. J. Exp. Med. 204, 2439–2448 (2007). 
266. F. Gragnano, S. Sperlongano, E. Golia, F. Natale, R. Bianchi, M. Crisci, F. 
Fimiani, I. Pariggiano, V. Diana, A. Carbone, A. Cesaro, C. Concilio, G. 
Limongelli, M. Russo,  and P. C. The Role of von Willebrand Factor in Vascular 
Inflammation: From Pathogenesis to Targeted Therapy. Mediators Inflamm. 2017, 
(2017). 
267. Walenga, J. M. et al. Vascular damage correlates between heparin-induced 
thrombocytopenia and the antiphospholipid syndrome. Clin Appl Thromb Hemost 
5 Suppl 1, S76-84 (1999). 
268. Ostertag, E. M. et al. ADAMTS13 autoantibodies cloned from patients with 
acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal 
model. Transfusion 56, 1775–1785 (2016). 
269. Mody, N. A., Lomakin, O., Doggett, T. A., Diacovo, T. G. & King, M. R. Mechanics 
of transient platelet adhesion to von Willebrand factor under flow. Biophys. J. 88, 
1432–1443 (2005). 
270. Witsch, T. et al. Recombinant human ADAMTS13 treatment improves myocardial 
remodeling and functionality after pressure overload injury in mice. J. Am. Heart 
Assoc. 7, 1–14 (2018). 
215 
271. Cai, Z. et al. Atomic description of the immune complex involved in heparin-
induced thrombocytopenia. Nat. Commun. 6, 1–10 (2015). 
272. Denis, C. et al. A mouse model of severe von Willebrand disease: defects in 
hemostasis and thrombosis. Proc Natl Acad Sci USA 95, 9524–9529 (1998). 
273. Martens, C. L. et al. Peptides which bind to E-selectin and block neutrophil 
adhesion. J. Biol. Chem. 270, 21129–21136 (1995). 
274. Ataga, K. I. et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell 
Disease. N. Engl. J. Med. 376, 429–439 (2017). 
275. Zahr, A. et al. Endomucin prevents leukocyte-endothelial cell adhesion and has a 
critical role under resting and inflammatory conditions. Nat. Commun. 7, (2016). 
276. Barnado, A., Crofford, L. J. & Oates, J. C. At the Bedside: Neutrophil extracellular 
traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. J. 
Leukoc. Biol. 99, 265–278 (2016). 
277. Lapponi, M. J. et al. Regulation of Neutrophil Extracellular Trap Formation by Anti-
Inflammatory Drugs. J. Pharmacol. Exp. Ther. 345, 430–437 (2013). 
 
 
 
 
 
 
 
 
 
 
